ANNUAL REPORT

FY 2025 — Annual report

FY 2025PDF · 86 pages10.3 MB
2025 Annual Report

-- 1 of 86 --

1 	Letter to shareholders
5 	Durable by design
6 	Building on breadth
8 	Creating the future
10 	Driven by people
12 	Biowearables
14 	Neuromodulation
16 	Cardiac Rhythm Management
18 	Electrophysiology
20 	Structural Heart
22 	Vascular
24 	Heart Failure Management
26 	Medicines
28 	Laboratory Diagnostics
30 	Rapid and Molecular Diagnostics
32 	Nutrition
34 	Making a difference
36 	Financial Report
2025 Annual Report	
When Stran, a rancher and rodeo world
champion, had a stroke at 32 caused by a patent
foramen ovale (PFO) — an opening between
the right and left sides of the upper chambers
of the heart — he received an Amplatzer PFO
occluder. Today, he’s back in the saddle and
working his ranch with his family.
Front Cover:
STRAN SMITH
Childress, Texas, USA
Amplatzer
PFO occluder

-- 2 of 86 --

Dear fellow shareholder,	Dear fellow shareholder,
In a year of rapid, constant, and volatile	In a year of rapid, constant, and volatile
change, Abbott again demonstrated what	change, Abbott again demonstrated what
has set it apart and kept it thriving for	has set it apart and kept it thriving for
138 years: vision, know-how, adaptability,	138 years: vision, know-how, adaptability,
and the determination that comes from	and the determination that comes from
a compelling sense of purpose.	a compelling sense of purpose.
Robert Ford
Chairman of the Board
and Chief Executive Officer

-- 3 of 86 --

$5.15
Adjusted diluted
EPS reflects
double-digit growth **
6.7%
Organic sales
growth underlying
base business*
$44.3B
Worldwide
sales
2025:
Strong performance
across key financial
measures
2
Abbott / 2025 Annual Report
Navigating the environment
2025 was a year that favored the long
view — looking to both the past and
the future. Our deep experience has
prepared us to deal with challenges
and put them in perspective. And our
established long-term orientation
helps us look past the turbulence of
the day to the decades ahead and
keep building accordingly.
The fundamental key to our success,
as always, is our diversified business
strategy. We’re a broad-based
medical technology company, not
dependent on any single business.
Abbott investors understand well
how our breadth gives us more
ways to win, balancing challenges in
one market with over-performance
in another. Last year once again
demonstrated the value of this
strength.
But the advantages of our diversity
go much further. Because Abbott has
the broadest range of businesses of
any healthcare company, we have
expertise in more therapeutic areas
and in more health technologies, so
we see the biggest and fullest picture
of global health and of medical
science. That gives us a unique
position and ability to bring trends
and opportunities together to help
more people around the world.
Financial performance
Abbott’s global sales in the year
were $44.3 billion, which reflects
an increase of 6.7% on an organic
basis for the base business.*
Adjusted earnings per share
were $5.15.**
In the year, Abbott extended its
record of more than a century
of uninterrupted returns to investors
when it paid its 408th consecutive
quarterly dividend. And our dividends
have risen in each of the last 54 years,
again earning Abbott membership
in the exclusive ranks of Dividend
Kings. Sustaining this legacy, in
December we announced a dividend
increase of 6.8 percent for 2026.
We continue our concerted margin-
improvement efforts and our steady
progress on this front. In 2025, we
delivered top-tier operating margin
expansion with an increase of
100 basis points, despite the impact
of tariffs.
Expanding access and impact
Our goal at Abbott is to help as many
people as possible to live fuller lives
through better health. And we’re
taking disciplined strategic actions
to make that happen through the
products we develop and the way
we manufacture them, through
the markets we participate in, and
through our efforts to build healthier
communities.
Our innovation engine
Innovation is everything in healthcare.
At Abbott, our efforts are clearly
focused on expanding access and
affordability to help more people get
the care they need. Our new-product
pipeline is robust, productive, and
highly innovative. Highlights include:
• Volt, our pulsed field ablation
system designed to deliver precise,
targeted energy during cardiac
ablation procedures, received both
U.S. FDA approval and CE Mark.
• TactiFlex Duo, our device to
provide more effective treatment
for complex cardiac arrhythmias,
was granted breakthrough
designation by the FDA as well
as CE Mark.
• Tendyne, our transcatheter mitral
valve replacement system, received
FDA approval.
• i-STAT High Sensitivity Troponin-I
test, a rapid point-of-care
diagnostic to aid in the early
detection of heart attack, was
launched in the U.S.
• We introduced new formulations
of Ensure, our leading adult
nutritional, and PediaSure, our
nutritional supplement for children.
* Excluding COVID-19 tests
** Full-year 2025 GAAP diluted EPS of $3.72 and adjusted
diluted EPS of $5.15, which excludes specified items and
reflects growth of 10%. For full financial data and
reconciliation of non-GAAP measures, please see Abbott’s
2025 earnings release at www.abbottinvestor.com

-- 4 of 86 --

Dividend increase
since 2020
60+%
Consecutive
years of rising
dividends
54
Consecutive
quarterly
dividends paid
408
Delivering durable
Abbott returns
A decades-long
record of growth
3
Abbott / 2025 Annual Report
• We’re launching multiple biosimilar
medications in emerging markets
to treat a range of conditions,
including autoimmune diseases
and cancer.
• TriClip, our first-of-its-kind,
minimally invasive treatment
option for patients with tricuspid
regurgitation, was approved
in Japan.
• Navitor, our transcatheter aortic
valve implantation (TAVI) system,
received CE Mark to treat
people with symptomatic severe
aortic stenosis who are at low
or intermediate risk for open-
heart surgery.
• We filed for approval of our dual
glucose/ketone sensor for people
living with diabetes. Ketones are
chemicals made by the liver when
the body burns fat for energy.
When insulin levels are too low,
ketones can rise to dangerous
levels, leading to diabetic
ketoacidosis.
• And we conducted more clinical
trials in 2025 than ever before,
with over 200 studies in progress.
This includes initiation of
TECTONIC, our U.S. pivotal trial
to evaluate investigational coronary
intravascular lithotripsy; and
Veritas, our investigational trial
to evaluate Amulet 360, our
next-generation left atrial
appendage occluder designed
to reduce risk of stroke in patients
with atrial fibrillation (AFib).
Over the past three years, our
pipeline has been the richest we’ve
seen, and we — and the customers
we serve — will be reaping the
benefits for years to come.
An exciting new business
In November, we announced our
agreement to acquire Exact Sciences,
a leader in the $60 billion cancer
screening and precision oncology
diagnostics segments, including
market-leading tests such as
CologuardTM and Oncotype DX TM .
This will add a strong new growth
vertical, providing us leadership in
these large and fast-growing areas.
The acquisition will be immediately
accretive to our revenue growth
and gross margin. Exact Sciences
generated more than $3 billion in
2025 revenue, with an organic sales
growth rate in the high teens. It will
become a subsidiary of Abbott,
raising our total diagnostics sales to
more than $12 billion annually.
And Abbott will multiply the
business’s growth potential, as Exact
Sciences has been concentrated
primarily in the U.S. Abbott’s global
presence will bring these important
products to many more people who
need them around the world. We
expect to close the acquisition in the
second quarter of 2026.
Meeting demand
Our global manufacturing network
has been built strategically over
decades to ensure we can get our
products to the people who need
them as reliably and efficiently as
possible. With more than 90 facilities
around the world, we manufacture
close to the markets served. This
has proven particularly helpful
in the current international trade
environment.
We recently enhanced our network
with the opening of a major new
medical devices plant in Querétaro,
Mexico. This state-of-the-art
facility will provide electrophysiology
technologies to help people
with AFib — a life-threatening
condition that today affects
an estimated 37 million people
worldwide and is growing rapidly.
And we’ve initiated plans to
develop a new cardiovascular device
manufacturing facility in the state of
Georgia to be completed by 2028.

-- 5 of 86 --

4
Investing in
Abbott Innovation
Driving future
growth with more
than 200 clinical
trials in 2025.
Key trials include:
Abbott / 2025 Annual Report
Community
And Abbott helps more people
still through our efforts in citizenship
and sustainability. In 2025:
We donated over $36 million in
cash and products to support
humanitarian efforts in more than
50 countries around the world,
including food banks in the U.S.,
to help address childhood hunger
and increased community needs.
In its second year, The We Give Blood
Drive — our partnership with the Big
Ten collegiate athletics conference
to increase blood donation — grew
exponentially, inspiring more than
80,000 donations, enough to save
almost a quarter of a million lives.
We marked the 20th year of our
proactive “disaster pack” initiative
originally launched in response to
Hurricane Katrina. Over the last two
decades, this program has helped
nearly a million people with more
than $70 million in total disaster aid.
Our Abbott Future Well Communities
program addresses chronic diseases
by breaking down social and
economic barriers to health. Through
programs in Stockton, California;
Minneapolis, Minnesota; and
Chicago and Waukegan, Illinois, we
collaborate with local organizations
to provide services and resources
such as nutritious food through
our Healthy Food Rx program,
health education and screenings,
and transportation to medical
appointments.
Resilience
As an Abbott shareholder, we know
there are things that you expect from
the company. Things like stability.
Like reliability. Like focus on what
matters most.
These are timeless, enduring virtues.
And we believe they’re the right ones
to have. They’ve sustained us for
almost 140 years and counting; and
they’ve helped make Abbott the most
profitable healthcare stock of all time.
As always, your company is focused
on disciplined execution across
our operations. We’re sticking to
the fundamentals of our business,
concentrating on quality, on efficiency
and, above all, on innovation for the
future — always finding the new and
better ways to work and succeed
that have kept Abbott growing for so
many generations.
Our business is about building human
resilience in the face of complex
challenges to health. Operating
that business successfully is about
building organizational resilience
in the face of equally complex
challenges — economic, regulatory,
and competitive. Abbott remains
uniquely ready and committed to do
both in the years to come.
Abbott proud,
Robert B. Ford
Chairman of the Board and
Chief Executive Officer
March 2, 2026
TECTONIC
Coronary intravascular
lithotripsy (IVL) uses
sound waves to
break up hard calcium
buildup in blood
vessels
TactiFlex Duo
ablation catheter
to treat abnormal
heart rhythms
FLEXPULSE
Amulet 360,
our next-
generation left
atrial appendage
occluder
VERITAS

-- 6 of 86 --

5
Abbott delivers consistent value and growth,
continually demonstrating the strength
and durability of our diversified business
model, the benefits of our focus on the
long term and, most importantly, the talent
and commitment of our people
Durable
by design

-- 7 of 86 --

6
Diverse geographic
market presence
Abbott’s strength and presence
across the world’s major geographies
help insulate us from challenges in
any one region or market
Abbott / 2025 Annual Report
Distributed
manufacturing
Locating our
manufacturing close to
our customers around
the world reduces
supply chain complexity
and cost, helps us
respond more quickly
to market changes, and
gives us flexibility to
manage economic and
trade policy challenges
Libre portfolio
products, manufactured
in Kilkenny, Ireland
GLP Systems Track, our automated and flexible lab
system, is manufactured in Hamburg, Germany
Building
on breadth

-- 8 of 86 --

Abbott / 2025 Annual Report
7
Wide-ranging vision
Our business breadth gives
us a full-spectrum view
of healthcare’s evolving,
increasingly connected
opportunities that helps guide
our growth strategies
Broad-based stability
and opportunity
Our diversified model
helps balance out
varying cycles of
performance across
our businesses while
maximizing our
opportunities in higher-
growth areas
Our global presence and broad mix
of leading, highly relevant businesses
help us optimize and diversify our
opportunities to grow while managing
and mitigating challenges
FreeStyle
Libre 3 glucose
monitoring
system
Glucerna, a meal or
snack replacement
to help manage blood
sugar response

-- 9 of 86 --

Abbott innovation —
fueled by a strong bench
of scientific talent,
partnerships with other
leading institutions,
and highly selective
strategic acquisitions —
has resulted in a
robust pipeline
designed to support
long-term growth
An integrated
approach
Expanding access
to innovation
Abbott medicines,
including a
growing portfolio
of biologics and
biosimilars,
provide broader
access to important
treatments for
millions worldwide
8
Abbott / 2025 Annual Report
Creating
the future

-- 10 of 86 --

9
Abbott is
empowering people
to take more control
of their health with
home diagnostic
tests, science-based
nutrition products
and our world-leading
Libre biosensing
technology
Making
healthcare
personal
Abbott / 2025 Annual Report
A critical part of Abbott’s durable
performance is consistent investment
in innovation, driving a steady stream
of advanced new technologies
to create the future of healthcare
Our AVEIR DR
LP system, the
world’s first
dual-chamber
leadless
pacemaker, is just
one example of
Abbott innovation
firsts in critical
areas of need
Delivering
technology
firsts

-- 11 of 86 --

10
Driven
by people
Abbott / 2025 Annual Report
A deep pool of talent
Across every function and in every corner
of our business, Abbott talent is world
class and united by our commitment
to helping people live healthier, fuller lives
through our life-changing technologies
and products

-- 12 of 86 --

11
The power of
115,000 Abbott people
Operating in
160+ countries
Touching the lives of
2B people worldwide
Structure and strategy help position
Abbott for success, but the dedication
and commitment of Abbott people
is the ultimate driver of our long-term
growth and impact on lives
Abbott / 2025 Annual Report

-- 13 of 86 --

12
Maureen Gamble
Acworth, Georgia, USA
FreeStyle Libre 3 system
Maureen has lived with Type 1 diabetes
since 1981. She relies on her Libre 3
Plus sensor, authorized to work with her
insulin pump, to help keep her glucose
within her optimal target range.
Leveraging data and insights to
support healthier and fuller lives
Biowearables
Abbott / 2025 Annual Report

-- 14 of 86 --

Lets people living with diabetes see
their glucose levels in real time to make
more confident choices1,3
FreeStyle
Libre 3 system
13
$14B
Continuous
glucose monitoring
global market
Abbott / 2025 Annual Report
Our over-the-counter
glucose biosensor
empowers people to
track glucose in real
time with data
and insights on their
metabolic health
Lingo
Abbott is leveraging its industry-leading glucose-
sensing technology to help more people, with and
without diabetes, track key health metrics.
Abbott’s biowearables use innovative sensor
technology to provide continuous glucose readings in
real-time. With the power of personalized data in your
hand, Abbott’s biowearables are designed to empower
people to build better habits and take small steps in
the moment that add up to big wins for their health.
Convenience and access to one’s own health markers
has resulted in improvements in health outcomes1,2,3
worldwide.4
The Libre portfolio, Abbott’s flagship continuous
glucose monitors (CGM), are the most widely used
biowearables worldwide 5 , helping more than 8 million
people 4 better manage their glucose 2,3,6,7
. In 2025, we
launched a new feature on the Libre App8 called Libre
Assist9 , leveraging AI to predict how food choices may
affect glucose levels10 based on photos of food,
provide personalized suggestions11 , and confirm
glucose impact.
Abbott has entered into partnerships to allow Libre
Plus sensors to work with automated insulin delivery
(AID) systems, which use sensor data to help an insulin
pump automatically adjust insulin levels, reducing
manual calculations.4,12,13
Abbott has expanded our biowearables leadership
with Lingo — a glucose tracking system that’s available
without a prescription for people focused on health
and wellness. Lingo is designed to help people decode
how their body reacts to food, exercise and stress,
and use their unique data to build better habits in a way
that works for their body and health. Studies show
that, with awareness and lifestyle changes, conditions
such as prediabetes can be managed or reversed.14,15

-- 15 of 86 --

14
Ed McQuaid
Bonita Springs, Florida, USA
Liberta RC
Ed has lived with Parkinson’s disease for
years. After managing his condition with
medications, he turned to Liberta RC
deep brain stimulation (DBS) to take more
control of his life and get back to doing
the things he loves.
Abbott’s next-generation
technologies provide
new solutions for chronic pain
and movement disorders
Abbott / 2025 Annual Report
Neuromodulation

-- 16 of 86 --

15
people in the	people in the
U.S. suffer from	U.S. suffer from
chronic pain	chronic pain
50M+	Abbott’s Xtend energy tech
reduces charging frequency to just
five times per year, making it the
lowest recharge burden platform
on the market 6
Eterna SCS
Deep brain stimulation (DBS)
system engineered with
the longest-lasting battery
charge4 and smallest5 DBS
implantable pulse generator
on the market
Liberta RC
DBS system
Abbott / 2025 Annual Report
At Abbott, we’re continuing to expand our global
market presence in neuromodulation, with
technologies to treat chronic pain and movement
disorders, and new opportunities to address
treatment-resistant depression.
Abbott’s Neuromodulation business offers
differentiated rechargeable systems with upgradable
platforms and strong digital connectivity.
The Proclaim SCS Family and Eterna SCS System
(the smallest implantable, rechargeable spinal cord
stimulator currently available 1 ) are designed for the
treatment of chronic pain. These systems offer an
upgradeable software platform so patients can receive
the latest technology without another surgery. Abbott’s
SCS devices use its proprietary low-dose BurstDR
stimulation, 2 which is preferred by 91% of patients over
traditional tonic stimulation.
The Infinity and Liberta deep brain stimulation
(DBS) systems — the only in the U.S. with remote
programming — deliver mild pulses of electricity
to precise areas within the brain to help alleviate
symptoms of Parkinson’s and essential tremor. In
2024, Abbott initiated a pivotal clinical trial, called
the TRANSCEND study, to evaluate the use of the
company’s DBS system to manage treatment-resistant
depression (TRD). 3
Each of these systems can take advantage of Abbott’s
NeuroSphere Virtual Clinic, allowing them to receive
remote programming, letting patients receive real-time
support and care without the need for an office visit.

-- 17 of 86 --

16
Next-generation
pacing
AVEIR CSP LP, Abbott’s
leadless conduction system
pacemaker, currently in early
human feasibility studies,
received FDA Breakthrough
designation in 2025
With a focus on miniaturization, connectivity, and
patient-centric design, Abbott is a trusted partner for
physicians and patients seeking safer, more efficient
cardiac care.
Abbott’s Cardiac Rhythm Management (CRM) business
delivers advanced solutions for diagnosing and treating
heart rhythm disorders, with a portfolio that includes
pacemakers, implantable cardioverter defibrillators
(ICDs), cardiac resynchronization therapy (CRT) devices,
and insertable cardiac monitors.
Abbott is driving the next generation of CRM technology
with its AVEIR leadless pacemaker platform, which
includes atrial, ventricular, and dual-chamber — the
world’s first — leadless systems, all designed to reduce
complications and improve patient comfort.
Abbott also offers MRI-conditional devices like the
AssurityMRI pacemaker, a compact, dual-chamber
system with wireless connectivity and extended battery
life; implantable cardioverter defibrillators (ICDs)
including the Gallant ICD, which offers Bluetooth®
connectivity and smartphone remote communication;
and insertable cardiac monitors like Assert IQ, a
Bluetooth®-enabled, long-lasting insertable cardiac
monitor designed to reduce false positives and simplify
clinic workflows.
Abbott’s comprehensive portfolio also includes remote
monitoring capability through Merlin.net, a system that
lets clinicians track patient data and optimize therapy
from anywhere.
This portfolio also includes Gallant and Entrant
implantable cardioverter defibrillators (ICD) and
Cardiac Resynchronization Therapy Devices (CRT-D) —
advanced implantable devices designed for arrhythmia
management and heart failure therapy.
Improving heart-rhythm management
by transforming the standard of care
Cardiac Rhythm
Management
Abbott / 2025 Annual Report
Global rhythm
management market
$10B

-- 18 of 86 --

Abbott / 2025 Annual Report
17
Vijay Bali
Gurugram, India
AVEIR VR LP system
When Vijay, a retired mechanical
engineer, began experiencing chest
heaviness and fatigue, his doctors
recommended a pacemaker.
Determined to maintain his active
lifestyle without compromising
arm mobility — especially for
golf — he opted for AVEIR VR LP.
Dual-chamber pacing system
uses a unique communication
paradigm, in which two leadless
pacemakers exchange information
on a beat-to-beat basis
AVEIR DR
LP system

-- 19 of 86 --

18
Dr. Boris Schmidt
Frankfurt, Germany
Volt and EnSite X
Dr. Schmidt and his partners
perform an average of 12 catheter
ablation procedures every day.
They use Abbott’s EnSite X mapping
system and Volt PFA catheter to
provide high-precision mapping
and catheter navigation and fast,
safer, more-efficient ablation.
Expanding possibilities in
the treatment of atrial fibrillation
Abbott / 2025 Annual Report
Electrophysiology

-- 20 of 86 --

19
Abbott / 2025 Annual Report
Next-generation 3D-mapping platform
designed to provide a powerful,
reliable and efficient user experience
for every procedure
Pulsed field
ablation
destroys cells
causing AFib
while reducing
damage to
surrounding
tissue
Volt PFA
Expected number
of people in the U.S.
over the age of 65 to
have atrial fibrillation
(AFib) by 2045
24MEnSite X
system
Abbott’s Electrophysiology (EP) business focuses
on advancing the diagnosis and treatment of cardiac
arrhythmias through innovative technologies that
improve procedural efficiency, safety, and outcomes.
The company’s portfolio spans diagnostic mapping
systems, ablation catheters, and integrated
connectivity solutions. At its core is the EnSite X
system, a next-generation 3D-mapping platform that
lets physicians create accurate cardiac maps quickly,
even in complex arrhythmias. Abbott’s line of mapping
catheters includes the Advisor HD Grid X Mapping
Catheter, Sensor Enabled, which helps boost accuracy,
speed, and versatility in mapping procedures.
The Volt pulsed field ablation (PFA) system integrates
mapping and ablation in a single catheter, streamlining
workflow and reducing procedure time. Volt delivers
non-thermal energy for safer, faster procedures.
Abbott’s ablation portfolio also includes the TactiFlex
Ablation Catheter, Sensor Enabled for radiofrequency
ablation. TactiFlex was the world’s first ablation
catheter designed with a unique flexible electrode and
contact-force sensing to provide real-time, quantitative
feedback, which improves safety and streamlines
procedures.
Abbott also supports connectivity and remote care
through the first-of-its-kind EnSite Connected Care
solution, which combines two novel tools: EnSite
Connect Remote Support and Medinbox, to connect
clinicians to a global community through the ability
to stream cases, helping them increase EP lab
effectiveness and efficiency.

-- 21 of 86 --

20
Transcatheter aortic valve
implantation (TAVI) system
Navitor
Our first-of-its-kind
device for tricuspid
valve repair
Abbott continues to expand its comprehensive
portfolio of innovative solutions for treating valve
disease, congenital heart defects, and reducing
stroke risk, helping improve patient outcomes, reduce
recovery times, and expand treatment options for
complex structural heart conditions.
Abbott pioneered minimally invasive transcatheter
treatment options for patients with mitral regurgitation
with MitraClip and for tricuspid regurgitation with
TriClip. In 2025, Abbott gained FDA approval for the
latest generations of these devices. In July, the U.S.
Centers for Medicare & Medicaid Services (CMS)
announced the TriClip G5 system is now covered under
a National Coverage Determination (NCD) for tricuspid
transcatheter edge-to-edge repair, making it available
to more patients.
In 2025, Abbott announced two-year findings from
the TRILUMINATE Pivotal study that showed TriClip
reduces heart failure hospitalizations and highlighted
significant improvements in tricuspid regurgitation and
quality of life.
Our Tendyne transcatheter mitral valve replacement
(TMVR) system, which received FDA approval in 2025,
is a first-in-class technology that is designed to replace
mitral valves that are not functioning properly.
Our Navitor transcatheter aortic valve implantation
(TAVI) system received CE Mark in Europe for an
expanded indication to treat people with symptomatic,
severe aortic stenosis who are at low or intermediate
risk for open-heart surgery. The Navitor system is
equipped with our low-profile, highly flexible FlexNav
delivery system, designed to help clinicians achieve a
controlled, predictable placement of the device.
Abbott / 2025 Annual Report
Leading the way in advanced
cardiac repair and replacement
technologies
Structural Heart
TriClip

-- 22 of 86 --

Abbott / 2025 Annual Report
21
Nancy Ellis-Robinson
Chicago, Illinois, USA
Navitor and Amulet
Now that her heart is working
more efficiently, thanks to
Abbott’s structural heart
devices, Nancy can resume
her active lifestyle, including
her regular swims.
Left atrial
appendage
occluder
Amplatzer Amulet

-- 23 of 86 --

22
Brock Lambert
Lubbock, Texas, USA
Perclose ProStyle
When Brock was seriously injured in
a car accident, he needed a fast
and effective repair on a torn artery.
His father, John, a clinical care specialist,
asked the surgeons to use Abbott’s
Perclose ProStyle at the end of surgery.
Brock is now completely healed
and enjoying his time as a student
at Texas Tech University.
Expanding our portfolio of solutions for people
with arterial injuries and disease
Vascular
Abbott / 2025 Annual Report

-- 24 of 86 --

23
Esprit BTK
For people with
chronic limb-
threatening ischemia
below the knee
20-year growth
in peripheral artery
disease cases
(1990–2021)
102%
Abbott / 2025 Annual Report
With a strong emphasis on continuous innovation
and evidence-based performance, Abbott’s Vascular
business empowers physicians to treat complex
cardiovascular disease less invasively than surgery,
improving quality of life for millions worldwide.
Abbott’s Vascular business delivers advanced
life-changing technologies for the treatment of
peripheral and coronary artery disease and for closing
the femoral access site following catheter-based
procedures. Our goal is to restore blood flow, support
healing, and improve patient outcomes through
minimally invasive solutions.
The portfolio includes drug-eluting stents such as
XIENCE, recognized globally for safety and long-term
efficacy in coronary interventions, and vascular closure
devices like Perclose ProStyle. Abbott is also a leader
in endovascular therapies, offering balloon angioplasty
systems and self-expanding stents for peripheral
interventions, addressing conditions like critical limb
ischemia and carotid artery disease.
For peripheral interventions in blocked arteries in the
lower limbs, Abbott offers the Esprit BTK drug-eluting	Esprit BTK drug-eluting	Esprit
resorbable scaffold system, designed to manage
chronic limb-threatening ischemia by treating below-
the-knee (BTK) peripheral artery disease.
Abbott’s portfolio also includes imaging and
physiology tools like the Optis Next Imaging System,	Optis Next Imaging System,	Optis Next
which uses optical coherence tomography (OCT)
in conjunction with its Ultreon 2.0 AI-powered
imaging software, to provide doctors with automatic
insights to help guide precision treatment and
optimize outcomes.
Perclose ProStyle
suture-mediated closure
and repair system

-- 25 of 86 --

24
Nancy Rajanen
Minneapolis, Minnesota, USA
CardioMEMS
Nancy hasn’t let early-stage
heart failure slow her
down. With Abbott’s
CardioMEMS pulmonary
pressure monitor, her
doctor can keep track of her
symptoms and adjust her
treatment accordingly to
help her live a fuller, more
active life.
Management solutions for every
stage of heart failure
Heart Failure
Management
Abbott / 2025 Annual Report

-- 26 of 86 --

Abbott / 2025 Annual Report
25
The CardioMEMS HF system
remotely monitors changes
in pulmonary artery (PA) pressure,
an early indicator of the onset of
worsening heart failure
of individuals
develop heart failure
in their lifetime
24%
Left ventricular assist device for the
treatment of advanced heart failure
HeartMate 3	CardioMEMS
HF system
With a portfolio that includes implantable sensors,
mechanical circulatory support, and remote
monitoring, Abbott’s Heart Failure business is
delivering better outcomes for thousands worldwide.
Abbott’s Heart Failure business delivers advanced
technologies to help clinicians monitor, manage, and
treat patients with chronic heart failure, aiming to
improve quality of life and reduce hospitalizations.
For early-stage patients, the company offers the
CardioMEMS HF system, a wireless implantable sensor
that measures pulmonary artery pressure and transmits
data remotely, enabling proactive therapy adjustments
before symptoms worsen. This device has demonstrated
significant reductions in heart failure-related
hospitalizations. In 2025, the Centers for Medicare &
Medicaid Services (CMS) expanded CardioMEMS’
indication to cover earlier-stage heart failure, potentially
extending to 1.2 million more U.S. patients.
For patients whose hearts can no longer pump
effectively, Abbott created HeartMate LVAD
(left ventricular assist device) systems, including
HeartMate 3, which uses Abbott’s proprietary Full
MagLev technology for frictionless blood flow, reducing
damage to the blood as it flows through the pump.
These solutions integrate with remote monitoring
platforms, empowering clinicians with actionable
insights and patients with greater independence.
Abbott’s Merlin.net HF Portal lets clinicians triage alerts,
adjust treatments proactively, and reduce heart-failure
hospitalizations.

-- 27 of 86 --

26
Nguyễn Văn Thiết
Hồ Chí Minh City, Vietnam
Influvac
When flu season came, Nguyễn would
withdraw, worried that getting sick
would keep him from his work running
a small department store. He received
his first flu shot in 2023 and has had
an annual vaccination since then. He
hasn’t had the flu in two years now,
and feels stronger, more resilient and,
importantly, less worried.
Providing access to better care in
underserved markets worldwide
Abbott / 2025 Annual Report
Medicines

-- 28 of 86 --

27
Abbott / 2025 Annual Report
of deaths from
influenza in children
under 5 years
old are in emerging
countries
99%
Our
biosimilars
help treat
auto immune
diseases
and cancer
Abbott’s top-selling biologic
vaccine is available in more than
50 countries
Influvac influenza
vaccine
By combining the highest manufacturing standards
with local market insights, Abbott’s Medicines
business helps expand access to essential treatments
and improve health outcomes for millions worldwide.
Abbott’s Medicines business provides trusted
medicines to emerging markets, with a portfolio that
spans cardiovascular, metabolic, gastrointestinal,
respiratory, central nervous system, women’s health,
and pain management products. Abbott emphasizes
quality, affordability, and local relevance, tailoring
formulations and delivery systems to meet regional
healthcare needs.
In 2025, Abbott continued to build on the trust it
has established in these markets by expanding
its offering of biosimilars, generic versions of biologic
medicines, in markets around the world, including
the first denosumab biosimilar in Thailand, expanding
access to this important bone-disease treatment. In
launching this advanced biologic treatment as Resyniv
for osteoporosis and Dnoclast for cancer-related
bone loss, Abbott is providing a more affordable and
accessible treatment option for the estimated 3 million
people suffering from these illnesses in Thailand.
The company also broadened access to cancer
treatment options in the Asia Pacific region with its first
Clesoniz (Bevacizumab) biosimilar launch in Malaysia.
Abbott gained its first biosimilar approval in Brazil
with Bisintex (Trastuzumab), an advanced therapy for
early-stage HER2-positive breast cancer and advanced
gastric cancer. This marks the first approval in a planned
comprehensive oncology portfolio to be offered in
the country. Abbott also secured regulatory approval
for Olizu — a serplulimab molecule — in Peru, a first-line
biologic for extensive-stage small cell lung cancer.

-- 29 of 86 --

Ilija Kevo
Zagreb, Croatia
Alinity s
28
By combining advanced instrumentation, robust assay
menus, and advanced automation, Abbott’s Laboratory
Diagnotics business helps labs deliver fast, accurate
diagnoses—ultimately improving patient care and
supporting health systems around the world.
Abbott’s Laboratory Diagnostics portfolio is centered
on the Alinity family of systems, which integrates clinical
chemistry, immunoassay, hematology, and transfusion
screening on a unified platform. These systems are
designed for scalability, automation, and interoperability,
helping labs improve efficiency, reduce errors, and
manage growing test volumes with limited resources.
Abbott is developing the Alinity n system and assays,
which will add nucleic acid testing to its blood and
plasma screening portfolio.1
In 2025, Abbott added a key test to its U.S. assay
portfolio with the FDA clearance of its NT-proBNP assay
for Alinity i, which helps identify congestive heart failure
and mild forms of cardiac dysfunction.
Laboratories around the world are also benefitting from
Abbott’s GLP Systems Track, a scalable system that
redefines laboratory automation through its intelligent,
modular, and autonomous architecture — delivering
flexibility and efficient sample throughput to meet
growing clinical demand.
In 2025, Abbott’s acquisition of iSens added proprietary
technology for real-time sample tracking, routing,
and management to the company’s portfolio — helping
laboratories streamline workflows, and improve
operational efficiency.
Abbott / 2025 Annual Report
Increasing the capabilities
of high-volume
laboratories worldwide
Laboratory
Diagnostics

-- 30 of 86 --

29
ALINITY s
Purpose-built for blood and plasma screening, this
system can process up to 600 samples per hour, making
it ideal for large blood banks and plasma centers
70% of healthcare
decisions involve
a diagnostic test
Abbott / 2025 Annual Report
When Ilija was being treated
for leukemia, he needed
frequent transfusions. His
doctors relied on Abbott blood-
screening technology to
help keep him safe. Today,
Ilija is an active, happy — and
cancer-free — 7-year-old.

-- 31 of 86 --

Rapid, instrument-based
isothermal system for
the qualitative detection
of infectious diseases in
just minutes
ID NOW	ID NOW
Lab-quality
results in
a hand-held
device
i-STAT
Alinity
30
Timely and convenient results
to support better care
Abbott / 2025 Annual Report
Rapid and Molecular
Diagnostics
For faster
detection of heart
attack, our test
can quantify
cardiac troponin I
in about 15
minutes, right
at the patient’s
bedside
i-STAT
High Sensitivity
Troponin-I

-- 32 of 86 --

Karen de Sousa Machado Santos
São Paulo, Brazil
Bioline Dengue Duo
Karen was very ill with dengue, but an
earlier test had delivered a negative
result. She used Abbott’s Bioline
Dengue Duo test and confirmed that
she did, in fact, have the infection.
She went to the hospital not a moment
too soon. She spent five days in
intensive care but recovered fully.
31
Abbott / 2025 Annual Report
Abbott’s Rapid Diagnostics business delivers fast,
accurate testing solutions that empower clinicians
and consumers to make timely health decisions.
These tests give clinicians and patients reliable
diagnostic tools for early detection, treatment
decisions, and improved outcomes. Our point-of-
care tests for infectious diseases, cardiometabolic
conditions, and toxicology includes leading brands like
BinaxNOW, Panbio, and i-STAT, providing results in
minutes in clinics, pharmacies, and home settings.
Globally, Abbott offers the i-STAT High Sensitivity
Troponin-I assay, enabling faster detection of heart
attack.
In the U.S., Abbott offers the BinaxNOW COVID-19/
Flu A&B Combo Self Test, which uses a single
sample to provide results for COVID-19 and both flu
strains (A & B) in about 15 minutes, helping doctors
quickly determine appropriate treatment and reduce
unnecessary antibiotic use.
Abbott rapid tests also support public health initiatives
in underserved regions of the world. For example, in
Africa, the company’s Antenatal Care Panel includes
rapid diagnostic tests for key conditions that can
impact maternal and fetal health, such as HIV, syphilis,
malaria, and anemia. By combining essential tests
into one package, the panel helps improve maternal
outcomes, reduce neonatal complications, and support
public health goals across Africa.
Abbott’s Molecular business is making lab testing more
convenient and accessible. Our Simpli-COLLECT STI
and HPV solution is designed to simplify specimen
collection for sexually transmitted infections (STIs) and
human papillomavirus (HPV) testing, helping public
health systems implement screen-and-treat strategies,
especially in regions with limited lab infrastructure.

-- 33 of 86 --

32
Koo Soo Ming
Kuala Lumpur, Malaysia
Ensure
As the leader of Malaysia’s only
traditional dance troupe for women
over 50, Soo is always on the go.
When she needs a boost of extra
nutrition to get her though her busy
day, she relies on Ensure.
Science-based support for
healthy living at every age of
life and stage of health
Nutrition
Abbott / 2025 Annual Report

-- 34 of 86 --

33
#1 Ensure is the
leading nutritional
supplement
drink in the world
#1 Pediatric nutrition
in the U.S.
Dual-action formula
to support both
muscle building and
immunity
Ensure Life
StrengthPro
Abbott’s global reach lets the company provide high-
quality nutrition in both developed and emerging
markets, helping people live healthier lives through
clinically proven solutions.
Abbott is a global leader in science-based nutritional
products that support health across all life stages—
from infancy through adulthood. The portfolio spans
pediatric nutrition, adult and therapeutic nutrition,
and performance products, addressing diverse
needs such as growth, immunity, chronic disease
management, and recovery.
In pediatric nutrition, the company’s Similac line of
infant formulas is trusted by millions of families
around the world, offering sensitive and tolerance
formulas, organic European-sourced formulas, as
well as metabolic formulas for babies with complex
medical conditions or inborn errors of metabolism.
For adults, the Ensure line delivers complete, balanced
nutrition for healthy people looking for a convenient
supplement as well as for patients recovering from
illness or surgery. Abbott’s portfolio also includes
condition-specific options such as Glucerna, which
helps people manage diabetes with low-glycemic
formulations, and Nepro, for people on hemodialysis.
In 2025 Abbott demonstrated its continued focus on
the health of older adults with the launches of Ensure
Max Protein 42g, a new shake that helps build muscle
tissue alongside resistance training; and Ensure Max
Protein 2-in-1 Muscle Support, which includes HMB
(beta-hydroxy-beta-methylbutyrate) to help slow the
breakdown of muscle in aging adults.
Abbott / 2025 Annual Report
Our
portfolio
of nutrition
products
continues
to evolve

-- 35 of 86 --

34
The We Give Blood Drive
We’ve partnered with the Big Ten
collegiate athletics conference
to inspire a new generation of blood
donors, an initiative that put us on
Fortune magazine’s “Change the
World” list for its life-saving impact
for almost 250,000 people.
Abbott / 2025 Annual Report
Expanding our positive
impact on the world
Making a
difference

-- 36 of 86 --

35
Abbott and Sesame Workshop
help families live healthier
Real Madrid partnership
Along with the Real Madrid
Foundation, we’re working
to instill healthy habits
in the lives of thousands of
children worldwide
$36M+ in cash and products
donated to support global
communities affected by
natural disasters
Abbott / 2025 Annual Report
Abbott’s fundamental purpose is to help people live
fuller lives through better health. We’re here to
make a difference that’s as durable as the business
we’ve built.
We’re dedicated to doing the most good we can, for the
most people we can reach. In 2025, that commitment
led to some 2 billion lives impacted through Abbott
products and services. And we’re focused on
increasing that number by expanding access to our
life-changing technologies and products. But across
our business, and in partnership with others, we’re also
working to build communities, respond to disasters,
and remove barriers to care to help people live their
healthiest lives.
Abbott is teaming up with Sesame Workshop, the
nonprofit behind Sesame Street, to launch a global
program designed to help families everywhere create
healthy routines that last.
And throughout our 25-year partnership with the
Tanzanian government, we have helped strengthen
the country’s health system in several key areas,
including providing emergency care services to more
than 1.3 million people since 2010.
Through our partnership with the Real Madrid
Foundation, more than 31,000 hours of our Future
Well Kids curriculum, which is focused on preventing
noncommunicable diseases, was delivered by the
Foundation’s coaches, staff, and volunteers, reaching
more than 4,000 children across 12 countries.
Abbott is also a longtime supporter of disaster relief
efforts worldwide. Over the past decade, Abbott and
Abbott Fund have provided more than $70 million in
funding and products to help meet both immediate
needs and support long-term recovery efforts.
In recent years, this has included rapid responses to
wildfires in California and Hawaii, Hurricanes Debby,
Beryl, Milton, and Helene in the U.S. and the Caribbean,
earthquakes in Turkey, Morocco, Japan and Taiwan,
and severe flooding in Southern California.

-- 37 of 86 --

Abbott / 2025 Annual Report
36
37 Consolidated Statement
of Earnings
38 Consolidated Statement
of Comprehensive Income
39 Consolidated Statement
of Cash Flows
40 Consolidated Balance Sheet
42 Consolidated Statement
of Shareholders’ Investment
43 Notes to Consolidated
Financial Statements
62 Management Report
on Internal Control Over
Financial Reporting
62 Report of Independent
Registered Public
Accounting Firm
64 Report of Independent
Registered Public
Accounting Firm
65 Financial Instruments and
Risk Management
66 Financial Review
79 Performance Graph
80 Summary of Selected
Financial Data
81 Directors and
Corporate Officers
82 Shareholder and
Corporate Information
2025
Financial
Report

-- 38 of 86 --

37
Abbott / 2025 Annual Report
Year Ended December 31 	2025 	2024 	2023
Net Sales 	$44,328 	$41,950 	$40,109
Cost of products sold, excluding amortization of intangible assets 	19,319 	18,706 	17,975
Amortization of intangible assets 	1,682 	1,878 	1,966
Research and development 	2,942 	2,844 	2,741
Selling, general and administrative 	12,332 	11,697 	10,949
Total Operating Cost and Expenses 	36,275 	35,125 	33,631
Operating Earnings 	8,053 	6,825 	6,478
Interest expense 	493 	559 	637
Interest income 	(308) 	(344) 	(385)
Net foreign exchange (gain) loss 	(50) 	(27) 	41
Other (income) expense, net 	(548) 	(376) 	(479)
Earnings before Taxes 	8,466 	7,013 	6,664
Taxes on Earnings 	1,942 	(6,389) 	941
Net Earnings 	$ 6,524 	$13,402 	$ 5,723
Basic Earnings Per Common Share 	$ 	3.73 	$ 	7.67 	$ 	3.28
Diluted Earnings Per Common Share 	$ 	3.72 	$ 	7.64 	$ 	3.26
Average Number of Common Shares Outstanding Used for Basic
Earnings Per Common Share 	1,741 	1,740 	1,740
Dilutive Common Stock Options 	7 	8 	9
Average Number of Common Shares Outstanding Plus Dilutive
Common Stock Options 	1,748 	1,748 	1,749
Outstanding Common Stock Options Having No Dilutive Effect 	1 	7 	5
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Statement of Earnings
(in millions except per share data)

-- 39 of 86 --

38
Abbott / 2025 Annual Report
Year Ended December 31 	2025 	2024 	2023
Net Earnings 	$ 6,524 	$13,402 	$ 5,723
Foreign currency translation gain (loss) adjustments, net of taxes of
$62 in 2025 and $— in 2024 and 2023 	1,574 	(1,001) 	229
Net actuarial gains (losses) and prior service cost and credits and
amortization of net actuarial losses and prior service cost and credits,
net of taxes of $149 in 2025, $228 in 2024, and $31 in 2023 	610 	765 	117
Net gains (losses) on derivative instruments designated as cash flow
hedges, net of taxes of $(60) in 2025, $48 in 2024, and $(66) in 2023 	(279) 	169 	(134)
Other Comprehensive Income (Loss) 	1,905 	(67) 	212
Comprehensive Income 	$ 8,429 	$13,335 	$ 5,935
Supplemental Accumulated Other Comprehensive Income (Loss)
Information, net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments 	$(5,931) 	$ (7,505) 	$(6,504)
Net actuarial (losses) and prior service (cost) and credits 	(1) 	(611) 	(1,376)
Cumulative gains (losses) on derivative instruments designated as
cash flow hedges 	(69) 	210 	41
Accumulated other comprehensive income (loss) 	$(6,001) 	$ (7,906) 	$(7,839)
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Statement of Comprehensive Income
(in millions)

-- 40 of 86 --

39
Abbott / 2025 Annual Report
Year Ended December 31 	2025 	2024 	2023
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 6,524 	$13,402 	$ 5,723
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation 	1,434 	1,340 	1,277
Amortization of intangible assets 	1,682 	1,878 	1,966
Share-based compensation 	664 	673 	644
Investing and financing losses, net 	65 	482 	126
Trade receivables 	(652) 	(691) 	(356)
Inventories 	195 	(58) 	(232)
Prepaid expenses and other assets 	(1,295) 	(796) 	(542)
Trade accounts payable and other liabilities 	954 	356 	(760)
Income taxes 	(5) 	(8,028) 	(585)
Net Cash From Operating Activities 	9,566 	8,558 	7,261
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(2,171) 	(2,207) 	(2,202)
Acquisitions of businesses and technologies, net of cash acquired 	(105) 	— 	(877)
Proceeds from business dispositions 	— 	1 	40
Purchases of investment securities 	(167) 	(169) 	(159)
Proceeds from sales of investment securities 	3 	28 	43
Other 	18 	9 	22
Net Cash From (Used in) Investing Activities 	(2,422) 	(2,338) 	(3,133)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of) short-term debt, net and other 	(115) 	(100) 	21
Proceeds from issuance of long-term debt and debt with maturities over 3 months 	5 	223 	2
Repayments of long-term debt and debt with maturities over 3 months 	(1,504) 	(660) 	(2,498)
Purchases of common shares 	(893) 	(1,295) 	(1,227)
Proceeds from stock options exercised 	396 	264 	167
Dividends paid 	(4,116) 	(3,836) 	(3,556)
Other 	(82) 	— 	—
Net Cash From (Used in) Financing Activities 	(6,309) 	(5,404) 	(7,091)
Effect of exchange rate changes on cash and cash equivalents 	71 	(96) 	(23)
Net Increase (Decrease) in Cash and Cash Equivalents 	906 	720 	(2,986)
Cash and Cash Equivalents, Beginning of Year 	7,616 	6,896 	9,882
Cash and Cash Equivalents, End of Year 	$ 8,522 	$ 7,616 	$ 6,896
Supplemental Cash Flow Information:
Income taxes paid 	$ 1,933 	$ 1,723 	$ 1,475
Interest paid 	545 	604 	662
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Statement of Cash Flows
(in millions)

-- 41 of 86 --

40
Abbott / 2025 Annual Report
December 31 	2025 	2024
Assets
Current assets:
Cash and cash equivalents 	$ 8,522 	$ 7,616
Investments, primarily bank time deposits and U.S. treasury bills 	417 	351
Trade receivables, less allowances of — 2025: $490; 2024: $439 	7,929 	6,925
Inventories:
Finished products 	3,976 	3,700
Work in process 	904 	840
Materials 	1,608 	1,654
Total inventories 	6,488 	6,194
Other prepaid expenses and receivables 	2,640 	2,570
Total current assets 	25,996 	23,656
Investments 	918 	886
Property and equipment, at cost:
Land 	541 	528
Buildings 	4,543 	4,207
Equipment 	17,571 	15,517
Construction in progress 	2,567 	2,488
25,222 	22,740
Less: accumulated depreciation and amortization 	13,406 	12,082
Net property and equipment 	11,816 	10,658
Intangible assets, net of amortization 	5,526 	6,647
Goodwill 	24,035 	23,108
Deferred income taxes and other assets 	18,422 	16,459
$86,713 	$81,414
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Balance Sheet
(dollars in millions)

-- 42 of 86 --

41
Abbott / 2025 Annual Report
December 31 	2025 	2024
Liabilities and Shareholders’ Investment
Current liabilities:
Trade accounts payable 	$ 4,240 	$ 4,195
Salaries, wages, and commissions 	1,745 	1,701
Other accrued liabilities 	5,812 	5,143
Dividends payable 	1,097 	1,024
Income taxes payable 	569 	594
Current portion of long-term debt 	3,033 	1,500
Total current liabilities 	16,496 	14,157
Long-term debt 	9,896 	12,625
Post-employment obligations and other long-term liabilities 	7,550 	6,731
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2025: 1,996,795,525; 2024: 1,991,472,630 	25,527 	25,153
Common shares held in treasury, at cost — Shares: 2025: 260,196,074; 2024: 259,774,639 	(17,177) 	(16,844)
Earnings employed in the business 	49,781 	47,261
Accumulated other comprehensive income (loss) 	(6,001) 	(7,906)
Total Abbott Shareholders’ Investment 	52,130 	47,664
Noncontrolling interests in subsidiaries 	641 	237
Total Shareholders’ Investment 	52,771 	47,901
$ 86,713 	$ 81,414
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Balance Sheet
(dollars in millions)

-- 43 of 86 --

42
Abbott / 2025 Annual Report
Year Ended December 31 	2025 	2024 	2023
Common Shares:
Beginning of Year
Shares: 2025: 1,991,472,630; 2024: 1,987,883,852; 2023: 1,986,519,278 	$ 25,153 	$ 24,869 	$ 24,709
Issued under incentive stock programs
Shares: 2025: 5,322,895; 2024: 3,588,778; 2023: 1,364,574 	295 	173 	66
Share-based compensation 	664 	673 	646
Issuance of restricted stock awards 	(585) 	(562) 	(552)
End of Year
Shares: 2025: 1,996,795,525; 2024: 1,991,472,630; 2023: 1,987,883,852 	$ 25,527 	$ 25,153 	$ 24,869
Common Shares Held in Treasury:
Beginning of Year
Shares: 2025: 259,774,639; 2024: 253,807,494; 2023: 248,724,257 	$(16,844) 	$(15,981) 	$(15,229)
Issued under incentive stock programs
Shares: 2025: 4,530,646; 2024: 4,423,897; 2023: 4,881,031 	296 	280 	297
Purchased
Shares: 2025: 4,952,081; 2024: 10,391,042; 2023: 9,964,268 	(629) 	(1,143) 	(1,049)
End of Year
Shares: 2025: 260,196,074; 2024: 259,774,639; 2023: 253,807,494 	$(17,177) 	$(16,844) 	$(15,981)
Earnings Employed in the Business:
Beginning of Year 	$ 47,261 	$ 37,554 	$ 35,257
Net earnings 	6,524 	13,402 	5,723
Cash dividends declared on common shares
(per share — 2025: $2.40; 2024: $2.24; 2023: $2.08) 	(4,189) 	(3,904) 	(3,625)
Effect of common and treasury share transactions 	185 	209 	199
End of Year 	$ 49,781 	$ 47,261 	$ 37,554
Accumulated Other Comprehensive Income (Loss):
Beginning of Year 	$ (7,906) 	$ (7,839) 	$ (8,051)
Other comprehensive income (loss) 	1,905 	(67) 	212
End of Year 	$ (6,001) 	$ (7,906) 	$ (7,839)
Noncontrolling Interests in Subsidiaries:
Beginning of Year 	$ 	237 	$ 	224 	$ 	219
Changes to noncontrolling ownership interest 	387 	— 	—
Noncontrolling Interests’ share of income, net of distributions and
share repurchases 	17 	13 	5
End of Year 	$ 	641 	$ 	237 	$ 	224
The accompanying notes to consolidated financial statements are an integral part of this statement.
Consolidated Statement of Shareholders’ Investment
(in millions except shares and per share data)

-- 44 of 86 --

43
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Note 1 — Summary of Significant Accounting Policies
Nature of Business — Abbott’s principal business is the discovery,
development, manufacture, and sale of a broad line of healthcare
products.
Basis of Consolidation — The consolidated financial statements
include the accounts of the parent company, subsidiaries, and
any variable interest entities for which Abbott is the primary
beneficiary. Intercompany transactions are eliminated in consolida-
tion. Investments in affiliates over which Abbott has a significant
influence, but not a controlling interest, are accounted for using the
equity method of accounting.
Use of Estimates — The consolidated financial statements have
been prepared in accordance with generally accepted accounting
principles in the United States (U.S.) and necessarily include
amounts based on estimates and assumptions by management.
Actual results could differ from those amounts. Significant esti-
mates include amounts for sales rebates, income taxes, pension
and other post-employment benefits, valuation of intangible assets,
litigation, derivative financial instruments, and inventory and
accounts receivable exposures.
Foreign Currency Translation — The statements of earnings of for-
eign subsidiaries whose functional currencies are other than the U.S.
dollar are translated into U.S. dollars using average exchange rates
for the period. The net assets of foreign subsidiaries whose func-
tional currencies are other than the U.S. dollar are translated into
U.S. dollars using exchange rates as of the balance sheet date. The
U.S. dollar effects that arise from translating the net assets of these
subsidiaries at changing rates are recorded in the foreign currency
translation adjustment account, which is included in equity as a
component of Accumulated other comprehensive income (loss).
Transaction gains and losses are recorded on the Net foreign
exchange (gain) loss line of the Consolidated Statement of Earnings.
Revenue Recognition — Revenue from product sales is recognized
upon the transfer of control, which is generally upon shipment or
delivery, depending on the delivery terms set forth in the customer
contract. Provisions for discounts, rebates, and sales incentives to
customers, returns, and other adjustments are provided for in the
period the related sales are recorded. Sales incentives to customers
are not material. Historical data is readily available and reliable and
is used for estimating the amount of the reduction in gross sales.
Revenue from the launch of a new product, from an improved
version of an existing product, or for shipments in excess of a
customer’s normal requirements are recorded when the conditions
noted above are met. In those situations, management records a
returns reserve for such revenue, if necessary. In certain Abbott
businesses, primarily within diagnostics, Abbott participates in
selling arrangements that include multiple performance obligations
(e.g., instruments, reagents, procedures, and service agreements).
The total transaction price of the contract is allocated to each
performance obligation in an amount based on the estimated
relative standalone selling prices of the promised goods or services
underlying each performance obligation.
Income Taxes — Deferred income taxes are provided for the tax
effect of differences between the tax bases of assets and liabilities
and their reported amounts in the financial statements at the
enacted statutory rate to be in effect when the taxes are paid.
No additional income taxes have been provided for any remaining
undistributed foreign earnings not subject to the transition tax
related to the U.S. Tax Cuts and Jobs Act (TCJA), or any additional
outside basis differences that exist, as these amounts continue to
be indefinitely reinvested in foreign operations. The TCJA subjects
taxpayers to tax on global intangible low-taxed income (GILTI)
earned by certain foreign subsidiaries. Abbott treats the GILTI tax
as a period expense and provides for the tax in the year that the
tax is incurred. Interest and penalties on income tax obligations
are included in taxes on earnings.
Earnings Per Share — Unvested restricted stock units and awards
that contain non-forfeitable rights to dividends are treated as
participating securities and are included in the computation of
earnings per share under the two-class method. Under the two-
class method, net earnings are allocated between common shares
and participating securities. Net earnings allocated to common
shares in 2025, 2024, and 2023 were $6.5 billion, $13.4 billion, and
$5.7 billion, respectively.
Pension and Post-Employment Benefits — Abbott accrues for
the actuarially determined cost of pension and post-employment
benefits over the service attribution periods of the employees.
Abbott must develop long-term assumptions, the most significant
of which are the healthcare cost trend rates, discount rates, and the
expected return on plan assets. Differences between the expected
long-term return on plan assets and the actual return are amortized
over a five-year period. Actuarial losses and gains are amortized
over the remaining service attribution periods of the employees
under the corridor method.
Fair Value Measurements — For assets and liabilities that are
measured using quoted prices in active markets, total fair value is
the published market price per unit multiplied by the number of
units held without consideration of transaction costs. Assets and
liabilities that are measured using significant other observable
inputs are valued by reference to similar assets or liabilities,
adjusted for contract restrictions and other terms specific to that
asset or liability. For these items, a significant portion of fair value is
derived by reference to quoted prices of similar assets or liabilities
in active markets. For all remaining assets and liabilities, fair value
is derived using a fair value model, such as a discounted cash flow
model or Black-Scholes model. Purchased intangible assets are
recorded at fair value. The fair value of significant purchased intan-
gible assets is based on independent appraisals. Abbott uses a
discounted cash flow model to value intangible assets. The dis-
counted cash flow model requires assumptions about the timing
and amount of future net cash flows, risk, the cost of capital, termi-
nal values, and market participants. Intangible assets are reviewed
for impairment on a quarterly basis. Goodwill and indefinite-lived
intangible assets are tested for impairment at least annually.
Share-Based Compensation — The fair value of stock options and
restricted stock awards and units are amortized over their requisite
service period, which could be shorter than the vesting period if an
employee is retirement eligible, with a charge to compensa-
tion expense.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. Legal fees are recorded as incurred.

-- 45 of 86 --

44
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Cash, Cash Equivalents, and Investments — Cash equivalents
consist of bank time deposits, U.S. government securities, money
market funds, and U.S. treasury bills with original maturities of three
months or less. Abbott holds certain investments with a carrying
value of $131 million that are accounted for under the equity
method of accounting. Investments held in a rabbi trust and invest-
ments in publicly traded equity securities are recorded at fair value
and changes in fair value are recorded in earnings. Investments in
equity securities that are not traded on public stock exchanges are
recorded at cost minus impairment, if any, plus or minus changes
resulting from observable price changes in orderly transactions for
identical or similar investments of the same issuer.
Trade Receivable Valuations — Accounts receivable are stated at
the net amount expected to be collected. The allowance for doubt-
ful accounts reflects the current estimate of credit losses expected
to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjusting
its allowance for doubtful accounts, including the aging of the
accounts and aging trends, the historical level of charge-offs, and
specific exposures related to particular customers. Abbott also
monitors other risk factors and forward-looking information, such
as country risk, when determining credit limits for customers and
establishing adequate allowances. Accounts receivable are
charged off after all reasonable means to collect the full amount
(including litigation, where appropriate) have been exhausted.
Inventories — Inventories are stated at the lower of cost (first-in,
first-out basis) or net realizable value. Cost includes material and
conversion costs.
Property and Equipment — Depreciation and amortization are
provided on a straight-line basis over the estimated useful lives of
the assets. The following table shows estimated useful lives of
property and equipment:
Classification 	Estimated Useful Lives
Buildings 	10 to 50 years
Equipment 	2 to 20 years
Product Liability — Abbott accrues for product liability claims when
it is probable that a liability has been incurred and the amount of
the liability can be reasonably estimated based on existing informa-
tion. The liabilities are adjusted quarterly as additional information
becomes available. Product liability losses are self-insured.
Research and Development Costs — Internal research and develop-
ment costs are expensed as incurred. Clinical trial costs incurred
by third parties are expensed as the contracted work is performed.
Where contingent milestone payments are due to third parties
under research and development arrangements, the milestone
payment obligations are expensed when the milestone results
are achieved.
Acquired In-Process and Collaborations Research and Development
(IPR&D) — The initial costs of rights to IPR&D projects obtained in
an asset acquisition are expensed as IPR&D unless the project has
an alternative future use. These costs include initial payments
incurred prior to regulatory approval in connection with research
and development collaboration agreements that provide rights to
develop, manufacture, market and/or sell pharmaceutical or medi-
cal device products. The fair value of IPR&D projects acquired in a
business combination or a consolidated variable interest entity are
capitalized and accounted for as indefinite-lived intangible assets
until completed and are then amortized over the remaining useful
life. Collaborations are not significant.
Concentration of Risk and Guarantees — Due to the nature of its
operations, Abbott is not subject to significant concentration risks
relating to customers, products, or geographic locations. Product
warranties are not significant.
Abbott has no material exposures to off-balance sheet arrange-
ments; no special purpose entities; nor activities that include
non-exchange-traded contracts accounted for at fair value. Abbott
periodically acquires a business or product rights in which Abbott
agrees to pay contingent consideration based on attaining certain
thresholds or based on the occurrence of certain events.
Note 2 — New Accounting Standards
Recently Adopted Accounting Standards
In December 2023, the FASB issued Accounting Standards Update
(ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income
Tax Disclosures, which requires an entity to disclose annually
additional information related to the company’s income tax rate
reconciliation and income taxes paid during the period. The guid-
ance is required to be applied prospectively with the option to
apply the standard retrospectively. Abbott adopted the standard on
January 1, 2025, and applied the guidance prospectively. The new
standard did not have an impact on Abbott’s consolidated financial
statements, but required additional disclosures, as presented in
Note 15 — Taxes on Earnings.
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of required
segment disclosures. The guidance is required to be applied retro-
spectively to all periods presented in the financial statements.
Abbott adopted the standard on January 1, 2024. The new standard
did not have an impact on Abbott’s consolidated financial state-
ments, but required additional disclosures, retrospectively applied
to all periods presented in Note 16 — Segment and Geographic
Area Information.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income
Statement (Subtopic 220-40): Reporting Comprehensive Income –
Expense Disaggregation Disclosures, which requires an entity to
disclose on an annual and interim basis, disaggregated information
about specific income statement expense categories. The guidance
should be applied prospectively with the option to apply the stan-
dard retrospectively. The standard becomes effective for Abbott for
full year 2027 reporting. Abbott is currently evaluating the impact
of this new standard on its consolidated financial statements.
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad
line of healthcare products under short-term receivable arrange-
ments. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under
a contract, most impact which products are sold; price controls,
competition and rebates most impact the net selling prices of
products; and foreign currency translation impacts the measure-
ment of net sales and costs. Abbott’s products are generally sold
directly to retailers, wholesalers, distributors, hospitals, healthcare
facilities, laboratories, physicians’ offices, and government agen-
cies throughout the world. Abbott has four reportable segments:
Established Pharmaceutical Products, Diagnostic Products,
Nutritional Products, and Medical Devices.

-- 46 of 86 --

45
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The following tables provide detail by sales category:
2025 	2024 	2023
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— 	$ 4,167 	$ 4,167 	$ 	— 	$ 3,858 	$ 3,858 	$ 	— 	$ 3,807 	$ 3,807
Other 	— 	1,369 	1,369 	— 	1,336 	1,336 	— 	1,259 	1,259
Total 	— 	5,536 	5,536 	— 	5,194 	5,194 	— 	5,066 	5,066
Nutritional Products —
Pediatric Nutritionals 	2,158 	1,816 	3,974 	2,208 	1,815 	4,023 	1,977 	1,957 	3,934
Adult Nutritionals 	1,448 	3,029 	4,477 	1,481 	2,909 	4,390 	1,436 	2,784 	4,220
Total 	3,606 	4,845 	8,451 	3,689 	4,724 	8,413 	3,413 	4,741 	8,154
Diagnostic Products —
Core Laboratory 	1,425 	3,935 	5,360 	1,332 	3,903 	5,235 	1,243 	3,916 	5,159
Molecular 	150 	367 	517 	150 	371 	521 	172 	402 	574
Point of Care 	422 	184 	606 	408 	180 	588 	396 	169 	565
Rapid Diagnostics 	1,538 	916 	2,454 	1,940 	1,057 	2,997 	2,518 	1,172 	3,690
Total 	3,535 	5,402 	8,937 	3,830 	5,511 	9,341 	4,329 	5,659 	9,988
Medical Devices —
Rhythm Management 	1,334 	1,315 	2,649 	1,154 	1,236 	2,390 	1,085 	1,170 	2,255
Electrophysiology 	1,283 	1,481 	2,764 	1,141 	1,326 	2,467 	1,008 	1,187 	2,195
Heart Failure 	1,107 	341 	1,448 	986 	293 	1,279 	888 	273 	1,161
Vascular 	1,118 	1,877 	2,995 	1,056 	1,781 	2,837 	978 	1,703 	2,681
Structural Heart 	1,172 	1,351 	2,523 	1,051 	1,195 	2,246 	883 	1,061 	1,944
Neuromodulation 	773 	237 	1,010 	767 	195 	962 	725 	165 	890
Diabetes Care 	3,181 	4,817 	7,998 	2,633 	4,172 	6,805 	2,129 	3,632 	5,761
Total 	9,968 	11,419 	21,387 	8,788 	10,198 	18,986 	7,696 	9,191 	16,887
Other 	17 	— 	17 	16 	— 	16 	14 	— 	14
Total 	$17,126 	$27,202 	$44,328 	$16,323 	$25,627 	$41,950 	$15,452 	$24,657 	$40,109
Products sold by the Diagnostics segment include various types of
diagnostic tests to detect COVID-19. Abbott’s COVID-19 testing-
related sales totaled $297 million in 2025, $747 million in 2024, and
$1.6 billion in 2023.
Abbott recognizes revenue from product sales upon the transfer
of control, which is generally upon shipment or delivery, depending
on the delivery terms set forth in the customer contract. For
maintenance agreements that provide service beyond Abbott’s
standard warranty and other service agreements, revenue is rec-
ognized ratably over the contract term. A time-based measure of
progress appropriately reflects the transfer of services to the
customer. Payment terms between Abbott and its customers vary
by the type of customer, country of sale, and the products or
services offered. The term between invoicing and the payment
due date is not significant.
Management exercises judgment in estimating variable consider-
ation. Provisions for discounts, rebates, and sales incentives to
customers, returns, and other adjustments are provided for in the
period the related sales are recorded. Sales incentives to customers
are not material. Historical data is readily available and reliable and
is used for estimating the amount of the reduction in gross sales.
Abbott provides rebates to government agencies, wholesalers,
group purchasing organizations and other private entities.
Rebate amounts are usually based upon the volume of purchases
using contractual or statutory prices for a product. Factors used in
the rebate calculations include the identification of which products
have been sold subject to a rebate, which customer or government
agency price terms apply, and the estimated lag time between sale
and payment of a rebate. Using historical trends, adjusted for cur-
rent changes, Abbott estimates the amount of the rebate that will
be paid, and records the liability as a reduction of gross sales when
Abbott records its sale of the product. Settlement of the rebate
generally occurs from one to six months after sale. Abbott regularly
analyzes the historical rebate trends and makes adjustments to
reserves for changes in trends and terms of rebate programs.
Historically, adjustments to prior years’ rebate accruals have not
been material to net earnings.
Other allowances charged against gross sales include cash
discounts and returns, which are not significant. Cash discounts
are known within 15 to 30 days of sale and therefore can be reliably
estimated. Returns can be reliably estimated because Abbott’s
historical returns are low, and because sales return terms and other
sales terms have remained relatively unchanged for several periods.
Product warranties are also not significant.

-- 47 of 86 --

46
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Abbott also applies judgment in determining the timing of revenue
recognition related to contracts that include multiple performance
obligations. The total transaction price of the contract is allocated
to each performance obligation in an amount based on the esti-
mated relative standalone selling prices of the promised goods or
services underlying each performance obligation. For goods or
services for which observable standalone selling prices are not
available, Abbott uses an expected cost plus a margin approach
to estimate the standalone selling price of each performance
obligation.
Remaining Performance Obligations
As of December 31, 2025, the estimated revenue expected to be
recognized in the future related to performance obligations that
are unsatisfied (or partially unsatisfied) was $6.1 billion in the
Diagnostic Products segment and $444 million in the Medical
Devices segment. Abbott expects to recognize revenue on approxi-
mately 52 percent of these remaining performance obligations over
the next 24 months, approximately 17 percent over the subsequent
12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale
of reagents/consumables in contracts with minimum purchase
obligations, extended warranty or service obligations related to
previously sold equipment, and remote monitoring services related
to previously implanted devices. Abbott has applied the practical
expedient described in ASC 606-10-50-14 and has not included
remaining performance obligations related to contracts with original
expected durations of one year or less in the amounts above.
Assets Recognized for Costs to Obtain a Contract with a Customer
Abbott has applied the practical expedient in ASC 340-40-25-4
and records as an expense the incremental costs of obtaining
contracts with customers in the period of occurrence when the
amortization period of the asset that Abbott otherwise would have
recognized is one year or less. Upfront commission fees paid to
sales personnel as a result of obtaining or renewing contracts with
customers are incremental to obtaining the contract. Abbott capi-
talizes these amounts as contract costs. Capitalized commission
fees are amortized based on the contract duration to which the
assets relate, which ranges from two to ten years. The amounts
as of December 31, 2025, and 2024 were not significant.
Additionally, the cost of transmitters provided to customers that
use Abbott’s remote monitoring service with respect to certain
medical devices are capitalized as contract costs. Capitalized
transmitter costs are amortized based on the timing of the transfer
of services to which the assets relate, which typically ranges from
eight to ten years. The amounts as of December 31, 2025, and 2024
were not significant.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Consolidated
Balance Sheet at the net amount expected to be collected.
Contract assets primarily relate to Abbott’s conditional right to
consideration for work completed but not billed at the reporting
date. Contract assets at the beginning and end of the period, as
well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from
customers in advance of performance under the contract. Abbott’s
contract liabilities arise primarily in the Medical Devices reportable
segment when payment is received upfront for various multi-period
extended service arrangements. Changes in the contract liabilities
during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2023 	$ 545
Unearned revenue from cash received during the period 	483
Revenue recognized related to contract liability balance 	(460)
Balance at December 31, 2024 	568
Unearned revenue from cash received during the period 	488
Revenue recognized related to contract liability balance 	(423)
Balance at December 31, 2025 	$ 633
Note 4 — Supplemental Financial Information
Other (income) expense, net, for 2025, 2024, and 2023 includes
$590 million, $542 million, and $498 million of income, respectively,
related to the non-service cost components of the net periodic
benefit costs associated with the pension and post-retirement
medical plans.
In 2024, Abbott sold a non-core business related to its Established
Pharmaceutical Products segment. Abbott recorded a loss of
$143 million on the sale in Other (income) expense, net in its
Consolidated Statement of Earnings. Net assets which primarily
related to inventory and net property and equipment, and had a
carrying value of $28 million, were included in the sale. The loss on
the sale also included $116 million of cumulative foreign currency
translation adjustment previously recorded in Accumulated other
comprehensive income (loss).
The following summarizes the activity related to the allowance for
doubtful accounts:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2023 	$241
Provisions/charges to income 	61
Amounts charged off and other deductions 	(55)
Balance at December 31, 2024 	247
Provisions/charges to income 	75
Amounts charged off and other deductions 	(32)
Balance at December 31, 2025 	$290
The allowance for doubtful accounts reflects the current estimate
of credit losses expected to be incurred over the life of the
accounts receivable. Abbott considers various factors in establish-
ing, monitoring, and adjusting its allowance for doubtful accounts,

-- 48 of 86 --

47
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
including the aging of the accounts and aging trends, the historical
level of charge-offs, and specific exposures related to particular
customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining credit
limits for customers and establishing adequate allowances.
The detail of various balance sheet components is as follows:
(in millions)
December 31 	2025 	2024
Long-term Investments:
Equity securities 	$597 	$553
Other 	321 	333
Total 	$918 	$886
Abbott’s equity securities as of December 31, 2025, and
December 31, 2024, include $323 million and $313 million, respec-
tively, of investments in mutual funds that are held in a rabbi trust.
These investments, which are specifically designated as available
for the purpose of paying benefits under a deferred compensation
plan, are not available for general corporate purposes and are
subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2025,
with a carrying value of $131 million that are accounted for under
the equity method of accounting and other equity investments with
a carrying value of $124 million that do not have a readily determin-
able fair value.
(in millions)
December 31 	2025 	2024
Other Accrued Liabilities:
Accrued rebates payable to government agencies 	$ 682 	$ 621
Accrued other rebates 	1,257 	1,098
All other 	3,873 	3,424
Total 	$5,812 	$5,143
(in millions)
December 31 	2025 	2024
Post-employment Obligations and
Other Long-term Liabilities:
Defined benefit pension plans and post-employment
medical and dental plans for significant plans 	$2,125 	$1,880
Net unrecognized tax benefits 	1,397 	857
Deferred income taxes 	559 	512
Operating lease liabilities 	931 	896
All other 	2,538 	2,586
Total 	$7,550 	$6,731
Note 5 — Accumulated Other Comprehensive Income (Loss)
The components of the changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
(in millions)
Cumulative Foreign
Currency Translation
Adjustments
Net Actuarial Gains
(Losses) and Prior
Service (Costs)
and Credits
Cumulative Gains
(Losses) on Derivative
Instruments Designated
as Cash Flow Hedges 	Total
Balance at December 31, 2023 	$(6,504) 	$(1,376) 	$ 41 	$(7,839)
Other comprehensive income (loss) before reclassifications 	(1,117) 	757 	245 	(115)
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	116 	8 	(76) 	48
Net current period other comprehensive income (loss) 	(1,001) 	765 	169 	(67)
Balance at December 31, 2024 	(7,505) 	(611) 	210 	(7,906)
Other comprehensive income (loss) before reclassifications 	1,574 	610 	(227) 	1,957
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	— 	(52) 	(52)
Net current period other comprehensive income (loss) 	1,574 	610 	(279) 	1,905
Balance at December 31, 2025 	$(5,931) 	$ 	(1) 	$ (69) 	$(6,001)
(a) (Income) loss amounts reclassified from accumulated other comprehensive income related to cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior
service cost are included as a component of net periodic benefit cost. See Note 14 — Post-Employment Benefits for additional information. The reclassification of $116 million out of
Accumulated other comprehensive income (loss) in 2024 is included in the loss related to the sale of a non-core business included in Other (income) expense.

-- 49 of 86 --

48
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Note 6 — Business Acquisitions
On November 19, 2025, Abbott entered into a definitive agreement
to acquire Exact Sciences Corporation (Exact Sciences), which is
expected to enable Abbott to enter the cancer diagnostics market.
The acquisition is subject to customary closing conditions, includ-
ing the approval of Exact Sciences shareholders, and obtaining the
required regulatory clearances. Under the terms of the agreement,
Abbott will pay $105 per common share in cash at the completion
of the transaction, representing a total equity value of approxi-
mately $21 billion and an estimated enterprise value of $23 billion.
Abbott’s financing contemplates absorption of Exact Sciences’
estimated $1.8 billion of net debt.
On November 19, 2025, Abbott obtained a commitment for a
364-day senior unsecured bridge term loan facility for an amount
not to exceed $20.0 billion in conjunction with its pending acquisi-
tion of Exact Sciences. While Abbott plans to fund this transaction
with cash on hand and borrowings, the bridge facility will provide
back-up financing.
On September 22, 2023, Abbott completed the acquisition of
Bigfoot Biomedical, Inc. (Bigfoot), which furthers Abbott’s efforts to
develop connected solutions for making diabetes management
more personal and precise. The purchase price, the final allocation
of acquired assets and liabilities, and the revenue and net income
contributed by Bigfoot since the date of acquisition are not material
to Abbott’s consolidated financial statements.
On April 27, 2023, Abbott completed the acquisition of
Cardiovascular Systems, Inc. (CSI) for $20 per common share,
which equated to a purchase price of $851 million. The transaction
was funded with cash on hand and accounted for as a business
combination. CSI’s atherectomy system, which is used in treating
peripheral and coronary artery disease, adds complementary
technologies to Abbott’s portfolio of vascular device offerings.
The final allocation of the purchase price of the CSI acquisition
resulted in the recording of two non-deductible developed technol-
ogy intangible assets totaling $305 million; a non-deductible IPR&D
asset of $15 million, which will be accounted for as an indefinite-
lived intangible asset until regulatory approval or discontinuation;
non-deductible goodwill of $369 million; net deferred tax assets
of $46 million and other net assets of $116 million. The goodwill is
identifiable to the Medical Devices reportable segment and is
attributable to expected synergies from combining operations,
as well as intangible assets that do not qualify for separate
recognition. Revenues and earnings of CSI included in Abbott’s
consolidated financial statements since the acquisition date are
not material to Abbott’s consolidated revenue and earnings.
Note 7 — Goodwill and Intangible Assets
The total amount of reported goodwill was $24.0 billion at
December 31, 2025, and $23.1 billion at December 31, 2024.
Foreign currency translation adjustments increased goodwill by
$880 million in 2025 and decreased goodwill by $533 million in
2024. In 2025, business acquisitions increased goodwill by
$47 million. The amount of goodwill related to reportable segments
at December 31, 2025, was $2.7 billion for the Established
Pharmaceutical Products segment, $285 million for the Nutritional
Products segment, $3.6 billion for the Diagnostic Products seg-
ment, and $17.4 billion for the Medical Devices segment. There were
no reductions of goodwill relating to impairments in 2025 and 2024.
The gross amount of amortizable intangible assets, primarily
product rights and technology, was $27.6 billion and $27.1 billion as
of December 31, 2025, and 2024, respectively. In 2025, the gross
amount of amortizable intangible assets increased by $48 million
due to a business acquisition and other transactions. Accumulated
amortization was $23.3 billion and $21.3 billion as of December 31,
2025, and 2024, respectively. Foreign currency translation adjust-
ments increased intangible assets by $86 million in 2025 and
decreased intangible assets by $78 million in 2024. The estimated
annual amortization expense for intangible assets recorded at
December 31, 2025, is approximately $1.5 billion in 2026, $1.2 billion
in 2027, $650 million in 2028, $608 million in 2029, and $363 million
in 2030. Amortizable intangible assets are amortized over 2 to
20 years.
Indefinite-lived intangible assets, which relate to IPR&D acquired in
a business combination and consolidated variable interest entities,
were $1.2 billion and $784 million at December 31, 2025, and 2024,
respectively. In 2025, IPR&D increased $428 million, related to
transactions in the Medical Devices reportable segment. In 2024,
IPR&D decreased by $39 million due to charges recorded in
Research and development in the Consolidated Statement of
Earnings for the impairment of an indefinite-lived intangible asset
related to the Medical Devices reportable segment, and was par-
tially offset by a $35 million increase resulting from the finalization
of purchase accounting related to a business acquisition.

-- 50 of 86 --

49
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Note 8 — Restructuring Plans
In 2025, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
its Diagnostics, Nutritionals, Established Pharmaceuticals, and
Medical Devices businesses. Abbott recorded employee related
severance and other charges of $274 million, of which $109 million
was recorded in Cost of products sold, $53 million was recorded
in Research and development, and $112 million was recorded in
Selling, general, and administrative expenses. Payments related to
these actions totaled $94 million in 2025 and the remaining liabili-
ties totaled $180 million at December 31, 2025. In addition, in 2025,
Abbott recognized fixed asset impairment charges of $28 million
related to these restructuring plans.
In 2024, Abbott management approved plans to streamline certain
operations in order to reduce costs and improve efficiencies in its
Diagnostics, Medical Devices, Established Pharmaceuticals, and
Nutritionals businesses, including the discontinuation of its
ZonePerfect® product line. Abbott recorded employee related
severance and other charges of $129 million, of which $62 million
was recorded in Cost of products sold, $21 million was recorded in
Research and development, and $46 million was recorded in
Selling, general and administrative expenses. In addition, Abbott
recognized inventory related charges of $34 million and fixed asset
impairment charges of $12 million related to these restructur-
ing plans.
The following summarizes the activity related to the 2024
restructuring actions and the status of the related accruals as
of December 31, 2025:
(in millions)
Restructuring charges in 2024 	$129
Payments and other adjustments 	(32)
Accrued balance at December 31, 2024 	97
Payments and other adjustments 	(70)
Accrued balance at December 31, 2025 	$ 27
In 2023, Abbott management approved plans to restructure
various operations in order to reduce costs in its Medical Devices,
Diagnostics, and Established Pharmaceuticals businesses. Abbott
recorded employee related severance and other charges of
$144 million, of which $56 million was recorded in Cost of products
sold, $22 million was recorded in Research and development, and
$66 million was recorded in Selling, general and administrative
expenses. In addition, Abbott recognized fixed asset impairment
and inventory related charges of $31 million related to these
restructuring plans.
The following summarizes the activity related to the 2023
restructuring actions and the status of the related accruals as
of December 31, 2025:
(in millions)
Restructuring charges in 2023 	$144
Payments and other adjustments 	(65)
Accrued balance at December 31, 2023 	79
Payments and other adjustments 	(58)
Accrued balance at December 31, 2024 	21
Payments and other adjustments 	(15)
Accrued balance at December 31, 2025 	$ 	6
Note 9 — Incentive Stock Program
The 2017 Incentive Stock Program authorizes the granting of non-
qualified stock options, restricted stock awards, restricted stock
units, performance awards, foreign benefits, and other share-based
awards. Stock options and restricted stock awards and units
comprise the majority of benefits that have been granted and are
currently outstanding under this program and a prior program. In
2025, Abbott granted 1,486,579 stock options, 365,499 restricted
stock awards, and 4,439,430 restricted stock units under this
program.
Under Abbott’s stock incentive programs, the purchase price of
shares under option must be at least equal to the fair market value
of the common stock on the date of grant, and the maximum term
of an option is 10 years. Options generally vest equally over three
years. Restricted stock awards generally vest over three years, with
no more than one-third of the award vesting in any one year upon
Abbott reaching a minimum return on equity target. Restricted
stock units vest over three years and, upon vesting, the recipient
receives one share of Abbott stock for each vested restricted stock
unit. The aggregate fair market value of options and restricted stock
awards and units is recognized as expense over the requisite ser-
vice period, which may be shorter than the vesting period if an
employee is retirement eligible. Forfeitures are estimated at the
time of grant. Restricted stock awards and settlement of vested
restricted stock units are issued out of treasury shares. Abbott
generally issues new shares for exercises of stock options. As a
policy, Abbott does not purchase its shares relating to its share-
based programs.
In April 2017, Abbott’s shareholders authorized the 2017 Incentive
Stock Program under which a maximum of 170 million shares were
available for issuance. At December 31, 2025, approximately
51 million shares remained available for future issuance.

-- 51 of 86 --

50
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The following table summarizes restricted stock awards and units
activity for the year ended December 31, 2025.
Share Units
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31, 2024 	10,509,572 	$113.48
Granted 	4,804,929 	135.22
Vested 	(5,191,859) 	113.61
Forfeited 	(580,907) 	121.81
Outstanding at December 31, 2025 	9,541,735 	$123.85
The fair market value of restricted stock awards and units vested
in 2025, 2024, and 2023 was $685 million, $570 million, and
$536 million, respectively.
The total intrinsic value of options exercised in 2025, 2024, and
2023 was $389 million, $238 million, and $102 million, respectively.
The total unrecognized compensation cost related to all share-
based compensation plans at December 31, 2025, amounted to
$467 million, which is expected to be recognized over the next
three years.
Total non-cash stock compensation expense charged against
income in 2025, 2024, and 2023 for share-based plans totaled
$664 million, $673 million, and $644 million, respectively, and the
tax benefit recognized was $223 million, $181 million, and
$144 million, respectively. Stock compensation cost capitalized
as part of inventory is not significant.
The table below summarizes the fair value of an option granted in
2025, 2024, and 2023 and the assumptions included in the Black-
Scholes option-pricing model used to estimate the fair value:
2025 	2024 	2023
Fair value 	$36.27 	$31.10 	$26.87
Risk-free interest rate 	4.2% 	4.3% 	4.0%
Average life of options (years) 	6.0 	6.0 	6.0
Volatility 	24.8% 	25.2% 	24.4%
Dividend yield 	1.7% 	1.9% 	1.9%
The risk-free interest rate is based on the rates available at the time
of the grant for zero-coupon U.S. government issues with a remain-
ing term equal to the option’s expected life. The average life of an
option is based on both historical and projected exercise and
lapsing data. Expected volatility is based on implied volatilities from
traded options on Abbott’s stock and historical volatility of Abbott’s
stock over the expected life of the option. Dividend yield is based
on the option’s exercise price and annual dividend rate at the time
of grant.
Note 10 — Debt and Lines of Credit
The following is a summary of long-term debt at December 31:
(in millions) 	2025 	2024
2.95% Notes, due 2025 	$ 	— 	$ 1,000
3.875% Notes, due 2025 	— 	500
1.50% Notes, due 2026 	1,344 	1,188
3.75% Notes, due 2026 	1,700 	1,700
0.375% Notes, due 2027 	695 	615
1.15% Notes, due 2028 	650 	650
5-year term loan due 2029 	589 	583
1.40% Notes, due 2030 	650 	650
4.75% Notes, due 2036 	1,650 	1,650
6.15% Notes, due 2037 	547 	547
6.00% Notes, due 2039 	515 	515
5.30% Notes, due 2040 	694 	694
4.75% Notes, due 2043 	700 	700
4.90% Notes, due 2046 	3,250 	3,250
Unamortized debt issuance costs 	(47) 	(53)
Other, including fair value adjustments
relating to interest rate hedge contracts
designated as fair value hedges 	(8) 	(64)
Total carrying amount of long-term debt 	12,929 	14,125
Less: Current portion 	3,033 	1,500
Total long-term portion 	$ 9,896 	$12,625
On November 19, 2025, Abbott obtained a commitment for a
364-day senior unsecured bridge term loan facility for an amount
not to exceed $20.0 billion in conjunction with its pending acquisi-
tion of Exact Sciences. While Abbott plans to fund this transaction
with cash on hand and borrowings, the bridge facility will provide
back-up financing.
On September 15, 2025, Abbott repaid the $500 million outstanding
principal amount of its 3.875% Notes upon maturity. On March 17,
2025, Abbott repaid the $1.0 billion outstanding principal amount of
its 2.95% Notes upon maturity. On November 19, 2024, Abbott
The following table summarizes stock option activity for the year ended December 31, 2025, and the outstanding stock options as of
December 31, 2025.
(intrinsic values in millions) 	Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Life (Years)
Aggregate
Intrinsic Value
Outstanding at December 31, 2024 	26,546,749 	$ 80.70 	4.6 	$906
Granted 	1,486,579 	135.26
Exercised 	(5,337,114) 	55.36
Lapsed 	(107,419) 	121.45
Outstanding at December 31, 2025 	22,588,795 	$ 90.09 	4.4 	$810
Exercisable at December 31, 2025 	19,426,784 	$ 84.71 	3.8 	$788

-- 52 of 86 --

51
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
repaid the €590 million outstanding principal amount of its 0.10%
Notes upon maturity. The repayment equated to approximately
$640 million. On November 30, 2023, Abbott repaid the $1.05 billion
outstanding principal amount of its 3.40% Notes upon maturity.
On September 27, 2023, Abbott repaid the €1.14 billion outstanding
principal amount of its 0.875% Notes upon maturity. The repayment
equated to approximately $1.2 billion. In September 2023, Abbott
repaid approximately $197 million of debt assumed as part of a prior
business acquisition.
In 2024, Abbott modified its existing, yen-denominated 5-year term
loan scheduled to mature in November 2024. The amended terms
included a net increase in principal debt from ¥59.8 billion to
¥92.0 billion, with a new maturity date in June 2029. The modified,
5-year term loan bears interest at the Tokyo Interbank Offered Rate
(TIBOR) plus a fixed spread, and the interest rate is reset quarterly.
The net proceeds equated to approximately $201 million.
Abbott has readily available financial resources, including unused
lines of credit that support commercial paper borrowing arrange-
ments and provide Abbott with the ability to borrow up to $5 billion
on an unsecured basis. In 2024, Abbott terminated its 2020 Five
Year Credit Agreement (2020 Agreement) and entered into a new
Five Year Credit Agreement (Revolving Credit Agreement). There
were no outstanding borrowings under the 2020 Agreement at the
time of its termination. Any borrowings under the Revolving Credit
Agreement will mature and be payable on January 29, 2029, and
will bear interest, at Abbott’s option, based on either a base rate
or Secured Overnight Financing Rate (SOFR), plus an applicable
margin based on Abbott’s credit ratings.
Principal payments required on long-term debt outstanding at
December 31, 2025, are $3.0 billion in 2026, $700 million in 2027,
$653 million in 2028, $591 million in 2029, $650 million in 2030,
and $7.4 billion in 2031 and thereafter.
At December 31, 2025, Abbott’s long-term debt rating was AA- by
S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott
expects to maintain an investment grade rating.
Note 11 — Leases
Leases where Abbott is the Lessee
Abbott has entered into operating leases as the lessee for office
space, manufacturing facilities, R&D laboratories, warehouses,
vehicles, and equipment. Finance leases are not significant.
Abbott’s operating leases generally have remaining lease terms
of 1 to 10 years. Some leases include options to extend beyond the
original lease term, generally up to 10 years and some include
options to terminate early. These options have been included in the
determination of the lease liability when it is reasonably certain
that the option will be exercised.
For all of its asset classes, Abbott elected the practical expedient
allowed under FASB ASC No. 842, “Leases” to account for each
lease component (e.g., the right to use office space) and the
associated non-lease components (e.g., maintenance services) as a
single lease component. Abbott also elected the short-term lease
accounting policy for all asset classes; therefore, Abbott is not
recognizing a lease liability or right of use (ROU) asset for any lease
that, at the commencement date, has a lease term of 12 months or
less and does not include an option to purchase the underlying
asset that Abbott is reasonably certain to exercise.
As Abbott’s leases typically do not provide an implicit rate,
the interest rate used to determine the present value of the pay-
ments under each lease typically reflects Abbott’s incremental
borrowing rate based on information available at the lease
commencement date.
The following table provides information related to Abbott’s
operating leases:
(in millions, except weighted averages) 	2025 	2024 	2023
Operating lease cost (a) 	$391 	$366 	$356
Cash paid for amounts included in the
measurement of operating lease liabilities 	315 	300 	276
ROU assets arising from entering into new
operating lease obligations 	300 	253 	253
Weighted average remaining lease term at
December 31 (in years) 	7 	7 	7
Weighted average discount rate at December 31 	3.9% 	3.6% 	3.4%
(a) Includes short-term lease expense and variable lease costs, which were immaterial in
the years ended December 31, 2025, 2024, and 2023.
Future minimum lease payments under non-cancellable operating
leases as of December 31, 2025, were as follows:
(in millions)
2026 	$ 316
2027 	254
2028 	197
2029 	151
2030 	111
Thereafter 	362
Total future minimum lease payments – undiscounted 	1,391
Less: imputed interest 	(184)
Present value of lease liabilities 	$1,207
The following table summarizes the amounts and location of oper-
ating lease ROU assets and lease liabilities:
(in millions)
December 31 	2025 	2024 	Balance Sheet Caption
Operating Lease –
ROU Asset
$1,126 	$1,075 	Deferred income taxes
and other assets
Operating Lease Liability:
Current 	$ 276 	$ 254 	Other accrued liabilities
Non-current 	931 	896 	Post-employment
obligations and other
long-term liabilities
Total Liability 	$1,207 	$1,150
Leases where Abbott is the Lessor
Certain assets, primarily diagnostic instruments, are leased to
customers under contractual arrangements that typically include
an operating or sales-type lease as well as performance obligations
for reagents and other consumables. Sales-type leases are not
significant. Contract terms vary by customer and may include
options to terminate the contract or options to extend the contract.
Where instruments are provided under operating lease arrange-
ments, some portion or the entire lease revenue may be variable

-- 53 of 86 --

52
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
and subject to subsequent non-lease component (e.g., reagent)
sales. The allocation of revenue between the lease and non-lease
components is based on standalone selling prices. Operating lease
revenue represented less than 3 percent of Abbott’s total net sales
in the years ended December 31, 2025, 2024, and 2023.
Assets related to operating leases are reported within Net property
and equipment on the Consolidated Balance Sheet. The original
cost and the net book value of such assets were $4.6 billion and
$2.1 billion, respectively, as of December 31, 2025, and $3.9 billion
and $1.8 billion, respectively, as of December 31, 2024.
Note 12 — Financial Instruments, Derivatives, and
Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates, primarily related to anticipated intercom-
pany purchases by subsidiaries whose functional currencies are
not the U.S. dollar. These contracts, with gross notional amounts
totaling $7.4 billion at December 31, 2025, and $7.0 billion at
December 31, 2024, are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign exchange
rates and are recorded at fair value. Accumulated gains and losses
as of December 31, 2025, will be included in Cost of products sold
at the time the products are sold, generally through the next
twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to
manage currency exposures for foreign currency denominated
third-party trade payables and receivables, and for intercompany
loans and trade accounts payable where the receivable or payable
is denominated in a currency other than the functional currency of
the entity. For intercompany loans, the contracts require Abbott to
sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and European currencies. For
intercompany and trade payables and receivables, the currency
exposures are primarily the U.S. dollar and European currencies.
At December 31, 2025, and 2024, Abbott held gross notional
amounts of $13.1 billion and $16.2 billion, respectively, of such
foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of
$589 million and $583 million as of December 31, 2025, and
December 31, 2024, respectively, as a hedge of the net investment
in certain foreign subsidiaries. The change in the value of the debt is
due to changes in foreign exchange rates, recorded in Accumulated
other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts to manage its
exposure to changes in the fair value of fixed-rate debt. These
contracts are designated as fair value hedges of the variability of
the fair value of fixed-rate debt due to changes in the long-term
benchmark interest rates. The effect of the hedge is to change a
fixed-rate interest obligation to a variable rate for that portion of
the debt. Abbott records the contracts at fair value and adjusts the
carrying amount of the fixed-rate debt by an offsetting amount.
Abbott had interest rate contracts totaling $1.2 billion at
December 31, 2025, and $2.2 billion at December 31, 2024.
The following table summarizes the amounts and location of certain derivative financial instruments as of December 31:
(in millions)
Fair Value—Assets 	Fair Value—Liabilities
2025 	2024 	Balance Sheet Caption 	2025 	2024 	Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current 	$ — 	$ — 	Deferred income taxes
and other assets
$ — 	$ 51 	Post-employment
obligations and other
long-term liabilities
Current 	— 	1 	Prepaid expenses
and other receivables
19 	— 	Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments 	57 	243 	Prepaid expenses
and other receivables
231 	19 	Other accrued liabilities
Others not designated as hedges 	51 	147 	Prepaid expenses
and other receivables
66 	112 	Other accrued liabilities
Debt designated as a hedge of net investment in a
foreign subsidiary
— 	— 	n/a 	589 	583 	Long-term debt
$108 	$391 	$905 	$765
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt desig-
nated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and
location of income (expense) and gain (loss) reclassified into income.
(in millions)
Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income Statement Caption	2025 	2024 	2023 	2025 	2024 	2023
Foreign currency forward exchange contracts
designated as cash flow hedges
$(282) 	$347 	$(22) 	$63 	$103 	$187 	Cost of products sold
Debt designated as a hedge of net investment in a
foreign subsidiary
(6) 	37 	27 	n/a 	n/a 	n/a 	n/a
Interest rate swaps designated as fair value hedges 	n/a 	n/a 	n/a 	32 	44 	61 	Interest expense
Income (expense) and Gain (loss)
Reclassified into Income

-- 54 of 86 --

53
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Gains of $104 million and $131 million, and a loss of $44 million were
recognized in 2025, 2024, and 2023, respectively, related to foreign
currency forward exchange contracts not designated as hedges.
These amounts are reported in the Consolidated Statement of
Earnings on the Net foreign exchange (gain) loss line.
The interest rate swaps are designated as fair value hedges of
the variability of the fair value of fixed-rate debt due to changes
in the long-term benchmark interest rates. The hedged debt is
marked to market, offsetting the effect of marking the interest
rate swaps to market.
The carrying values and fair values of certain financial instruments
as of December 31 are shown in the table below. The carrying values
of all other financial instruments approximate their estimated fair
values. The counterparties to financial instruments consist of select
major international financial institutions. Abbott does not expect any
losses from nonperformance by these counterparties.
(in millions)
2025 	2024
Carrying Value 	Fair Value 	Carrying Value 	Fair Value
Long-term Investment Securities:
Equity securities 	$ 	597 	$ 	597 	$ 	553 	$ 	553
Other 	321 	321 	333 	333
Total long-term debt 	(12,929) 	(12,772) 	(14,125) 	(13,710)
Foreign Currency Forward Exchange Contracts:
Receivable position 	108 	108 	390 	390
(Payable) position 	(297) 	(297) 	(131) 	(131)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	1 	1
(Payable) position 	(19) 	(19) 	(51) 	(51)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted Prices in
Active Markets
Significant Other
Observable
Inputs
Significant
Unobservable
Inputs
December 31, 2025:
Equity securities 	$ 342 	$342 	$ 	— 	$ —
Foreign currency forward exchange contracts 	108 	— 	108 	—
Total Assets 	$ 450 	$342 	$ 108 	$ —
Fair value of hedged long-term debt 	$1,133 	$ — 	$1,133 	$ —
Interest rate swap derivative financial instruments 	19 	— 	19 	—
Foreign currency forward exchange contracts 	297 	— 	297 	—
Contingent consideration related to business combinations 	1 	— 	— 	1
Total Liabilities 	$1,450 	$ — 	$1,449 	$ 1
December 31, 2024:
Equity securities 	$ 323 	$323 	$ 	— 	$ —
Interest rate swap derivative financial instruments 	1 	— 	1 	—
Foreign currency forward exchange contracts 	390 	— 	390 	—
Total Assets 	$ 714 	$323 	$ 391 	$ —
Fair value of hedged long-term debt 	$2,096 	$ — 	$2,096 	$ —
Interest rate swap derivative financial instruments 	51 	— 	51 	—
Foreign currency forward exchange contracts 	131 	— 	131 	—
Contingent consideration related to business combinations 	38 	— 	— 	38
Total Liabilities 	$2,316 	$ — 	$2,278 	$38

-- 55 of 86 --

54
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The fair value of foreign currency forward exchange contracts is
determined using a market approach, which utilizes values for
comparable derivative instruments. The fair value of the debt was
determined based on the face value of the debt adjusted for the fair
value of the interest rate swaps, which is based on a discounted
cash flow analysis using significant other observable inputs.
Contingent consideration relates to businesses acquired by Abbott.
The fair value of the contingent consideration was determined
based on independent appraisals at the time of acquisition,
adjusted for the time value of money and other changes in fair
value. The decrease in the amount of contingent consideration from
December 31, 2024, reflects a contingent consideration payment
related to a previous business combination.
Note 13 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for
investigation and cleanup costs at a number of locations in the
United States and Puerto Rico under federal and state remediation
laws and is investigating potential contamination at a number of
company-owned locations. Abbott has recorded an estimated
cleanup cost for each site for which management believes Abbott
has a probable loss exposure. No individual site cleanup exposure
is expected to exceed $4 million, and the aggregate cleanup expo-
sure is not expected to exceed $10 million.
Abbott has been named as a defendant in a number of lawsuits
alleging that its preterm infant formula and human milk fortifier
products that contain cow’s milk ingredients cause an intestinal
disease known as necrotizing enterocolitis (NEC) and inadequately
warn about the risk of NEC. These lawsuits claim that certain
preterm infants suffered injury or death as a result of contracting
NEC. Two cases have gone to trial. In a Missouri state case, a jury
awarded a plaintiff $495 million in damages. In a second Missouri
state court case, a jury found in Abbott’s favor, and the judge later
ordered a new trial in that matter. The two Missouri cases are on
appeal. In the first three federal Multidistrict Litigation (MDL) “bell-
wether” cases, the U.S. District Court for the Northern District of
Illinois granted summary judgment in favor of Abbott. The plaintiff
in the first case has filed an appeal. Abbott stands by its products
and the information it provided about them. Abbott does not believe
that it is probable that a material loss will be incurred related to
these lawsuits and therefore, no reserves have been recorded.
Given the uncertainty as to the possible outcome in each of these
lawsuits, Abbott is unable to reasonably estimate a range of possi-
ble loss related to these lawsuits.
Abbott is involved in various claims and legal proceedings, and
Abbott estimates the range of possible loss for its legal proceed-
ings and environmental exposures to be from approximately
$170 million to $180 million. The recorded accrual balance at
December 31, 2025, for these proceedings and exposures was
approximately $175 million and included $165 million for legal
reserves related to a negotiated settlement. This accrual represents
management’s best estimate of probable loss, as defined by FASB
ASC No. 450, “Contingencies.” Within the next year, legal proceed-
ings may occur that may result in a change in the estimated loss
accrued by Abbott. While it is not feasible to predict the outcome
of all such proceedings and exposures with certainty, management
believes that their ultimate disposition should not have a material
adverse effect on Abbott’s financial position, cash flows, or results
of operations, except for the cases discussed in the second para-
graph of this note, the resolution of which could be material to
Abbott’s financial position, cash flows, or results of operations.
Note 14 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution,
and medical and dental plans. Information for Abbott’s major
defined benefit plans and post-employment medical and dental
benefit plans is as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2025 	2024 	2025 	2024
Projected benefit
obligations, January 1 	$ 9,450 	$10,030 	$ 1,166 	$1,181
Service cost — benefits
earned during the year 	216 	242 	43 	39
Interest cost on projected
benefit obligations 	493 	469 	68 	54
(Gains) losses, primarily
changes in discount rates,
plan design changes, law
changes and differences
between actual and
estimated healthcare costs 	(95) 	(763) 	186 	(33)
Benefits paid 	(433) 	(398) 	(78) 	(73)
Other, including foreign
currency translation 	249 	(130) 	1 	(2)
Projected benefit
obligations, December 31 	$ 9,880 	$9,450 	$ 1,386 	$1,166
Plan assets at fair value,
January 1 	$14,143 	$13,085 	$ 	277 	$ 288
Actual return (loss)
on plan assets 	1,891 	1,259 	53 	26
Company contributions 	309 	349 	86 	36
Benefits paid 	(433) 	(398) 	(78) 	(73)
Other, including foreign
currency translation 	337 	(152) 	— 	—
Plan assets at fair value,
December 31 	$16,247 	$14,143 	$ 	338 	$ 277
Projected benefit obligations
less (greater) than plan
assets, December 31 	$ 6,367 	$ 4,693 	$(1,048) 	$ (889)
Long-term assets 	$ 7,490 	$ 5,724 	$ 	— 	$ 	—
Short-term liabilities 	(44) 	(38) 	(2) 	(2)
Long-term liabilities 	(1,079) 	(993) 	(1,046) 	(887)
Net asset (liability) 	$ 6,367 	$ 4,693 	$(1,048) 	$ (889)
Amounts Recognized in
Accumulated Other
Comprehensive
Income (loss):
Actuarial (gains) losses, net 	$ 	(156) $ 	772 	$ 	188 	$ 	29
Prior service costs (credits) 	4 	5 	1 	(8)
Total 	$ 	(152) $ 	777 	$ 	189 	$ 	21

-- 56 of 86 --

55
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The $95 million of defined benefit plan gains in 2025 that decreased
the projected benefit obligations primarily reflect the favorable
impact of actual asset returns in excess of expected returns and
the year-over-year increase in discount rates used to measure the
obligations. The $186 million of medical and dental plan loss that
increased the projected benefit obligations primarily reflects higher
claims. The $763 million of defined benefit plan gains and
$33 million of medical and dental plan gains in 2024 that decreased
the projected benefit obligations primarily reflect the year-over-
year increase in the discount rates used to measure the obligations.
The projected benefit obligations for non-U.S. defined benefit plans
were $2.4 billion and $2.3 billion at December 31, 2025, and 2024,
respectively. The accumulated benefit obligations for all defined
benefit plans were $9.2 billion and $8.7 billion at December 31,
2025, and 2024, respectively.
For plans where the projected benefit obligations exceeded plan
assets at December 31, 2025 and 2024, the projected benefit obli-
gations and the aggregate plan assets were as follows:
(in millions) 	2025 	2024
Projected benefit obligation 	$1,275 	$1,180
Fair value of plan assets 	152 	149
For plans where the accumulated benefit obligations exceeded
plan assets at December 31, 2025, and 2024, the aggregate accu-
mulated benefit obligations, the projected benefit obligations and
the aggregate plan assets were as follows:
(in millions) 	2025 	2024
Accumulated benefit obligation 	$1,196 	$1,112
Projected benefit obligation 	1,275 	1,180
Fair value of plan assets 	152 	149
Retirement plans consist of defined benefit, defined contribution,
and medical and dental plans. Net periodic benefit costs, other than
service costs, are recognized in the Other (income) expense, net
line of the Consolidated Statement of Earnings. The components of
the net periodic benefit cost as of December 31 were as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2025 	2024 	2023 	2025 	2024 	2023
Service cost — benefits
earned during the year 	$ 216 $ 242 $ 230 	$ 43 	$ 39 	$ 38
Interest cost on projected
benefit obligations 	493 	469 	455 	68 	54 	59
Expected return on
plans’ assets 	(1,124) (1,050) 	(971) 	(27) 	(24) 	(23)
Amortization of actuarial
losses (gains) 	8 	24 	11 	— 	(2) 	(2)
Amortization of prior
service costs (credits) 	1 	1 	1 	(9) 	(13) 	(13)
Total net cost (income) 	$ (406) $(314) $(274) 	$ 75 	$ 54 	$ 59
In addition, approximately $15 million of income was recognized in
2023 related to the curtailment of a non-U.S. defined benefit plan.
Other comprehensive income (loss) for each respective year
includes the amortization of actuarial losses (gains) and prior
service costs (credits) as noted in the previous table. Other com-
prehensive income (loss) for each respective year also includes:
net actuarial gains of $861 million for defined benefit plans and a
loss of $160 million for medical and dental plans in 2025; net
actuarial gains of $971 million for defined benefit plans and a gain
of $36 million for medical and dental plans in 2024, and net actuar-
ial gains of $182 million for defined benefit plans and a loss of
$33 million for medical and dental plans in 2023. The net actuarial
gains in 2025 related to defined benefit plans are primarily due to
the favorable impact of actual asset returns in excess of expected
returns and the year-over-year increase in discount rates. The net
actuarial loss in 2025 related to medical and dental plans is primar-
ily due to higher claims. The net actuarial gains in 2024 related to
defined benefit plans are primarily due to the favorable impact of
actual asset returns in excess of expected returns and the year-
over-year increase in discount rates. The net actuarial gain in 2024
related to medical and dental plans is primarily due to the year-
over-year increase in discount rates.
The weighted average assumptions used to determine benefit
obligations for defined benefit plans and medical and dental plans
are as follows:
2025 	2024 	2023
Discount rate 	5.5% 	5.4% 	4.8%
Expected aggregate average long-
term change in compensation 	4.6% 	4.6% 	4.6%
The weighted average assumptions used to determine the net cost
for defined benefit plans and medical and dental plans are as
follows:
2025 	2024 	2023
Discount rate 	5.4% 	4.8% 	5.0%
Expected return on plan assets 	7.6% 	7.6% 	7.6%
Expected aggregate average long-
term change in compensation 	4.6% 	4.6% 	4.5%
The assumed healthcare cost trend rates for medical and dental
plans at December 31 were as follows:
2025 	2024 	2023
Healthcare cost trend rate assumed
for the next year 	9% 	8% 	8%
Rate that the cost trend rate
gradually declines to 	5% 	5% 	5%
Year that rate reaches the assumed
ultimate rate 	2033 	2031 	2029
The discount rates used to measure liabilities were determined
based on high-quality fixed income securities that match the
duration of the expected retiree benefits. The healthcare cost
trend rates represent Abbott’s expected annual rates of change
in the cost of healthcare benefits and are forward projections of
healthcare costs as of the measurement date.

-- 57 of 86 --

56
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted
Prices in
Active Markets
Significant
Other Observable
Inputs
Significant
Unobservable
Inputs
Measured
at NAV (j)
December 31, 2025
Equities:
U.S. large cap (a) 	$ 4,323 	$3,072 	$ 	— 	$— 	$1,251
U.S. mid and small cap (b) 	952 	941 	— 	4 	7
International (c) 	3,696 	604 	— 	— 	3,092
Fixed income securities:
U.S. government securities (d) 	485 	7 	463 	— 	15
Corporate debt instruments (e) 	1,775 	127 	1,213 	— 	435
Non-U.S. government securities (f) 	783 	61 	3 	— 	719
Other (g) 	999 	362 	180 	— 	457
Absolute return funds (h) 	2,136 	404 	— 	— 	1,732
Cash and Cash Equivalents 	396 	16 	— 	— 	380
Other (i) 	1,040 	— 	3 	— 	1,037
$16,585 	$5,594 	$1,862 	$ 4 	$9,125
December 31, 2024
Equities:
U.S. large cap (a) 	$ 3,873 	$2,714 	$ 	— 	$— 	$1,159
U.S. mid and small cap (b) 	918 	909 	— 	1 	8
International (c) 	2,827 	518 	— 	— 	2,309
Fixed income securities:
U.S. government securities (d) 	441 	7 	420 	— 	14
Corporate debt instruments (e) 	1,558 	120 	1,032 	— 	406
Non-U.S. government securities (f) 	627 	43 	2 	— 	582
Other (g) 	916 	335 	175 	— 	406
Absolute return funds (h) 	1,814 	283 	— 	— 	1,531
Cash and Cash Equivalents 	314 	16 	— 	— 	298
Other (i) 	1,132 	7 	— 	— 	1,125
$14,420 	$4,952 	$1,629 	$ 1 	$7,838
(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.
(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices.
(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.
(d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices.
(e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices.
(f) Primarily United Kingdom, Canada, Japan and Eurozone government bonds.
(g) Primarily asset backed securities, bank loans, interest rate swap positions and diversified fixed income vehicles benchmarked to SOFR, Sterling Overnight Interbank Average (SONIA),
or EURIBOR.
(h) Primarily hedge funds and funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies,
including but not limited to equities, fixed income, commodities, interest rate futures, currencies, and other securities to outperform an agreed upon benchmark with specific return and
volatility targets.
(i) Primarily investments in private funds, such as private equity, private credit, private real estate, and private energy funds.
(j) Investments measured at fair value using the net asset value (NAV) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this
table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

-- 58 of 86 --

57
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Equities that are valued using quoted prices are valued at the
published market prices. Equities in a common collective trust or
a registered investment company are valued at the NAV provided
by the fund administrator. The NAV is based on the value of the
underlying assets owned by the fund minus its liabilities. For
approximately half of these funds, investments may be redeemed
once per week or month, with a required 2 to 30 day notice period.
For the remaining funds, daily redemption of an investment is
allowed. Fixed income securities that are valued using significant
other observable inputs are valued at prices obtained from inde-
pendent financial service industry recognized vendors. Abbott did
not have any unfunded commitments related to fixed income funds
at December 31, 2025, and 2024. Fixed income securities in a com-
mon collective trust or a registered investment company are valued
at the NAV provided by the fund administrator. For the majority of
these funds, investments may be redeemed either weekly or
monthly, with a required 2 to 60 day notice period. For the remain-
ing funds, investments may be generally redeemed daily.
Absolute return funds are valued at the NAV provided by the fund
administrator. Abbott did not have any unfunded commitments
related to absolute return funds at December 31, 2025, and 2024.
Investments in these funds may be generally redeemed monthly or
quarterly with required notice periods ranging from 5 to 90 days.
For approximately $350 million of the absolute return funds,
redemptions are subject to a 25 percent gate and $60 million is
subject to a lock until 2028. All private funds are valued at the NAV
provided by the fund on a one-quarter lag adjusted for known cash
flows and significant events through the reporting date. Investments
in the private funds cannot be redeemed but the funds will make
distributions through liquidation. The estimate of the liquidation
period for each fund ranges from 2026 to 2035. Abbott’s unfunded
commitment in these funds was $630 million and $540 million as
of December 31, 2025, and 2024, respectively.
The investment mix of equity securities, fixed income, and other
asset allocation strategies is based upon achieving a desired
return, as well as balancing higher return, more volatile equity
securities with lower return, and less volatile fixed income securi-
ties. Investment allocations are made across a range of markets,
industry sectors, capitalization sizes, and in the case of fixed
income securities, maturities, and credit quality. The plans do not
directly hold any securities of Abbott. There are no known signifi-
cant concentrations of risk in the plans’ assets. Abbott’s medical
and dental plans’ assets are invested in a similar mix as the pension
plan assets. The actual asset allocation percentages at year end
are consistent with the company’s targeted asset allocation
percentages.
The plans’ expected return on assets, as shown above, is based on
management’s expectations of long-term average rates of return to
be achieved by the underlying investment portfolios. In establishing
this assumption, management considers historical and expected
returns for the asset classes in which the plans are invested, as well
as current economic and capital market conditions.
Abbott funds its domestic pension plans according to U.S. Internal
Revenue Service (IRS) funding limitations. International pension
plans are funded according to similar regulations. Abbott funded
$309 million in 2025 and $349 million in 2024 and 2023 to pension
plans. Abbott expects to contribute approximately $85 million to its
pension plans in 2026.
Total benefit payments expected to be paid to participants, which
include payments funded from company assets, as well as paid
from the plans, are as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2026 	$ 447 	$ 76
2027 	466 	81
2028 	489 	86
2029 	515 	91
2030 	540 	95
2031 to 2035 	3,077 	544
The Abbott Stock Retirement Plan is the principal defined contribu-
tion plan. Abbott’s contributions to this plan were $256 million in
2025, $207 million in 2024, and $199 million in 2023.
Note 15 — Taxes on Earnings
Taxes on earnings reflect the annual effective rates, including
charges for interest and penalties. Deferred income taxes reflect
the tax consequences on future years of differences between
the tax bases of assets and liabilities and their financial report-
ing amounts.
Taxes on earnings included $92 million, $50 million, and $22 million
in excess tax benefits associated with share-based compensation
in 2025, 2024, and 2023, respectively. As a result of the resolution
of various tax positions related to prior years, taxes on earnings in
2025, 2024, and 2023 also included approximately $70 million of
net tax benefit, $25 million, and $80 million of net tax expense,
respectively. In 2025, taxes on earnings included approximately
$610 million of tax expense related to a deferred tax asset that was
recognized as a significant non-cash tax benefit in a prior year. In
2024, taxes on earnings included $7.5 billion in non-cash valuation
allowance adjustments resulting from the restructuring of certain
foreign affiliates and the confirmation of certain tax filing positions.
The restructuring improved profitability to several of Abbott’s
affiliates and management concluded that the related preexisting
deferred tax assets, which historically had a full valuation allow-
ance, were more likely than not to be realizable in future periods.
In particular, Abbott considered the likelihood of sustained ongoing
profitability of the affiliates as a positive factor that outweighed all
available negative evidence considered. Accordingly, Abbott
released the full valuation allowance on such deferred tax assets
and recorded the offset to taxes on earnings.

-- 59 of 86 --

58
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The TCJA included a one-time transition tax that is based on
Abbott’s total post-1986 earnings and profits (E&P) that were previ-
ously deferred from U.S. income taxes. The tax computation also
required the determination of the amount of post-1986 E&P consid-
ered held in cash and other specified assets. As of December 31,
2025, the remaining balance of Abbott’s transition tax obligation
related to the TCJA was approximately $205 million. The final
installment will be paid in 2026 as allowed by the TCJA.
Undistributed foreign earnings remain indefinitely reinvested in
foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed foreign
earnings not subject to the transition tax and additional outside
basis difference in its foreign entities is not practicable.
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the
amount of $417 million. The primary adjustments proposed in the
SNOD relate to the reallocation of income between Abbott’s U.S.
entities and its foreign affiliates. Abbott believes that the income
reallocation adjustments proposed in the SNOD are without merit,
in part because certain adjustments contradict methods that were
agreed to with the IRS in prior audit periods. The SNOD also
contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S.
Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the 2017
and 2018 Federal tax years in the amount of $192 million. The
matters proposed in the 2017/2018 SNOD are substantially similar
to the income allocation adjustments included in the 2019 SNOD.
Abbott filed a petition in September 2024 with the U.S. Tax Court
contesting the 2017/2018 SNOD in a manner consistent with its
petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the
2020 Federal tax year assessing an additional $443 million of
income tax. The primary adjustments proposed in the SNOD are
substantially similar to the income allocation adjustments included
in the 2017/2018 and 2019 SNODs. Abbott believes that the income
reallocation adjustments proposed in the SNOD are without
merit. The SNOD also contains other proposed adjustments and
omissions that Abbott believes are erroneous and unsupported.
In addition to the tax assessment for the 2020 tax year, the 2020
SNOD also contested a deduction for which an estimated
$440 million cash tax benefit would be available in a different
taxable year as allowed under applicable U.S. tax law. Abbott
filed a petition with the U.S. Tax Court contesting the SNOD in
December 2024.
Abbott and the IRS are in active discussions regarding several of
the disputed items contained in the 2017–2020 SNODs.
In July 2024, Abbott received a $413 million tax assessment from
the Malaysian tax authorities for the 2023 tax year. The assessment
applies a property capital gains tax on the value of the shares asso-
ciated with the intercompany sale of an affiliate. Abbott believes the
assessment of the Malaysian tax authority to be without merit. In
October 2025, the Penang High Court upheld the assessment of the
Malaysian tax authority. In October 2025, Abbott filed an appeal with
the Malaysian Court of Appeals.
There are numerous other income tax jurisdictions for which tax
returns are not yet settled, none of which Abbott expects to be
individually significant. Abbott intends to vigorously defend its filing
positions in all jurisdictions in which it has unresolved tax matters
through ongoing discussions with taxing administrations and/or
through litigation as necessary. Abbott reserves for uncertain tax
positions related to unresolved tax matters where Abbott’s tax filing
position does not meet the standard for recognition of an income tax
benefit. Abbott continues to believe that the amount of its recorded
reserves for uncertain tax positions is appropriate. Reserves for
interest and penalties are not significant.
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised international
tax system. Pillar 1 proposes to reallocate taxing rights among the
jurisdictions in which in-scope multinational corporations operate.
Pillar 2 proposes to assess a 15 percent minimum tax on the earn-
ings of in-scope multinational corporations on a country-by-country
basis. Numerous countries have enacted legislation to adopt the
Pillar 2 model rules. On January 5, 2026, the OECD released admin-
istrative guidance that, when enacted, exempts US-parented
groups from the Pillar 2 minimum tax. Abbott continues to monitor
legislative developments and assess any potential impacts on
Abbott’s operations for both the Pillar 1 and Pillar 2 proposals.
Earnings before taxes, and the related provisions for taxes on
earnings, were as follows:
(in millions) 	2025 	2024 	2023
Earnings Before Taxes:
Domestic 	$1,762 	$ 	947 	$1,192
Foreign 	6,704 	6,066 	5,472
Total 	$8,466 	$ 7,013 	$6,664
(in millions) 	2025 	2024 	2023
Taxes on Earnings:
Current:
Domestic 	$ 	— 	$ 	497 	$ 528
Federal 	302
State 	85
Foreign 	1,114 	1,075 	874
Total current 	1,501 	1,572 	1,402
Deferred:
Domestic 	— 	(459) 	(382)
Federal 	(217)
State 	(40)
Foreign 	698 	(7,502) 	(79)
Total deferred 	441 	(7,961) 	(461)
Total 	$1,942 	$(6,389) 	$ 941

-- 60 of 86 --

59
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
Income taxes paid (net of refunds received) were as follows:
(in millions) 	2025
Income taxes paid (net of refunds received):
Federal 	$ 683
State 	33
Foreign:
Germany 	139
United Kingdom 	384
All other jurisdictions 	694
Total 	$1,933
Differences between the effective income tax rate and the U.S.
statutory tax rate were as follows:
2025
(dollars in millions) 	Amount 	Percent
U.S. federal statutory tax rate 	$1,778 	21.0%
Foreign tax effects
Costa Rica
Tax rate differential 	(116) 	(1.4)
Germany
Affiliate financing 	100 	1.2
Other 	40 	0.5
Luxembourg
Affiliate investing 	596 	7.0
Malta
Tax rate differential 	(137) 	(1.6)
Affiliate financing 	(159) 	(1.9)
Other 	(40) 	(0.5)
Other foreign jurisdictions 	128 	1.5
Effect of cross-border tax laws
Foreign derived intangible income (FDII) 	(148) 	(1.7)
Other 	40 	0.5
Other adjustments 	(140) 	(1.7)
Effective tax rate 	$1,942 	22.9%
2024 	2023
Statutory tax rate on earnings 	21.0% 	21.0%
Impact of foreign operations 	(1.8) 	(3.6)
Foreign-derived intangible income benefit 	(2.3) 	(2.2)
Valuation allowance adjustments 	(107.1) 	—
Excess tax benefits related to stock compensation 	(0.7) 	(0.3)
Research tax credit 	(1.0) 	(1.1)
Resolution of certain tax positions pertaining to
prior years 	0.4 	1.2
Intercompany restructurings and integration 	0.2 	(1.4)
State taxes, net of federal benefit 	0.3 	0.5
All other, net 	(0.1) 	—
Effective tax rate on earnings 	(91.1)% 	14.1%
Impact of foreign operations is primarily derived from operations in
Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica,
Singapore, Malta, and Malaysia.
The tax effect of the differences that give rise to deferred tax assets
and liabilities were as follows:
(in millions) 	2025 	2024
Deferred tax assets:
Trade receivable reserves 	$ 	227 	$ 	230
Research and development costs 	902 	773
Inventory reserves 	146 	168
Lease liabilities 	280 	265
Deferred intercompany profit 	319 	284
NOLs, reserves not currently deductible,
credit carryforwards and other 	9,730 	10,353
Total deferred tax assets before valuation
allowance 	11,604 	12,073
Valuation allowance 	(1,771) 	(1,664)
Total deferred tax assets 	9,833 	10,409
Deferred tax liabilities:
Compensation and employee benefits 	(520) 	(276)
Depreciation 	(489) 	(408)
Right of use lease assets 	(263) 	(249)
Other, primarily the excess of book basis over
tax basis of intangible assets 	(1,056) 	(1,365)
Total deferred tax liabilities 	(2,328) 	(2,298)
Total net deferred tax assets (liabilities) 	$ 7,505 	$ 8,111
The following table summarizes the gross amounts of unrecognized
tax benefits without regard to reduction in tax liabilities or additions
to deferred tax assets and liabilities if such unrecognized tax bene-
fits were settled:
(in millions) 	2025 	2024
January 1 	$3,568 	$3,323
Increase due to current year tax positions 	343 	167
Increase due to prior year tax positions 	245 	174
Decrease due to prior year tax positions 	(77) 	(50)
Settlements 	(18) 	(13)
Lapse of statute 	(24) 	(33)
December 31 	$4,037 	$3,568
Abbott’s unrecognized tax benefits table includes amounts related
to tax positions for which a deferred tax asset has not been recog-
nized because the recognition of the future benefit is not expected.
The total amount of unrecognized tax benefits that, if recognized,
would impact the effective tax rate is approximately $2.6 billion.

-- 61 of 86 --

60
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above,
and are not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
(in millions)
Net Sales to External
Customers (a)
Cost of
Products Sold
Research and
Development
Selling, General and
Administrative
Operating
Earnings (a)
2025 	2024 	2023 	2025 	2024 	2023 	2025 	2024 	2023 	2025 	2024 	2023 	2025 	2024 	2023
Established
Pharmaceuticals 	$ 5,536 $ 5,194 $ 5,066 $ (2,615) $ (2,444) $ (2,357) 	$ (176) $ (176) $ (173) $ (1,455) $ (1,341) $(1,330) 	$ 1,290 $ 1,233 $ 1,206
Nutritionals 	8,451 	8,413 	8,154 	(4,569) 	(4,532) 	(4,495) 	(213) 	(209) 	(204) 	(2,111) 	(2,167) 	(2,122) 	1,558 	1,505 	1,333
Diagnostics 	8,937 	9,341 	9,988 	(4,984) 	(4,995) 	(5,264) 	(602) 	(656) 	(698) 	(1,611) 	(1,617) 	(1,593) 	1,740 	2,073 	2,433
Medical Devices 	21,387 	18,986 	16,887 	(6,973) 	(6,408) 	(5,803) 	(1,753) 	(1,546) 	(1,362) 	(5,449) 	(4,879) 	(4,416) 	7,212 	6,153 	5,306
Total 	$44,311 $41,934 $40,095 $(19,141) $(18,379) $(17,919) 	$(2,744) $(2,587) $(2,437) $(10,626) $(10,004) $(9,461) 	$11,800 $10,964 $10,278
Other 	17 	16 	14
Net sales 	$44,328 $41,950 $40,109
Corporate functions
and plan benefit costs 	(157) 	(422) 	(308)
Net interest expense 	(185) 	(215) 	(252)
Share-based
compensation 	(664) 	(673) 	(644)
Amortization of
Intangible assets 	(1,682) 	(1,878) 	(1,966)
Other, net (b) 	(646) 	(763) 	(444)
Earnings before Taxes 	$ 8,466 $ 7,013 $ 6,664
(a) In 2025, foreign exchange favorably impacted net sales and unfavorably impacted operating earnings. In 2024 and 2023, foreign exchange unfavorably impacted net sales and
operating earnings.
(b) Other, net includes costs directly related to integrating acquired businesses and restructuring charges in 2025, 2024, and 2023. Charges and expenses for restructuring actions and
other cost reduction initiatives were $287 million in 2025, $185 million in 2024, and $122 million in 2023. Other, net also includes: in 2025, $165 million for legal reserves related to a
negotiated settlement; in 2024, a $143 million loss on the divestiture of a non-core business, as well as intangible and IPR&D asset impairments; and in 2023, charges of $100 million
related to intangible asset impairments, partially offset by income arising from fair value changes in contingent consideration related to previous business acquisitions.
Note 16 — Segment and Geographic Area Information
Abbott’s principal business is the discovery, development, manu-
facture, and sale of a broad line of healthcare products. Abbott’s
products are generally sold directly to retailers, wholesalers,
hospitals, healthcare facilities, laboratories, physicians’ offices,
and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a
broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult
and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems and
tests for blood banks, hospitals, commercial laboratories, and
alternate-care testing sites. For segment reporting purposes, the
Core Laboratory, Rapid Diagnostics, Molecular, and Point of Care
businesses are aggregated and reported as the Diagnostic
Products segment.
Medical Devices—Worldwide sales of rhythm management, electro-
physiology, heart failure, vascular, structural heart, neuromodulation,
and diabetes care products. For segment reporting purposes, the
Rhythm Management, Electrophysiology, Heart Failure, Vascular,
Structural Heart, Neuromodulation, and Diabetes Care businesses
are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal
entity basis for government and public reporting requirements.
Segment disclosures are on a performance basis consistent with
internal management reporting. The chief operating decision maker
(CODM) at Abbott is the Chief Executive Officer. The CODM
primarily considers sales and operating margin to assess the perfor-
mance of segments and to allocate resources, where segment
operating margin profitability includes cost of products sold and
operating expenses. The cost of some corporate functions and the
cost of certain employee benefits are charged to segments at pre-
determined rates that approximate cost. Remaining costs, if any, are
not allocated to segments. In addition, intangible asset amortization
is not allocated to operating segments, and intangible assets and
goodwill are not included in the measure of each segment’s assets.

-- 62 of 86 --

61
Abbott / 2025 Annual Report
Notes to Consolidated Financial Statements
(in millions)
Depreciation
Additions to Property
and Equipment (c) 	Total Assets
2025 	2024 	2023 	2025 	2024 	2023 	2025 	2024
Established Pharmaceuticals 	$ 101 	$ 	96 	$ 104 	$ 169 	$ 183 	$ 185 	$ 3,540 	$ 3,087
Nutritionals 	175 	159 	155 	302 	382 	457 	4,791 	4,404
Diagnostics 	533 	521 	499 	761 	758 	750 	8,273 	7,678
Medical Devices 	378 	343 	315 	658 	630 	604 	10,689 	9,472
Total Reportable Segments 	1,187 	1,119 	1,073 	1,890 	1,953 	1,996 	$27,293 	$24,641
Other 	247 	221 	204 	259 	292 	213
Total 	$1,434 	$1,340 	$1,277 	$2,149 	$2,245 	$2,209
(in millions) 	2025 	2024
Total Reportable Segment Assets 	$27,293 	$24,641
Cash and investments 	9,857 	8,853
Goodwill and intangible assets 	29,561 	29,755
All other (d) 	20,002 	18,165
Total Assets 	$86,713 	$81,414
(c) Amounts exclude property and equipment acquired through business acquisitions.
(d) All other includes long-term assets associated with the defined benefit plans of $7.5 billion in 2025 and $5.7 billion in 2024, and deferred tax assets of $8.1 billion in 2025
and $8.6 billion in 2024.
(in millions)
Net Sales to External Customers (e)
2025 	2024 	2023
United States 	$17,126 	$16,323 	$15,452
Germany 	2,759 	2,539 	2,345
China 	1,907 	2,113 	2,253
Switzerland 	1,871 	1,747 	1,638
India 	1,871 	1,817 	1,750
Japan 	1,475 	1,441 	1,513
United Kingdom 	1,340 	1,185 	991
All Other Countries 	15,979 	14,786 	14,168
Consolidated 	$44,328 	$41,950 	$40,109
(e) Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include property
and equipment. It excludes goodwill, intangible assets, deferred tax
assets, and financial instruments. At December 31, 2025, and 2024,
long-lived assets totaled $22.2 billion and $18.5 billion, respectively,
and in the U.S. such assets totaled $11.9 billion and $10.3 billion,
respectively. Long-lived asset balances associated with other
countries were not material on an individual country basis in either
of the two years.

-- 63 of 86 --

62
Abbott / 2025 Annual Report
Management Report on Internal
Control Over Financial Reporting
Report of Independent Registered Public Accounting Firm
The management of Abbott Laboratories is responsible for estab-
lishing and maintaining adequate internal control over financial
reporting. Abbott’s internal control system was designed to provide
reasonable assurance to the company’s management and board of
directors regarding the preparation and fair presentation of pub-
lished financial statements.
All internal control systems, no matter how well designed, have
inherent limitations. Therefore, even those systems determined to
be effective can provide only reasonable assurance with respect
to financial statement preparation and presentation.
Abbott’s management assessed the effectiveness of the company’s
internal control over financial reporting as of December 31, 2025.
In making this assessment, it used the criteria set forth in Internal
Control — Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations of the Treadway Commission. Based on
our assessment, we believe that, as of December 31, 2025, the
company’s internal control over financial reporting was effective
based on those criteria.
Abbott’s independent registered public accounting firm has issued
an audit report on their assessment of the effectiveness of the
company’s internal control over financial reporting. This report
appears on page 80.
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer
John A. McCoy, Jr.
Vice President, Finance and Controller
February 20, 2026
To the Shareholders and the Board of Directors of
Abbott Laboratories
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets
of Abbott Laboratories and subsidiaries (the Company) as of
December 31, 2025 and 2024, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment and
cash flows for each of the three years in the period ended
December 31, 2025, and the related notes (collectively referred
to as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material
respects, the financial position of the Company at December 31,
2025 and 2024, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 2025,
in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting
as of December 31, 2025, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013
framework), and our report dated February 20, 2026 expressed
an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a
public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regula-
tions of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial state-
ments are free of material misstatement, whether due to error or
fraud. Our audits included performing procedures to assess the risks
of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluat-
ing the overall presentation of the financial statements. We believe
that our audits provide a reasonable basis for our opinion.

-- 64 of 86 --

63
Abbott / 2025 Annual Report
Report of Independent Registered Public Accounting Firm
Critical Audit Matter
The critical audit matter communicated below is a matter arising
from the current period audit of the financial statements that was
communicated or required to be communicated to the audit com-
mittee and that: (1) relates to accounts or disclosures that are
material to the financial statements and (2) involved our especially
challenging, subjective or complex judgments. The communication
of the critical audit matter does not alter in any way our opinion on
the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing a
separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.
Income taxes – Unrecognized tax benefits
Description of the Matter
As disclosed in Note 15 to the consolidated financial statements,
unrecognized tax benefits were approximately $4.0 billion at
December 31, 2025. The Company operates in a complex global tax
environment and is subject to tax laws and regulations in numerous
countries. Uncertain tax positions may arise from interpretations
and judgments made by the Company in the application of the
relevant tax statutes, regulations, rulings and case law across the
numerous countries. The Company uses significant judgement in
the application of the tax laws and regulations in its accounting for
uncertain tax positions in certain countries.
Auditing the accounting for uncertain tax positions was challenging
because the recognition of some of the uncertain tax positions in
certain countries is judgmental and is based on interpretations of
tax statutes, regulations, rulings and case law.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the
operating effectiveness of controls over the Company’s process to
monitor and assess the technical merits of some of the tax positions
taken in certain countries. We also identified and tested controls
over the Company’s process to determine the application of the
relevant tax statutes, regulations, rulings and case law, including
management’s process to determine the amount, if any, to recog-
nize from the related tax positions.
With the assistance of our income tax professionals, we performed
audit procedures that included, among others, evaluating the tech-
nical merits of some of the Company’s tax positions in certain
countries, including the reasonableness of management’s judgment
with respect to the interpretation of tax laws and regulations by
reading and evaluating management’s documentation. We also
tested the appropriateness and consistency of management’s
methods and data associated with the measurement of unrecog-
nized tax benefits for those tax positions, including assessing the
amount of tax benefit, if any, to be recognized.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 20, 2026

-- 65 of 86 --

64
Abbott / 2025 Annual Report
Definition and Limitations of Internal Control Over
Financial Reporting
A company’s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted account-
ing principles. A company’s internal control over financial reporting
includes those policies and procedures that (1) pertain to the main-
tenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the com-
pany; (2) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial statements
in accordance with generally accepted accounting principles, and
that receipts and expenditures of the company are being made only
in accordance with authorizations of management and directors of
the company; and (3) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material
effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projec-
tions of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 20, 2026
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Directors of
Abbott Laboratories
Opinion on Internal Control Over Financial Reporting
We have audited Abbott Laboratories and subsidiaries’ internal
control over financial reporting as of December 31, 2025, based
on criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In our
opinion, Abbott Laboratories and subsidiaries (the Company) main-
tained, in all material respects, effective internal control over financial
reporting as of December 31, 2025, based on the COSO criteria.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of
December 31, 2025 and 2024, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2025, and the related notes and our report dated
February 20, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effec-
tive internal control over financial reporting and for its assessment
of the effectiveness of internal control over financial reporting
included in the accompanying Management Report on Internal
Control Over Financial Reporting. Our responsibility is to express
an opinion on the Company’s internal control over financial report-
ing based on our audit. We are a public accounting firm registered
with the PCAOB and are required to be independent with respect
to the Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and
Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal control
over financial reporting, assessing the risk that a material weakness
exists, testing and evaluating the design and operating effective-
ness of internal control based on the assessed risk, and performing
such other procedures as we considered necessary in the circum-
stances. We believe that our audit provides a reasonable basis for
our opinion.

-- 66 of 86 --

65
Abbott / 2025 Annual Report
Financial Instruments and Risk Management
Market Price Sensitive Investments
The fair value of equity securities held by Abbott with a readily
determinable fair value was approximately $20 million and
$10 million as of December 31, 2025, and 2024, respectively. These
equity securities are subject to potential changes in fair value.
A hypothetical 20 percent decrease in the share prices of these
investments would decrease their fair value at December 31, 2025,
by approximately $4 million. Changes in the fair value of these
securities are recorded in earnings. The fair value of investments in
mutual funds that are held in a rabbi trust for the purpose of paying
benefits under a deferred compensation plan was $323 million and
$313 million as of December 31, 2025, and 2024, respectively.
Changes in the fair value of these investments, as well as an offset-
ting change in the benefit obligation, are recorded in earnings.
Non-Publicly Traded Equity Securities
Abbott holds equity securities that are not traded on public stock
exchanges. The carrying value of these investments was
$124 million and $91 million as of December 31, 2025, and 2024,
respectively. No individual investment is recorded at a value in
excess of $25 million. Abbott measures these investments at cost
minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical
or a similar investment of the same issuer.
Interest Rate Sensitive Financial Instruments
At December 31, 2025, and 2024, Abbott had interest rate hedge
contracts with notional values totaling $1.2 billion and $2.2 billion,
respectively, to manage its exposure to changes in the fair value of
debt. The effect of these hedges is to change the fixed interest rate to
a variable rate for the portion of the debt that is hedged. Abbott does
not use derivative financial instruments, such as interest rate swaps,
to manage its exposure to changes in interest rates for its investment
securities. The fair value of long-term debt at December 31, 2025,
and 2024, amounted to $12.8 billion and $13.7 billion, respectively
(average interest rates of 3.8% as of December 31, 2025, and 2024,
respectively) with maturities through 2046. At December 31, 2025,
and 2024, the fair value of current and long-term investment
securities amounted to $1.3 billion and $1.2 billion, respectively.
A hypothetical 100-basis point change in the interest rates would
not have a material effect on cash flows, income, or fair values.
Foreign Currency Sensitive Financial Instruments
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates for anticipated intercompany purchases by
those subsidiaries whose functional currencies are not the U.S.
dollar. These contracts are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign currency
exchange rates and are marked-to-market with the resulting gains
or losses reflected in Accumulated other comprehensive income
(loss). Gains or losses will be included in Cost of products sold at
the time the products are sold, generally within the next twelve to
eighteen months. At December 31, 2025, and 2024, Abbott held
$7.4 billion and $7.0 billion of notional values, respectively, of such
contracts. Contracts held at December 31, 2025, will mature in
2026 or 2027 depending on the contract. Contracts held at
December 31, 2024, matured in 2025 or will mature in 2026
depending upon the contract.
Abbott enters into foreign currency forward exchange contracts to
manage its exposure to foreign currency denominated intercom-
pany loans and trade payables and third-party trade payables and
receivables. The contracts are marked-to-market, and resulting
gains or losses are reflected in income and are generally offset by
losses or gains on the foreign currency exposure being managed.
At December 31, 2025, and 2024, Abbott held $13.1 billion and
$16.2 billion of notional values, respectively, of such contracts,
which mature within 13 months.
Abbott has designated a yen-denominated, 5-year term loan of
$589 million and $583 million as of December 31, 2025, and
December 31, 2024, respectively, as a hedge of the net investment
in certain foreign subsidiaries. The change in the value of the debt is
due to changes in foreign exchange rates, recorded in Accumulated
other comprehensive income (loss), net of tax.
The following table reflects the total foreign currency forward exchange contracts outstanding at December 31:
(dollars in millions)
2025 	2024
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying Value
Receivable/
(Payable)
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying Value
Receivable/
(Payable)
Primarily U.S. dollars to be exchanged for the following currencies:
Euro 	$ 9,137 	1.1604 	$(121) 	$10,954 	1.0848 	$136
Chinese Yuan 	1,889 	7.0843 	(19) 	1,926 	7.1132 	22
Japanese Yen 	1,313 	149.5687 	37 	1,479 	149.1298 	51
All other currencies 	8,156 	n/a 	(86) 	8,832 	n/a 	50
Total 	$20,495 	$(189) 	$23,191 	$259

-- 67 of 86 --

Financial Review
66
Abbott / 2025 Annual Report
Abbott’s revenues are derived primarily from the sale of a broad line
of healthcare products, which include medical devices, diagnostic
testing products, nutritional products and branded generic pharma-
ceuticals. These products are sold under short-term receivable
arrangements. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under a
contract most impact which products are sold; price controls,
competition, and rebates most impact the net selling prices of
products; and the measurement of net sales and costs is impacted
by foreign currency translation. Sales in international markets
comprise 61 percent of consolidated net sales.
On November 19, 2025, Abbott entered into a definitive agreement
to acquire Exact Sciences Corporation (Exact Sciences), which is
expected to enable Abbott to enter the cancer diagnostics market.
The acquisition is subject to customary closing conditions, includ-
ing the approval of Exact Sciences shareholders, and obtaining the
required regulatory clearances. Under the terms of the agreement,
Abbott will pay $105 per common share in cash at the completion
of the transaction, representing a total equity value of approxi-
mately $21 billion and an estimated enterprise value of $23 billion.
Abbott’s financing contemplates absorption of Exact Sciences’
estimated $1.8 billion of net debt.
On November 19, 2025, Abbott obtained a commitment for a
364-day senior unsecured bridge term loan facility for an amount
not to exceed $20.0 billion in conjunction with its pending acquisi-
tion of Exact Sciences. While Abbott plans to fund this transaction
with cash on hand and borrowings, the bridge facility will provide
back-up financing.
Abbott’s sales growth in 2025 was primarily attributable to the
performance of the Medical Devices and Established
Pharmaceutical Products segments. Results reflect continued
progress across related research and development programs,
including the contribution of new and recently introduced products
and indication expansions. Results in the Nutritional Products
segment were flat, reflecting price increases and lower volumes,
particularly in the United States (U.S.). Sales also continued to be
affected by the decline in COVID-19 testing-related sales in the
Diagnostics segment. In 2025, 2024, and 2023, Abbott’s COVID-19
testing-related sales totaled $297 million, $747 million, and
$1.6 billion, respectively. Sales in emerging markets, which repre-
sent 37 percent of total company sales, increased 5.1 percent in
2025 and 8.2 percent in 2024, excluding the impact of foreign
exchange. (Emerging markets include all countries, except the U.S.,
Japan, Canada, Australia, New Zealand, the United Kingdom, and
Western European countries.)
Abbott’s operating margin profile increased in 2025 to 18.2 percent
from 16.3 percent in 2024 and 16.2 percent in 2023. The increase in
2025 reflects the favorable impact of margin improvement initia-
tives, partially offset by foreign exchange and inflation.
With respect to the performance of each reportable segment over
the last three years, sales in the Medical Devices segment, exclud-
ing the impact of foreign exchange, increased 11.9 percent in 2025
and 13.7 percent in 2024. In Medical Devices, sales in 2025 and
2024 increased across all businesses, with double-digit growth in
Diabetes Care, Heart Failure, Electrophysiology, and Structural
Heart, and in 2025, Rhythm Management. Growth was led by
Diabetes Care where sales of Abbott’s continuous glucose monitor-
ing (CGM) systems continued to increase and totaled $7.6 billion in
2025 and $6.4 billion in 2024.
In 2025, key product approvals in the Medical Devices seg-
ment included:
• U.S. Food and Drug Administration (FDA) approval and CE Mark
for the Volt™ Pulsed Field Ablation (PFA) System to treat patients
with atrial fibrillation,
• FDA approval of the Tendyne™ transcatheter mitral valve replace-
ment (TMVR) system to treat people with mitral valve disease,
• Regulatory approval in Japan for TriClip®, a minimally invasive
treatment option for patients with tricuspid regurgitation, or a
leaky tricuspid heart valve,
• CE Mark for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™,
designed to deliver radiofrequency (RF) and PFA energy to treat
patients battling atrial fibrillation, and
• CE Mark for an expanded indication for the Navitor® transcathe-
ter aortic valve implantation (TAVI) system to treat people with
symptomatic, severe aortic stenosis who are at low or intermedi-
ate risk for open-heart surgery.
Operating earnings for the Medical Devices segment increased
17.2 percent in 2025 and 16.0 percent in 2024. Operating margin
profile increased from 31.4 percent in 2023 to 32.4 percent in 2024
and to 33.7 percent in 2025. The increase in 2025 reflects the
impact of higher sales volumes across the Medical Devices
businesses.
In Abbott’s Diagnostics segment, sales decreased 4.5 percent in
2025 and 3.9 percent in 2024, excluding the impact of foreign
exchange. The 2025 and 2024 sales decreases were driven by
continued lower demand for the company’s portfolio of COVID-19
tests and challenging market conditions in China, including the
impact of volume-based procurement programs. The sales
decrease was partially offset by higher volume of routine diagnos-
tic tests and the continued deployment of Abbott’s Alinity® testing
platform and digital health solutions, as Abbott continues to expand
its diagnostic test menus.
In 2025, operating earnings for the Diagnostics segment decreased
16.1 percent. The operating margin profile decreased from
24.4 percent in 2023 to 19.5 percent in 2025 primarily due to lower
demand for Abbott’s COVID-19 tests.
In Abbott’s Nutritional Products segment, total pediatric nutrition
sales, excluding the impact of foreign exchange, decreased
0.7 percent in 2025, reflecting lower sales volumes in the U.S.,
partially offset by higher international sales and price increases.
In 2024, excluding the impact of foreign exchange, total pediatric
nutrition sales increased 3.7 percent, which included market share
recovery in the U.S. infant formula business following the voluntary
recall of certain products in 2022, and the favorable impact of price

-- 68 of 86 --

Financial Review
67
Abbott / 2025 Annual Report
increases. Excluding the impact of foreign exchange, total adult
nutrition sales increased 2.7 percent in 2025 and 8.0 percent in
2024, reflecting growth in international markets and favorable
impact of price increases. These increases were partially offset by
lower U.S. sales, including the impact from the discontinuation of
the ZonePerfect® product line in 2024.
In 2025, operating earnings for the Nutritional Products segment
increased 3.5 percent compared to 2024. Operating margin profile
for this segment increased from 16.4 percent in 2023 to 17.9 percent
in 2024 and to 18.4 percent in 2025. The increase in 2025 primarily
reflects the favorable effect of margin improvement initiatives and
price increases, partially offset by continued inflation in manufac-
turing and input costs and the impact of foreign exchange. The
increase in 2024 primarily reflected higher sales, the favorable
impact of price increases, and a continued execution of margin
improvement initiatives.
In Abbott’s Established Pharmaceutical Products segment, exclud-
ing the impact of foreign exchange, sales increased 7.4 percent in
2025 and 9.2 percent in 2024. Sales growth in both periods was
broad-based across countries and was led by higher revenue
across multiple therapeutic areas, including cardiometabolic,
gastroenterology, and central nervous system/pain management.
In 2024, growth in this segment also reflected higher respiratory
product sales. In 2025, operating earnings increased 4.7 percent.
Operating margin profile decreased from 23.8 percent in 2023 to
23.3 percent in 2025, reflecting increased business costs and
unfavorable foreign exchange, partially offset by higher volumes
and favorable price adjustment initiatives.
With respect to Abbott’s financial position, as of December 31,
2025, and December 31, 2024, Abbott’s cash and cash equivalents
and short-term investments totaled $8.9 billion and $8.0 billion,
respectively. Abbott’s long-term debt totaled $12.9 billion and
$14.1 billion at December 31, 2025, and 2024, respectively.
Abbott declared dividends of $2.40 per share in 2025 and $2.24
per share in 2024, an increase of 7.1 percent. Dividends paid totaled
$4.1 billion in 2025 compared to $3.8 billion in 2024. The year-over-
year change in the amount of dividends paid reflects the increase
in the dividend rate. In December 2025, Abbott increased the com-
pany’s quarterly dividend by 6.8 percent to $0.63 per share from
$0.59 per share, effective with the dividend paid in February 2026.
In December 2024, Abbott increased the company’s quarterly
dividend by 7.3 percent to $0.59 per share from $0.55 per share,
effective with the dividend paid in February 2025.
In 2026, Abbott will continue to invest in product development
areas that provide the opportunity for strong sustainable growth
over the next several years. In the diagnostics businesses, Abbott
will focus on driving sales growth from its Alinity suite of diagnostic
instruments, including expanded menu offerings and GLP track
integration, as well as its portfolio of rapid diagnostic testing sys-
tems, and growing digital health solutions. In the medical devices
businesses, Abbott will focus on growing recently launched
products and expanding its market position across its various
businesses. In the nutrition businesses, Abbott will focus on
introducing new products to adapt to evolving consumer
preferences and driving growth globally. In the established
pharmaceuticals businesses, Abbott will continue to focus on
growing the depth and breadth of its portfolio in emerging
markets, including expanding its biosimilars portfolio.
Critical Accounting Policies
Sales Rebates — In 2025, 44 percent of Abbott’s consolidated gross
revenues were subject to various forms of rebates and allowances
that Abbott recorded as reductions of revenues at the time of sale.
Most of these rebates and allowances in 2025 are in the Nutritional
Products and Diabetes Care businesses. Abbott provides rebates to
state agencies, wholesalers, group purchasing organizations, and
other government agencies and private entities. Rebate amounts
are usually based upon the volume of purchases using contractual
or statutory prices for a product. Factors used in the rebate calcula-
tions include the identification of which products have been sold
subject to a rebate, which customer or government agency price
terms apply, and the estimated lag time between sale and payment
of a rebate. Using historical trends, adjusted for current changes,
Abbott estimates the amount of the rebate that will be paid, and
records the liability as a reduction of gross sales when Abbott
records its sale of the product. Settlement of the rebate generally
occurs from one to six months after sale. Abbott regularly analyzes
the historical rebate trends and makes adjustments to reserves for
changes in trends and terms of rebate programs. Rebates and
chargebacks charged against gross sales in 2025, 2024, and 2023
amounted to $4.8 billion in 2025, $4.4 billion in 2024, and $3.9 billion
in 2023, or 21.1 percent, 18.6 percent, and 17.4 percent of gross sales,
respectively, based on gross sales of approximately $22.5 billion,
$23.5 billion, and $22.7 billion, respectively, subject to rebate.
A one-percentage point increase in the percentage of rebates to
related gross sales would decrease net sales by approximately
$225 million in 2025. Abbott considers a one-percentage point
increase to be a reasonably likely increase in the percentage of
rebates related to gross sales. Other allowances charged against
gross sales were $316 million, $319 million, and $263 million for
cash discounts in 2025, 2024, and 2023, respectively, and
$236 million, $211 million, and $169 million for returns in 2025, 2024,
and 2023, respectively. Cash discounts are known within 15 to 30
days of sale and therefore can be reliably estimated. Returns can be
reliably estimated because Abbott’s historical returns are low, and
because sales returns terms and other sales terms have remained
relatively unchanged for several periods.
Management analyzes the adequacy of ending rebate accrual
balances each quarter using both internal and external data avail-
able to estimate the accruals. Historically, adjustments to prior
years’ rebate accruals have not been material to net earnings.
Abbott employs various techniques to verify the accuracy of sub-
mitted claims, and where possible, works with the organizations
submitting claims to gain insight into changes that might affect the
rebate amounts. For government agency programs, the calculation
of a rebate involves interpretations of relevant regulations, which
are subject to challenge or change in interpretation.

-- 69 of 86 --

Financial Review
68
Abbott / 2025 Annual Report
Income Taxes — Abbott operates in numerous countries where its
income tax returns are subject to audits and adjustments. Because
Abbott operates globally, the nature of the audit items is often very
complex, and the objectives of the government auditors can result
in a tax on the same income in more than one country. Abbott
employs internal and external tax professionals to minimize audit
adjustment amounts where possible. In accordance with the
accounting rules relating to the measurement of tax contingencies,
in order to recognize an uncertain tax benefit, the taxpayer must
be more likely than not of sustaining the position, and the measure-
ment of the benefit is calculated as the largest amount that is
more than 50 percent likely to be realized upon resolution of the
benefit. Application of these rules requires a significant amount of
judgment. In the U.S., Abbott’s federal income tax returns through
2016 were settled as of December 31, 2025. Undistributed foreign
earnings remain indefinitely reinvested in foreign operations.
Determining the amount of unrecognized deferred tax liability
related to any remaining undistributed foreign earnings not subject
to the transition tax and additional outside basis difference in its
foreign entities is not practicable.
Pension and Post-Employment Benefits — Abbott offers pension
benefits and post-employment healthcare to many of its employ-
ees. Abbott engages outside actuaries to assist in the determination
of the obligations and costs under these programs. Abbott must
develop long-term assumptions, the most significant of which are
the healthcare cost trend rates, discount rates, and the expected
return on plan assets. The discount rates used to measure liabilities
were determined based on high-quality fixed income securities that
match the duration of the expected retiree benefits. The healthcare
cost trend rates represent Abbott’s expected annual rates of
change in the cost of healthcare benefits and are a forward projec-
tion of healthcare costs as of the measurement date. A difference
between the assumed rates and the actual rates, which will not be
known for years, can be significant in relation to the obligations and
the annual cost recorded for these programs. The net actuarial
gains for Abbott’s defined benefit plans in 2025 reflect the impact
of actual asset returns during the year in excess of expected
returns and the impact of higher discount rates on the measure-
ment of plan liabilities. The net actuarial losses for Abbott’s medical
and dental plans primarily reflect an increase in claims. At
December 31, 2025, pretax net actuarial gains (losses) and prior
service costs and credits recognized in Accumulated other com-
prehensive income (loss) were net gains of $152 million for Abbott’s
defined benefit plans and net losses of $189 million for Abbott’s
medical and dental plans. Actuarial losses and gains are amortized
over the remaining service attribution periods of the employees
under the corridor method, in accordance with the rules for
accounting for post-employment benefits. Differences between the
expected long-term return on plan assets and the actual annual
return are amortized over a five-year period.
Valuation of Intangible Assets — Abbott has acquired and continues
to acquire significant intangible assets that Abbott records at fair
value at the acquisition date. Transactions involving the purchase or
sale of intangible assets occur with some frequency between
companies in the healthcare field and valuations are usually based
on a discounted cash flow analysis. The discounted cash flow
model requires assumptions about the timing and amount of future
net cash flows, risk, cost of capital, terminal values, and market
participants. Each of these factors can significantly affect the value
of the intangible asset. Abbott engages independent valuation
experts who review Abbott’s critical assumptions and calculations
for acquisitions of significant intangible assets. Abbott reviews
definite-lived intangible assets for impairment each quarter. An
undiscounted net cash flows approach is used to test for impair-
ment. If the undiscounted cash flows of an intangible asset are less
than the carrying value of an intangible asset, the intangible asset
is written down to its fair value, which is usually the discounted
cash flow amount. Where cash flows cannot be identified for an
individual asset, the review is applied at the lowest group level for
which cash flows are identifiable. Goodwill and indefinite-lived
intangible assets, which relate to in-process research and develop-
ment (IPR&D) acquired in a business combination or consolidated
variable interest entities, are reviewed for impairment annually or
when an event that could result in an impairment occurs. At
December 31, 2025, goodwill amounted to $24.0 billion and net
intangible assets amounted to $5.5 billion. Amortization expense
for intangible assets amounted to $1.7 billion in 2025, $1.9 billion in
2024, and $2.0 billion in 2023. There was no reduction of goodwill
relating to impairments in 2025, 2024, and 2023.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. These estimates are often initially developed substan-
tially earlier than the ultimate loss is known, and the estimates are
refined each accounting period as additional information becomes
known. Accordingly, Abbott is often initially unable to develop a
best estimate of loss, and therefore the minimum amount, which
could be zero, is recorded. As information becomes known, either
the minimum loss amount is increased, resulting in additional loss
provisions, or a best estimate can be made, also resulting in addi-
tional loss provisions. Occasionally, a best estimate amount is
changed to a lower amount when events result in an expectation
of a more favorable outcome than previously expected. Abbott
estimates the range of possible loss to be from approximately
$170 million to $180 million for its legal proceedings and environ-
mental exposures. The recorded accruals balance at December 31,
2025, for these proceedings and exposures were approximately
$175 million and included $165 million for legal reserves related to
a negotiated settlement. These accruals represent management’s
best estimate of probable loss, as defined by FASB ASC No. 450,
“Contingencies.”

-- 70 of 86 --

Financial Review
69
Abbott / 2025 Annual Report
Results of Operations
Sales
The following table details the components of sales growth by
reportable segment for the last two years:
Total %
Change
Components of % Change
Price 	Volume 	Exchange
Total Net Sales
2025 vs. 2024 	5.7 	0.7 	4.8 	0.2
2024 vs. 2023 	4.6 	3.5 	3.7 	(2.6)
Total U.S.
2025 vs. 2024 	4.9 	— 	4.9 	—
2024 vs. 2023 	5.6 	1.9 	3.7 	—
Total International
2025 vs. 2024 	6.1 	1.2 	4.7 	0.2
2024 vs. 2023 	3.9 	4.6 	3.5 	(4.2)
Established Pharmaceutical Products Segment
2025 vs. 2024 	6.6 	4.1 	3.3 	(0.8)
2024 vs. 2023 	2.5 	8.2 	1.0 	(6.7)
Nutritional Products Segment
2025 vs. 2024 	0.4 	2.4 	(1.3) 	(0.7)
2024 vs. 2023 	3.2 	7.7 	(1.7) 	(2.8)
Diagnostic Products Segment
2025 vs. 2024 	(4.3) 	(2.1) 	(2.4) 	0.2
2024 vs. 2023 	(6.5) 	1.4 	(5.3) 	(2.6)
Medical Devices Segment
2025 vs. 2024 	12.6 	0.4 	11.5 	0.7
2024 vs. 2023 	12.4 	1.4 	12.3 	(1.3)
The increase in total net sales in 2025, excluding the impact of
foreign exchange, primarily reflects higher sales in the Medical
Devices and Established Pharmaceutical Products segments.
Nutritional Products segment sales for the year remained relatively
unchanged, reflecting price increases and lower volumes.
Diagnostic Products segment sales continued to be impacted by
the decline in COVID-19 testing-related sales and challenging
market conditions in China. Abbott’s COVID-19 testing-related sales
totaled $297 million in 2025, $747 million in 2024 and $1.6 billion in
2023. Abbott’s net sales in 2025 were not significantly impacted by
changes in foreign exchange rates as the relatively stronger U.S.
dollar at the beginning of the year weakened later in the year,
resulting in a 0.2 percent favorable impact on total international
sales and total sales.
The increase in total net sales in 2024, excluding the impact of
foreign exchange, primarily reflects higher sales in the Medical
Devices, Established Pharmaceutical Products, and Nutritional
Products segments, partially offset by a decrease in demand for
Abbott’s rapid diagnostic tests to detect COVID-19. Abbott’s net
sales in 2024 were unfavorably impacted by changes in foreign
exchange rates as the relatively stronger U.S. dollar decreased total
international sales by 4.2 percent and total sales by 2.6 percent.
The table below provides detail by sales category for the years
ended December 31. Percent changes are versus the prior year and
are based on unrounded numbers.
(dollars in millions) 	2025 	2024
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Established
Pharmaceutical
Products—
Key Emerging Markets $4,167 $3,858 	8.0% 	(1.5) % 	9.5%
Other Emerging
Markets 	1,369 	1,336 	2.5 	1.1 	1.4
Nutritional Products —
International Pediatric
Nutritionals 	1,816 	1,815 	0.1 	(1.2) 	1.3
U.S. Pediatric
Nutritionals 	2,158 	2,208 	(2.3) 	— 	(2.3)
International Adult
Nutritionals 	3,029 	2,909 	4.1 	(1.0) 	5.1
U.S. Adult Nutritionals 	1,448 	1,481 	(2.2) 	— 	(2.2)
Diagnostic Products —
Core Laboratory 	5,360 	5,235 	2.4 	0.3 	2.1
Molecular 	517 	521 	(0.7) 	0.5 	(1.2)
Point of Care 	606 	588 	3.1 	— 	3.1
Rapid Diagnostics 	2,454 	2,997 	(18.1) 	(0.1) 	(18.0)
Medical Devices —
Rhythm Management 	2,649 	2,390 	10.9 	0.7 	10.2
Electrophysiology 	2,764 	2,467 	12.0 	0.4 	11.6
Heart Failure 	1,448 	1,279 	13.2 	0.5 	12.7
Vascular 	2,995 	2,837 	5.6 	0.5 	5.1
Structural Heart 	2,523 	2,246 	12.3 	0.8 	11.5
Neuromodulation 	1,010 	962 	5.0 	0.2 	4.8
Diabetes Care 	7,998 	6,805 	17.5 	1.2 	16.3

-- 71 of 86 --

Financial Review
70
Abbott / 2025 Annual Report
(dollars in millions) 	2024 	2023
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Established
Pharmaceutical
Products —
Key Emerging Markets 	$3,858 $3,807 	1.3% 	(8.2) % 	9.5%
Other Emerging
Markets 	1,336 	1,259 	6.1 	(2.3) 	8.4
Nutritional Products —
International Pediatric
Nutritionals 	1,815 	1,957 	(7.3) 	(3.0) 	(4.3)
U.S. Pediatric
Nutritionals 	2,208 	1,977 	11.7 	— 	11.7
International Adult
Nutritionals 	2,909 	2,784 	4.5 	(6.0) 	10.5
U.S. Adult Nutritionals 	1,481 	1,436 	3.2 	— 	3.2
Diagnostic Products —
Core Laboratory 	5,235 	5,159 	1.5 	(4.1) 	5.6
Molecular 	521 	574 	(9.2) 	(0.7) 	(8.5)
Point of Care 	588 	565 	4.1 	— 	4.1
Rapid Diagnostics 	2,997 	3,690 	(18.8) 	(1.0) 	(17.8)
Medical Devices —
Rhythm Management 	2,390 	2,255 	6.0 	(0.9) 	6.9
Electrophysiology 	2,467 	2,195 	12.3 	(2.1) 	14.4
Heart Failure 	1,279 	1,161 	10.2 	(0.1) 	10.3
Vascular 	2,837 	2,681 	5.8 	(0.9) 	6.7
Structural Heart 	2,246 	1,944 	15.5 	(1.5) 	17.0
Neuromodulation 	962 	890 	8.2 	(1.3) 	9.5
Diabetes Care 	6,805 	5,761 	18.1 	(1.6) 	19.7
Notes:
To compute results excluding the impact of exchange rates, current year U.S. dollar sales
are multiplied or divided, as appropriate, by the current year average foreign exchange
rates and then those amounts are multiplied or divided, as appropriate, by the prior year
average foreign exchange rates.
Established Pharmaceutical Products segment sales increased
7.4 percent in 2025 and 9.2 percent in 2024, excluding the unfavor-
able impact of foreign exchange. Excluding the effect of foreign
exchange, sales in Key Emerging Markets for Established
Pharmaceutical Products increased 9.5 percent in 2025 and 2024,
led by higher revenue in several countries and across multiple
therapeutic areas, including cardiometabolic, gastroenterology,
and central nervous system/pain management. In 2024, growth in
this segment also reflected higher respiratory product sales. Other
Emerging Markets, excluding the effect of foreign exchange,
increased by 1.4 percent in 2025 and 8.4 percent in 2024. Growth
in 2025 was unfavorably impacted by the absence of deferred gain
amortization related to a prior transaction. The deferred gain was
fully amortized in 2024.
Excluding the impact of foreign exchange, total Nutritional
Products segment sales increased 1.1 percent in 2025 and
5.9 percent in 2024. U.S. Pediatric Nutritionals sales decreased
2.3 percent in 2025, primarily reflecting lower infant formula sales.
In 2024, U.S. Pediatric Nutritionals sales increased 11.7 percent,
driven by infant formula market share gains and the favorable
impact of price increases, partially offset by a decrease in
PediaSure® and Pedialyte® product sales.
Excluding the effect of foreign exchange, International Pediatric
Nutritionals sales increased 1.3 percent in 2025, driven primarily
by higher PediaSure product sales. Excluding the effect of foreign
exchange, the 4.3 percent decrease in International Pediatric
Nutritionals sales in 2024 reflects lower sales in the Asia Pacific
and Latin America regions, partially offset by increased sales in
Canada and the Europe/Middle East regions.
In 2025, U.S. Adult Nutritionals sales decreased 2.2 percent, reflect-
ing lower Ensure® product sales and the discontinuation of the
ZonePerfect product line in March 2024, partially offset by growth
in Glucerna® product sales. International Adult Nutritionals sales,
excluding the effect of foreign exchange, increased 5.1 percent due
to growth of Ensure and Glucerna product sales. In 2024, U.S. and
International Adult Nutritionals sales increased 3.2 percent and
10.5 percent, respectively, due to higher Ensure and Glucerna
product sales. In 2024, U.S. Adult Nutritionals sales were partially
offset by the discontinuation of the ZonePerfect product line.
Excluding the effect of foreign exchange, Diagnostic Products
segment sales decreased 4.5 percent in 2025 and 3.9 percent in
2024 due to the continued decline in COVID-19 testing-related
sales and challenging market conditions in China. Rapid
Diagnostics sales decreased 18.0 percent in 2025 and 17.8 percent
in 2024, excluding the effect of foreign exchange. The 2025 and
2024 sales decrease in Rapid Diagnostics reflects lower demand
for COVID-19 testing-related sales, which were $285 million in 2025
and $725 million in 2024.
In Core Laboratory, sales increased 2.1 percent in 2025 and
5.6 percent in 2024, driven by continued growth of Alinity product
sales outside of China. Lower sales in China were due to the impact
of challenging market conditions, including the impact of volume-
based procurement programs. In 2024, sales increased due to
higher volume of routine diagnostic testing performed in hospitals
and other laboratories along with price increases.
Excluding the effect of foreign exchange, total Medical Devices
segment sales grew 11.9 percent in 2025 and 13.7 percent in 2024,
led by double-digit growth in Diabetes Care, Heart Failure,
Electrophysiology, and Structural Heart, and in 2025, Rhythm
Management. Higher Diabetes Care sales were driven by continued
growth in Abbott’s CGM systems in the U.S. and internationally.
CGM sales totaled $7.6 billion in 2025, representing a 17.4 percent
increase, excluding the effect of foreign exchange, compared to
$6.4 billion in 2024.

-- 72 of 86 --

Financial Review
71
Abbott / 2025 Annual Report
In Heart Failure, sales grew 12.7 percent in 2025 and 10.3 percent
in 2024, excluding the effect of foreign exchange. The increase
primarily reflects growth across the portfolio of ventricular assist
devices and related accessories, as well as growth in CardioMEMs®,
an implantable sensor used for the early detection of heart failure.
In Structural Heart, sales increased 11.5 percent in 2025 and
17.0 percent in 2024, excluding the effect of foreign exchange,
primarily driven by growth in TriClip®, Navitor®, and Mitraclip®
product sales.
Electrophysiology sales, excluding the effect of foreign exchange,
increased 11.6 percent in 2025 and 14.4 percent in 2024, primarily
due to higher procedure volumes and increased demand for
Abbott’s portfolio of products designed to diagnose and treat
cardiac arrhythmias.
In Rhythm Management, sales increased 10.2 percent in 2025 and
6.9 percent in 2024, excluding the impact of foreign exchange,
primarily driven by growth in Aveir® leadless pacemakers. In 2025,
sales growth was partially offset by lower traditional pacemaker
and implantable cardioverter defibrillator sales.
Abbott’s operations in Russia and Ukraine represent approximately
2 percent of Abbott’s total revenues and net assets, and to date the
financial impact of Russia’s invasion of Ukraine has not been mate-
rial to Abbott’s operations or financial condition. Future implications
are difficult to predict, but at present Abbott does not anticipate
that the Russia-Ukraine conflict will have a material impact on its
operations or financial condition. A more detailed discussion of the
risks associated with the Russia-Ukraine conflict is contained in
Item 1A. Risk Factors.
The expiration of licenses and patent protection can affect the
future revenues and operating income of Abbott. There are no
significant patent or license expirations in the next three years
that are expected to materially affect Abbott.
Operating Earnings
Gross profit margins were 52.6 percent of net sales in 2025,
50.9 percent of net sales in 2024, and 50.3 percent of net sales
in 2023. The increase in 2025 reflects the favorable impact of
margin improvement initiatives, partially offset by higher costs,
including tariffs, and the unfavorable impact of foreign exchange.
The increase in 2024 reflects the favorable impact of margin
improvement initiatives, partially offset by the unfavorable effect
of foreign exchange.
Research and development (R&D) expenses were $2.9 billion in
2025, $2.8 billion in 2024, and $2.7 billion in 2023. The increases in
R&D expenses in 2025 and 2024 were primarily driven by higher
spending on various projects. In 2024, higher project spending was
partially offset by lower 2024 charges for the impairment of IPR&D
assets acquired in previous business combinations.
Selling, general and administrative (SG&A) expenses were
$12.3 billion in 2025, $11.7 billion in 2024, and $10.9 billion in 2023.
In 2025 and 2024, the increase in SG&A expenses was due to
higher selling and marketing spending to drive growth across
various businesses. In 2024, SG&A spending was partially offset
by the favorable impact of foreign exchange.
Restructurings
In 2025, Abbott management approved plans to streamline certain
operations in order to reduce costs and improve efficiencies in its
Diagnostics, Nutritionals, Established Pharmaceuticals, and
Medical Devices businesses. Abbott recorded employee related
severance and other charges of $274 million, of which $109 million
was recorded in Cost of products sold, $53 million was recorded in
R&D, and $112 million was recorded in SG&A expenses. Payments
related to these actions totaled $94 million in 2025 and the remain-
ing liabilities totaled $180 million at December 31, 2025. In addition,
in 2025, Abbott recognized fixed asset impairment charges of
$28 million related to these restructuring plans.
In 2024, Abbott management approved plans to streamline certain
operations in order to reduce costs and improve efficiencies in its
Diagnostics, Medical Devices, Established Pharmaceuticals, and
Nutritionals businesses, including the discontinuation of its
ZonePerfect product line. Abbott recorded employee related sever-
ance and other charges of $129 million, of which $62 million was
recorded in Cost of products sold, $21 million was recorded in R&D,
and $46 million was recorded in SG&A expenses. In addition,
Abbott recognized inventory-related charges of $34 million and
fixed asset impairment charges of $12 million related to these
restructuring plans.
In 2023, Abbott management approved plans to restructure vari-
ous operations in order to reduce costs in its Medical Devices,
Diagnostics, and Established Pharmaceuticals businesses. Abbott
recorded employee related severance and other charges of
$144 million, of which $56 million was recorded in Cost of products
sold, $22 million was recorded in R&D, and $66 million was
recorded in SG&A expenses. In addition, Abbott recognized fixed
asset impairment and inventory-related charges of $31 million
related to these restructuring plans.

-- 73 of 86 --

Financial Review
72
Abbott / 2025 Annual Report
Interest Expense and Interest (Income)
Interest expense, net decreased from $215 million in 2024 to
$185 million in 2025. In 2025, interest expense decreased primarily
due to the repayment of approximately $2.0 billion of long-term
debt in November 2024, March 2025, and September 2025, as well
as the maturity of an interest rate swap associated with the March
2025 debt. Interest expense decreased in 2024 due to the repay-
ment of $2.25 billion of long-term debt in September and November
of 2023, partially offset by a reduction in interest income due to
lower average cash and short-term investment balances versus
the prior year.
Other (Income) Expense, net
Other (income) expense, net was $548 million of income in 2025,
$376 million of income in 2024, and $479 million of income in 2023.
Other (income) expense, net includes income of $590 million,
$542 million, and $498 million in 2025, 2024, and 2023, respec-
tively, related to the non-service cost components of the net
periodic benefit costs associated with the pension and post-
retirement medical plans. The increase in 2025 and the decrease
in 2024 were primarily due to the recognition of a $143 million loss
on the sale of a non-core business related to the Established
Pharmaceutical Products segment in 2024. The increase in 2025
also reflects higher income associated with the non-service cost
components of net pension and post-retirement medical benefit
costs. The decrease in 2024 was partially offset by an increase in
income associated with the non-service cost components of net
pension and post-retirement medical benefit costs.
Taxes on Earnings
Taxes on earnings reflect the annual effective rates, including
charges for interest and penalties. Deferred income taxes reflect the
tax consequences on future years of differences between the tax
bases of assets and liabilities and their financial reporting amounts.
Taxes on earnings included $92 million, $50 million, and $22 million
in excess tax benefits associated with share-based compensation in
2025, 2024, and 2023, respectively. As a result of the resolution of
various tax positions related to prior years, taxes on earnings in
2025, 2024, and 2023 also included approximately $70 million of
net tax benefit, $25 million, and $80 million of net tax expense,
respectively. In 2025, taxes on earnings included approximately
$610 million of tax expense related to a deferred tax asset that was
recognized as a significant non-cash tax benefit in a prior year. In
2024, taxes on earnings included $7.5 billion in non-cash valuation
allowance adjustments resulting from the restructuring of certain
foreign affiliates and the confirmation of certain tax filing positions.
The restructuring improved profitability to several of Abbott’s
affiliates and management concluded that the related preexisting
deferred tax assets, which historically had a full valuation allowance,
were more likely than not to be realizable in future periods.
In particular, Abbott considered the likelihood of sustained ongoing
profitability of the affiliates as a positive factor that outweighed all
available negative evidence considered. Accordingly, Abbott
released the full valuation allowance on such deferred tax assets
and recorded the offset to taxes on earnings.
The U.S. Tax Cuts and Jobs Act (TCJA) included a one-time transition
tax that is based on Abbott’s total post-1986 earnings and profits
(E&P) that were previously deferred from U.S. income taxes. The
tax computation also required the determination of the amount of
post-1986 E&P considered held in cash and other specified assets.
As of December 31, 2025, the remaining balance of Abbott’s transition
tax obligation related to the TCJA was approximately $205 million.
The final installment will be paid in 2026 as allowed by the TCJA.
Undistributed foreign earnings remain indefinitely reinvested in
foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed foreign
earnings not subject to the transition tax and additional outside
basis difference in its foreign entities is not practicable.
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the IRS for the 2019 Federal tax year in the
amount of $417 million. The primary adjustments proposed in the
SNOD relate to the reallocation of income between Abbott’s U.S.
entities and its foreign affiliates. Abbott believes that the income
reallocation adjustments proposed in the SNOD are without merit,
in part because certain adjustments contradict methods that
were agreed to with the IRS in prior audit periods. The SNOD also
contains other proposed adjustments that Abbott believes are
erroneous and unsupported. Abbott filed a petition with the U.S.
Tax Court contesting the SNOD in December 2023.
In June 2024, Abbott received a SNOD from the IRS for the
2017 and 2018 Federal tax years in the amount of $192 million. The
matters proposed in the 2017/2018 SNOD are substantially similar
to the income allocation adjustments included in the 2019 SNOD.
Abbott filed a petition in September 2024 with the U.S. Tax Court
contesting the 2017/2018 SNOD in a manner consistent with its
petition for the 2019 SNOD.
In October 2024, Abbott received a SNOD from the IRS for the
2020 Federal tax year assessing an additional $443 million of
income tax. The primary adjustments proposed in the SNOD
are substantially similar to the income allocation adjustments
included in the 2017/2018 and 2019 SNODs. Abbott believes that
the income reallocation adjustments proposed in the SNOD are
without merit. The SNOD also contains other proposed adjustments
and omissions that Abbott believes are erroneous and unsupported.
In addition to the tax assessment for the 2020 tax year, the 2020
SNOD also contested a deduction for which an estimated
$440 million cash tax benefit would be available in a different
taxable year as allowed under applicable U.S. tax law. Abbott
filed a petition with the U.S. Tax Court contesting the SNOD in
December 2024.

-- 74 of 86 --

Financial Review
73
Abbott / 2025 Annual Report
Abbott and the IRS are in active discussions regarding several of
the disputed items contained in the 2017–2020 SNODs.
In July 2024, Abbott received a $413 million tax assessment from
the Malaysian tax authorities for the 2023 tax year. The assessment
applies a property capital gains tax on the value of the shares
associated with the intercompany sale of an affiliate. Abbott
believes the assessment of the Malaysian tax authority to be
without merit. In October 2025, the Penang High Court upheld the
assessment of the Malaysian tax authority. In October 2025, Abbott
filed an appeal with the Malaysian Court of Appeals.
There are numerous other income tax jurisdictions for which tax
returns are not yet settled, none of which Abbott expects to be
individually significant. Abbott intends to vigorously defend its filing
positions in all jurisdictions in which it has unresolved tax matters
through ongoing discussions with taxing administrations and/or
through litigation as necessary. Abbott reserves for uncertain tax
positions related to unresolved tax matters where Abbott’s tax filing
position does not meet the standard for recognition of an income
tax benefit. Abbott continues to believe that the amount of its
recorded reserves for uncertain tax positions is appropriate.
Reserves for interest and penalties are not significant.
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised international
tax system. Pillar 1 proposes to reallocate taxing rights among the
jurisdictions in which in-scope multinational corporations operate.
Pillar 2 proposes to assess a 15 percent minimum tax on the earn-
ings of in-scope multinational corporations on a country-by-country
basis. Numerous countries have enacted legislation to adopt the
Pillar 2 model rules. On January 5, 2026, the OECD released admin-
istrative guidance that, when enacted, exempts U.S.-parented
groups from the Pillar 2 minimum tax. Abbott continues to monitor
legislative developments and assess any potential impacts on
Abbott’s operations for both the Pillar 1 and Pillar 2 proposals.
See Note 15 — Taxes on Earnings to the consolidated financial
statements for a full reconciliation of the effective tax rate to the
U.S. federal statutory rate.
Research and Development Programs
Abbott currently has numerous pharmaceutical, medical device,
diagnostic and nutritional products in development.
Research and Development Process
In the Established Pharmaceutical Products segment, the develop-
ment process focuses on the geographic expansion and continuous
improvement of the segment’s existing products to provide benefits
to patients and customers. As Established Pharmaceutical Products
does not actively pursue primary research, development usually
begins with work on existing products or after the completion of
an acquisition or licensing agreement.
Depending upon the product, the phases of development
may include:
• Drug product development.
• Phase I bioequivalence studies to compare a future Established
Pharmaceutical’s brand with an already marketed compound
with the same active pharmaceutical ingredient (API).
• Phase II studies to test the efficacy of benefits in a small group
of patients.
• Phase III studies to broaden the testing to a wider population
that reflects the actual medical use.
• Phase IV and other post-marketing studies to obtain new clinical
use data on existing products within approved indications.
The specific requirements (e.g., scope of clinical trials) for obtaining
regulatory approval vary across different countries and geographic
regions. The process may range from one year for a bioequivalence
study project to six or more years for complex formulations, new
indications, or geographic expansion in specific countries.
In the Diagnostic Products segment, the phases of the research
and development process include:
• Discovery, which focuses on identification of a product that
will address a specific therapeutic area, platform, or unmet
clinical need.
• Concept/Feasibility, during which the materials and
manufacturing processes are evaluated; testing may include
product characterization and analysis is performed to confirm
clinical utility.
• Development, during which extensive testing is performed to
demonstrate that the product meets specified design require-
ments and that the design specifications conform to user needs
and intended uses.
The regulatory requirements for diagnostic products vary across
different countries and geographic regions. In the U.S., the FDA
classifies diagnostic products into classes (I, II, or III) and the
classification determines the regulatory process for approval.
While the Diagnostics segment has products in all three classes, the
vast majority of its products are categorized as Class I or Class II.
Submission of a separate regulatory filing is not required for Class I
products. Class II products typically require premarket notification
to the FDA through a regulatory filing known as a 510(k) submission.
Most Class III products are subject to the FDA’s Premarket Approval
(PMA) requirements. Other Class III products, such as those used to
screen blood, require the submission and approval of a Biological
License Application (BLA).

-- 75 of 86 --

Financial Review
74
Abbott / 2025 Annual Report
In the European Union (EU), diagnostic products are also catego-
rized into different categories and the regulatory process, which
had been governed by the European In Vitro Diagnostic Medical
Device Directive, depends upon the category. Certain product
categories require review and approval by an independent com-
pany, known as a Notified Body, before the manufacturer can affix
a CE mark to the product to declare conformity to the Directive.
Other products only require a self-certification process. In 2017,
the EU adopted the new In Vitro Diagnostic Regulation (IVDR)
which replaced the existing directive in the EU for in vitro diagnos-
tic products and imposed additional premarket and post-market
regulatory requirements on manufacturers of such products. In
July 2024, the IVDR was amended to extend the transition timeline
period for dates of compliance as long as December 2029,
depending on the diagnostic device classification. The diagnostic
device must meet additional specific conditions set out in
the amended regulations. However, the amendment did not delay
the date of application of the IVDR itself which took effect on
May 26, 2022.
In the Medical Devices segment, the research and development
process begins with research on a specific technology that is
evaluated for feasibility and commercial viability. If the research
program passes that hurdle, it moves forward into development.
The development process includes evaluation, selection and
qualification of a product design, completion of applicable clinical
trials to test the product’s safety and efficacy, and validation of the
manufacturing process to demonstrate its repeatability and ability
to consistently meet pre-determined specifications.
Similar to the diagnostic products discussed above, in the U.S.,
medical devices are classified as Class I, II, or III. Most of Abbott’s
medical device products are classified as Class II devices that
follow the 510(k) regulatory process or Class III devices that are
subject to the PMA process.
In the EU, medical devices are also categorized into different
classes and the regulatory process, which had been governed by
the European Medical Device Directive and the Active Implantable
Medical Device Directive, varies by class. In the second quarter of
2017, the EU adopted the new Medical Devices Regulation (MDR)
which replaced the existing directives in the EU for medical devices
and imposes additional premarket and post-market regulatory
requirements on manufacturers of such products. The MDR applies
to manufacturers as of May 26, 2021, with extended transition
periods lasting as long as December 31, 2028, depending on the
risk classification of the device in the regulation. Each product
must bear a CE mark to show compliance with the MDR.
Some products require submission of a design dossier to the
appropriate regulatory authority for review and approval prior to CE
marking of the device. For other products, the company is required
to prepare a technical file which includes testing results and clinical
evaluations but can self-certify its ability to apply the CE mark to
the product. Outside the U.S. and the EU, the regulatory require-
ments vary across different countries and regions.
After approval and commercial launch of some medical devices,
post-market trials may be conducted either due to a conditional
requirement of the regulatory market approval or with the objective
of proving product superiority.
In the Nutritional Products segment, the research and development
process generally focuses on identifying and developing ingredi-
ents and products that address the nutritional needs of particular
populations (e.g., infants and adults) or patients (e.g., people with
diabetes). Depending upon the country and/or region, if claims
regarding a product’s efficacy will be made, clinical studies typi-
cally must be conducted.
In the U.S., the FDA requires that it be notified of proposed new
formulations and formulation or packaging changes related to infant
formula products. Prior to the launch of an infant formula or product
packaging change, the company is required to obtain the FDA’s
confirmation that it has no objections to the proposed product or
packaging. For other nutritional products, notification or pre-approval
from the FDA is not required unless the product includes a new food
additive. In some countries, regulatory approval may be required for
certain nutritional products, including infant formula and medical
nutritional products.
Areas of Focus
In 2026 and beyond, Abbott expects to focus on the follow-
ing areas:
Established Pharmaceuticals — Abbott focuses on building
country-specific portfolios made up of high-quality medicines
that meet the needs of people in emerging markets. Over the next
several years, Abbott plans to expand its product portfolio in key
therapeutic areas and biosimilars with the aim of addressing the
health needs of more people in emerging markets and to be among
the first to launch new off-patent and differentiated medicines.
In addition, Abbott continues to expand existing brands into new
markets, implement product enhancements that provide value to
patients, and acquire strategic products and technology through
licensing activities. Abbott is also actively working on the further
development of several key brands such as Creon™, Duphaston™,
Femoston™, and Influvac™. Depending on the product, the activities
focus on development of new data, markets, formulations, delivery
systems, or indications.

-- 76 of 86 --

Financial Review
75
Abbott / 2025 Annual Report
Medical Devices — Abbott’s research and development programs
focus on:
• Cardiac Rhythm Management – Development of next-generation
rhythm management technologies, including advanced commu-
nication capabilities and leadless pacing therapies.
• Heart Failure – Continued enhancements to Abbott’s mechanical
circulatory support and pulmonary artery pressure systems,
including enhanced clinical performance and usability.
• Electrophysiology – Development of next-generation technolo-
gies in the areas of ablation, mapping and navigation, and
diagnostics.
• Vascular – Development of next-generation technologies for use
in coronary and peripheral vascular procedures.
• Structural Heart – Development of transcatheter and surgical
devices for the repair and replacement of heart valves, and
occlusion therapies for congenital heart defects and stroke-risk
reduction.
• Neuromodulation – Development of clinical evidence and
next-generation technologies leveraging digital health to support
improved patient clinical outcomes, physician engagement, and
expanded indications in the treatment of chronic pain, movement
disorders, and other indications.
• Diabetes Care – Develop enhancements, additional indications,
and tools for continuous monitoring products to help with the
management of diabetes, as well as to expand use beyond
diabetes.
Nutritionals — Abbott is focusing its research and development
spend on platforms that span the pediatric and adult nutrition
areas: gastrointestinal/immunity health, brain health, mobility and
metabolism, and user experience platforms. Numerous new prod-
ucts that build on advances in these platforms are currently under
development, including clinical outcome testing, and are expected
to be launched over the coming years.
Diagnostics — Abbott continues to develop and commercialize
next-generation blood and plasma screening systems and assays,
as well as Core Laboratory immunoassay, clinical chemistry and
hematology diagnostic systems and assays. Assay development
pipelines include a focus on unmet medical needs, in various areas
including infectious disease, cardiac care, metabolics, oncology,
women’s health, and neurologic assays, as well as informatics
solutions to help optimize diagnostic laboratory performance
and automation solutions to increase efficiency in laboratories.
Research and development programs also include development
of rapid diagnostic products for infectious disease, cardiometabolic
disease, and toxicology applications.
Given the diversity of Abbott’s business, its intention to remain a
broad-based healthcare company and the numerous sources for
potential future growth, no individual project is expected to be
material to cash flows or results of operations over the next five
years. Factors considered included research and development
expenses projected to be incurred for the project over the next year
relative to Abbott’s total research and development expenses, as
well as qualitative factors, such as marketplace perceptions and
impact of a new product on Abbott’s overall market position. There
were no delays in Abbott’s 2025 research and development activi-
ties that are expected to have a material impact on operations.
While the aggregate cost to complete the numerous projects
currently in development is expected to be material, the total cost
to complete will depend upon Abbott’s ability to successfully finish
each project, the rate at which each project advances, and the
ultimate timing for completion. Given the potential for significant
delays and the risk of failure inherent in the development of new
products and technologies, it is not possible to accurately estimate
the total cost to complete all projects currently in development.
Abbott plans to manage its portfolio of projects to achieve research
and development spending that will be competitive in each of the
businesses in which it participates, and such spending is targeted
at approximately 7 percent of total Abbott sales in 2026. Abbott
does not regularly accumulate or make management decisions
based on the total expenses incurred for a particular development
phase in a given period.
Goodwill
At December 31, 2025, goodwill recorded as a result of business
combinations totaled $24.0 billion. Goodwill is reviewed for impair-
ment annually in the third quarter or when an event that could result
in an impairment occurs, using a quantitative assessment to deter-
mine whether it is more likely than not that the fair value of any
reporting unit is less than its carrying amount. The income and
market approaches are used to calculate the fair value of each
reporting unit. The results of the last impairment test indicated that
the fair value of each reporting unit was substantially in excess of
its carrying value.
Financial Condition
Cash Flow
Net cash from operating activities amounted to $9.6 billion,
$8.6 billion, and $7.3 billion in 2025, 2024, and 2023, respectively.
The increase in Net cash from operating activities in 2025 as com-
pared to 2024, and in 2024 compared to 2023, was primarily due
to higher segment operating earnings and improved working capital
management, partially offset by higher cash payments for
income taxes.
A substantial portion of Abbott’s cash and cash equivalents at
December 31, 2025, is held by Abbott affiliates outside of the U.S. If
these funds were needed for operations in the U.S., Abbott does not
expect to incur significant additional income taxes in the future to
repatriate these funds.
Abbott funded $309 million in 2025 and $349 million in both 2024
and 2023 to defined benefit pension plans. Abbott expects to
contribute approximately $85 million to its pension plans in 2026.
Abbott expects annual cash flow from operating activities to con-
tinue to exceed Abbott’s capital expenditures and cash dividends.

-- 77 of 86 --

Financial Review
76
Abbott / 2025 Annual Report
Debt and Capital
At December 31, 2025, Abbott’s long-term debt rating was AA- by
S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott
expects to maintain an investment grade rating.
Abbott has readily available financial resources, including unused
lines of credit that support commercial paper borrowing arrange-
ments and provide Abbott with the ability to borrow up to $5 billion
on an unsecured basis. In 2024, Abbott terminated its 2020 Five
Year Credit Agreement (2020 Agreement) and entered into a new
Five Year Credit Agreement (Revolving Credit Agreement). There
were no outstanding borrowings under the 2020 Agreement at the
time of its termination. Any borrowings under the Revolving Credit
Agreement will mature and be payable on January 29, 2029, and
will bear interest, at Abbott’s option, based on either a base rate
or Secured Overnight Financing Rate (SOFR), plus an applicable
margin based on Abbott’s credit ratings.
As of December 31, 2025, Abbott’s total debt outstanding was
$12.9 billion, of which approximately $3.0 billion will mature in 2026.
In 2024, Abbott modified its existing, yen-denominated 5-year term
loan scheduled to mature in November 2024. The amended terms
included a net increase in principal debt from ¥59.8 billion to
¥92.0 billion, with a new maturity date in June 2029. The modified,
5-year term loan bears interest at the Tokyo Interbank Offered Rate
(TIBOR) plus a fixed spread, and the interest rate is reset quarterly.
The net proceeds equated to approximately $201 million. The
¥92.0 billion loan is designated as a hedge of Abbott’s net invest-
ment in certain foreign subsidiaries.
On November 19, 2025, Abbott obtained a commitment for a 364-
day senior unsecured bridge term loan facility for an amount not to
exceed $20.0 billion in conjunction with its pending acquisition of
Exact Sciences. While Abbott plans to fund this transaction with
cash on hand and borrowings, the bridge facility will provide
back-up financing.
On September 15, 2025, Abbott repaid the $500 million outstanding
principal amount of its 3.875% Notes upon maturity. On March 17,
2025, Abbott repaid the $1.0 billion outstanding principal amount
of its 2.95% Notes upon maturity. On November 19, 2024, Abbott
repaid the €590 million outstanding principal amount of its 0.10%
Notes upon maturity. The repayment equated to approximately
$640 million. On November 30, 2023, Abbott repaid the $1.05 billion
outstanding principal amount of its 3.40% Notes upon maturity.
On September 27, 2023, Abbott repaid the €1.14 billion outstanding
principal amount of its 0.875% Notes upon maturity. The repayment
equated to approximately $1.2 billion. In September 2023, Abbott
repaid approximately $197 million of debt assumed as part of a prior
business acquisition.
On October 11, 2024, the board of directors authorized the repur-
chase of up to $7 billion of Abbott common shares, from time to time
(the “2024 repurchase program”). The 2024 repurchase program
was in addition to the unused portion of the 2021 repurchase pro-
gram, which the board of directors approved in December 2021,
and authorized the repurchase of up to $5 billion of Abbott’s common
shares from time to time. In 2024 and 2023, Abbott repurchased
10.2 million and 9.8 million, respectively, of its common shares for
$1.1 billion and $1.0 billion, respectively, under the 2021 repurchase
program. In 2025, Abbott repurchased 4.8 million of its common
shares for $604 million, which fully utilized the $293 million authori-
zation remaining under the 2021 share repurchase program, and a
portion of the 2024 repurchase program. As of December 31, 2025,
$6.7 billion remains available for repurchase under the 2024 repur-
chase program.
Abbott declared dividends of $2.40 per share in 2025 compared to
$2.24 per share in 2024, an increase of 7.1 percent. Dividends paid
were $4.1 billion in 2025 compared to $3.8 billion in 2024. The
year-over-year change in dividends paid reflects the impact of the
increase in the dividend rate.
Working Capital
Working capital was $9.5 billion at December 31, 2025, and
December 31, 2024. Working capital remained unchanged from the
prior year primarily as an increase in cash and cash equivalents and
accounts receivable was offset by an increase in the current por-
tion of long-term debt and other accrued liabilities. The increase in
cash and cash equivalents from $7.6 billion at December 31, 2024,
to $8.5 billion at December 31, 2025, primarily reflects the cash
generated from operations, partially offset by the payment of
dividends and capital expenditures.
Abbott monitors the credit worthiness of customers and establishes
an allowance that reflects the current estimate of credit losses
expected to be incurred over the life of the financial asset. Abbott
considers various factors in establishing, monitoring, and adjusting
its allowance for doubtful accounts, including the aging of the
accounts and aging trends, the historical level of charge-offs, and
specific exposures related to particular customers. Abbott also
monitors other risk factors and forward-looking information, such
as country risk, when determining credit limits for customers and
establishing adequate allowances.

-- 78 of 86 --

Financial Review
77
Abbott / 2025 Annual Report
Capital Expenditures
Capital expenditures of $2.2 billion in 2025, 2024, and 2023 were
principally for upgrading and expanding manufacturing and
research and development facilities and equipment in various
segments, investments in information technology, and laboratory
instruments placed with customers.
Contractual Obligations
Abbott believes that its available cash and cash equivalents along
with its ability to generate operating cash flow and continued
access to debt markets are sufficient to fund existing and planned
cash requirements. Abbott’s material cash requirements include the
following contractual obligations:
Debt — Principal payments required on long-term debt outstanding
at December 31, 2025, are $3.0 billion in 2026, $700 million in 2027,
$653 million in 2028, $591 million in 2029, $650 million in 2030, and
$7.4 billion in 2031 and thereafter. Interest payments required on
long-term debt outstanding at December 31, 2025, are projected to
be $485 million in 2026, $401 million in 2027, $395 million in 2028,
$386 million in 2029, $377 million in 2030, and $4.3 billion in 2031
and thereafter.
Operating leases — As of December 31, 2025, estimated contrac-
tual obligations for operating lease payments were $1.4 billion, with
$316 million due within 12 months.
In addition, Abbott enters into purchase commitments in the normal
course of business to meet operational and capital expenditure
requirements. The majority of outstanding purchase commitments
generally do not extend past one year.
Contingent Obligations
Abbott periodically acquires a business or product rights in which
Abbott agrees to pay contingent consideration based on attaining
certain thresholds or based on the occurrence of certain events.
Business Acquisitions
On November 19, 2025, Abbott entered into a definitive agreement
to acquire Exact Sciences Corporation (Exact Sciences), which is
expected to enable Abbott to enter the cancer diagnostics market.
The acquisition is subject to customary closing conditions, includ-
ing the approval of Exact Sciences shareholders, and obtaining the
required regulatory clearances. Under the terms of the agreement,
Abbott will pay $105 per common share in cash at the completion
of the transaction, representing a total equity value of approxi-
mately $21 billion and an estimated enterprise value of $23 billion.
Abbott’s financing contemplates absorption of Exact Sciences’
estimated $1.8 billion of net debt.
On November 19, 2025, Abbott obtained a commitment for a
364-day senior unsecured bridge term loan facility for an amount
not to exceed $20.0 billion in conjunction with its pending acquisi-
tion of Exact Sciences. While Abbott plans to fund this transaction
with cash on hand and borrowings, the bridge facility will provide
back-up financing.
On September 22, 2023, Abbott completed the acquisition of
Bigfoot, which furthers Abbott’s efforts to develop connected solu-
tions for making diabetes management more personal and precise.
The purchase price, the final allocation of acquired assets and
liabilities, and the revenue and net income contributed by Bigfoot
since the date of acquisition are not material to Abbott’s consoli-
dated financial statements.
On April 27, 2023, Abbott completed the acquisition of
Cardiovascular Systems, Inc. (CSI) for $20 per common share,
which equated to a purchase price of $851 million. The transaction
was funded with cash on hand and accounted for as a business
combination. CSI’s atherectomy system, which is used in treating
peripheral and coronary artery disease, adds complementary
technologies to Abbott’s portfolio of vascular device offerings.
The final allocation of the purchase price of the CSI acquisition
resulted in the recording of two non-deductible developed technol-
ogy intangible assets totaling $305 million; a non-deductible
in-process research and development asset of $15 million, which
will be accounted for as an indefinite-lived intangible asset until
regulatory approval or discontinuation; non-deductible goodwill
of $369 million; net deferred tax assets of $46 million and other net
assets of $116 million. The goodwill is identifiable to the Medical
Devices reportable segment and is attributable to expected syner-
gies from combining operations, as well as intangible assets that
do not qualify for separate recognition. Revenues and earnings of
CSI included in Abbott’s consolidated financial statements since
the acquisition date are not material to Abbott’s consolidated
revenue and earnings.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to
substantial government regulations throughout the world. Abbott
expects debate to continue at all government levels worldwide
over the manufacture, quality assurance requirements, marketing
authorization processes, post-market surveillance requirements,
availability, method of delivery, and payment for healthcare prod-
ucts and services, as well as data privacy and security. It is not
possible to predict the extent to which Abbott or the healthcare
industry in general might be adversely affected by these factors
in the future. A more complete discussion of these factors is
contained in Item 1, Business, and Item 1A, Risk Factors.

-- 79 of 86 --

Financial Review
78
Abbott / 2025 Annual Report
Recently Issued Accounting Standards
Recently Adopted Accounting Standards
In December 2023, the FASB issued Accounting Standards Update
(ASU) 2023-09, Income Taxes (Topic 740): Improvements to Income
Tax Disclosures, which requires an entity to disclose annually
additional information related to the company’s income tax rate
reconciliation and income taxes paid during the period. The guid-
ance is required to be applied prospectively with the option to
apply the standard retrospectively. Abbott adopted the standard on
January 1, 2025, and applied the guidance prospectively. The new
standard did not have an impact on Abbott’s consolidated financial
statements, but required additional disclosures, as presented in
Note 15 — Taxes on Earnings.
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of required
segment disclosures. The guidance is required to be applied retro-
spectively to all periods presented in the financial statements.
Abbott adopted the standard on January 1, 2024. The new standard
did not have an impact on Abbott’s consolidated financial state-
ments, but required additional disclosures, retrospectively applied
to all periods presented in Note 16 — Segment and Geographic
Area Information.
Recent Accounting Standards Not Yet Adopted
In November 2024, the FASB issued ASU 2024-03, Income
Statement (Subtopic 220-40): Reporting Comprehensive Income –
Expense Disaggregation Disclosures, which requires an entity to
disclose on an annual and interim basis, disaggregated information
about specific income statement expense categories. The guidance
should be applied prospectively with the option to apply the stan-
dard retrospectively. The standard becomes effective for Abbott for
full year 2027 reporting. Abbott is currently evaluating the impact
of this new standard on its consolidated financial statements.
Private Securities Litigation Reform Act of 1995 — A Caution
Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, Abbott cautions investors that any forward-
looking statements or projections made by Abbott, including those
made in this document, are subject to risks and uncertainties that
may cause actual results to differ materially from those projected.
Economic, competitive, governmental, technological, and other
factors that may affect Abbott’s operations are discussed in Item 1A,
Risk Factors.

-- 80 of 86 --

Financial Review
79
Abbott / 2025 Annual Report
Performance Graph
Assuming $100 invested on December 31, 2020 with dividends reinvested.
Abbott Laboratories
S&P 500 Index
S&P 500 Health Care
2021	2020 	2022 	2023 	2024 	2025
$0
$50
$150
$100
$250
$200
This graph compares the change
in Abbott’s cumulative total shareholder
return on its common shares with the
Standard & Poor’s 500 Index and the
Standard & Poor’s 500 Health Care Index.

-- 81 of 86 --

80
Abbott / 2025 Annual Report
Summary of Selected Financial Data
(Dollars in millions except per share data)
Year Ended December 31 	2025 	2024 	2023 	2022 	2021
Summary of Operations:
Net Sales 	$ 	44,328 	41,950 	40,109 	43,653 	43,075
Cost of products sold 	$ 	21,001 	20,584 	19,941 	21,155 	20,584
Research & development 	$ 	2,942 	2,844 	2,741 	2,888 	2,742
Selling, general, and administrative 	$ 	12,332 	11,697 	10,949 	11,248 	11,324
Operating earnings 	$ 	8,053 	6,825 	6,478 	8,362 	8,425
Interest expense 	$ 	493 	559 	637 	558 	533
Interest income 	$ 	(308) 	(344) 	(385) 	(183) 	(43)
Other (income) expense, net (a) 	$ 	(598) 	(403) 	(438) 	(319) 	(276)
Earnings before taxes 	$ 	8,466 	7,013 	6,664 	8,306 	8,211
Taxes on earnings from continuing operations 	$ 	1,942 	(6,389) 	941 	1,373 	1,140
Earnings from continuing operations 	$ 	6,524 	13,402 	5,723 	6,933 	7,071
Net earnings 	$ 	6,524 	13,402 	5,723 	6,933 	7,071
Basic earnings per common share from continuing operations 	$ 	3.73 	7.67 	3.28 	3.94 	3.97
Basic earnings per common share 	$ 	3.73 	7.67 	3.28 	3.94 	3.97
Diluted earnings per common share from continuing operations 	$ 	3.72 	7.64 	3.26 	3.91 	3.94
Diluted earnings per common share 	$ 	3.72 	7.64 	3.26 	3.91 	3.94
Financial Positions:
Working capital 	$ 	9,500 	9,499 	8,829 	9,735 	11,134
Long-term investment securities 	$ 	918 	886 	799 	766 	816
Net property & equipment 	$ 	11,816 	10,658 	10,154 	9,162 	8,959
Total assets 	$ 	86,713 	81,414 	73,214 	74,438 	75,196
Long-term debt, including current portion 	$ 	12,929 	14,125 	14,679 	16,773 	18,050
Shareholders’ investment 	$ 	52,771 	47,901 	38,827 	36,905 	36,024
Book value per share 	$ 	30.39 	27.66 	22.39 	21.24 	20.42
Other Statistics:
Gross profit margin 	% 	52.6 	50.9 	50.3 	51.5 	52.2
Research and development to net sales 	% 	6.6 	6.8 	6.8 	6.6 	6.4
Net cash from operating activities 	$ 	9,566 	8,558 	7,261 	9,581 	10,533
Capital expenditures 	$ 	2,171 	2,207 	2,202 	1,777 	1,885
Cash dividends declared per common share 	$ 	2.40 	2.24 	2.08 	1.92 	1.82
Common shares outstanding (in thousands) 	1,736,599 	1,731,697 	1,734,076 	1,737,795 	1,764,082
Number of common shareholders 	29,122 	30,768 	32,449 	34,019 	35,926
Market price per share – high 	$ 	141.23 	121.64 	115.83 	139.83 	142.60
Market price per share – low 	$ 	110.86 	99.71 	89.67 	93.25 	105.36
Market price per share – close 	$ 	125.29 	113.11 	110.07 	109.79 	140.74
a) These amounts include debt extinguishment costs and net foreign exchange (gain) loss.

-- 82 of 86 --

81
Abbott / 2025 Annual Report
Directors and Corporate Officers
*Denotes executive officer
Nita Ahuja, M.D.
Dean of the University
of Wisconsin School of
Medicine and Public Health,
Vice Chancellor of Medical
Affairs, and professor in
the Department of Surgery
Robert J. Alpern, M.D.
Ensign Professor of
Medicine and Physiology
and Professor of Internal
Medicine and Cellular and
Molecular Physiology,
and Former Dean of Yale
School of Medicine
Claire Babineaux-Fontenot
Chief Executive Officer,
Feeding America
Sally E. Blount, Ph.D.
Chief Executive Officer,
Catholic Charities of the
Archdiocese of Chicago,
and Michael L. Nemmers
Professor of Strategy
and Former Dean of the
J.L. Kellogg Graduate
School of Management at
Northwestern University
Robert B. Ford
Chairman of the Board and
Chief Executive Officer,
Abbott Laboratories
Paola Gonzalez
Vice President, Global
Financial Planning
and Analysis, The Clorox
Company
Michelle A. Kumbier
President, Turf &
Consumer Products,
Briggs & Stratton, LLC
Darren W. McDew
Retired General, United
States Air Force, and
Former Commander of U.S.
Transportation Command
Nancy McKinstry
Retired Chief Executive
Officer and Chairman
of the Executive Board,
Wolters Kluwer N.V.
Michael G. O’Grady
Chairman and Chief
Executive Officer,
Northern Trust Corporation
Michael F. Roman
Retired Chairman of the
Board, President and
Chief Executive Officer,
3M Company
Daniel J. Starks
Retired Chairman, President
and Chief Executive Officer,
St. Jude Medical, Inc.
John G. Stratton
Retired Executive
Chairman, Frontier
Communications
Parent, Inc.
Directors
Robert B. Ford*
Chairman of the Board and
Chief Executive Officer
Philip P. Boudreau*
Executive Vice President,
Finance and
Chief Financial Officer
Elizabeth C. Cushman*
Executive Vice President,
General Counsel and
Secretary
Lisa D. Earnhardt*
Executive Vice President
and Group President,
Medical Devices
Mary K. Moreland*
Executive Vice President,
Human Resources
Louis H. Morrone*
Executive Vice President,
Core Diagnostics
Daniel Salvadori*
Executive Vice
President and Group
President, Established
Pharmaceuticals
and Nutritional Products
Christopher J. Scoggins*
Executive Vice President,
Diabetes Care
Melissa D. Brotz
Senior Vice President,
Public Affairs and
Corporate Marketing
Christopher J. Calamari
Senior Vice President,
U.S. Nutrition
Sabina Ewing
Senior Vice President,
Business and Technology
Services and Chief
Information Officer
Sammy Karam
Senior Vice President,
Established
Pharmaceuticals, Global
Commercial Operations
Brian Lehman
Senior Vice President, Core
Laboratory Diagnostics,
Commercial Operations
Scott M. Leinenweber
Senior Vice President,
Licensing, Acquisitions
and Ventures
Sandra Lesenfants
Senior Vice President,
Structural Heart
Fernando Mateus
Senior Vice President,
International Nutrition
Eric Shroff*
Senior Vice President,
Rapid and Molecular
Diagnostics
Julie L. Tyler
Senior Vice President,
Abbott Vascular
Randel W. Woodgrift
Senior Vice President,
Cardiac Rhythm
Management
Uri Yaron
Senior Vice President,
Electrophysiology
Senior Management
Alfredo Armengol
Vice President, Global
Commercial Operations,
Structural Heart
Elizabeth M. Balthrop
Vice President,
Transfusion Medicine
Erica L. Battaglia
Vice President, Chief Ethics
and Compliance Officer
Badia Boudaiffa
Vice President,
North America
Commercial Operations,
Diabetes Care
Keith Cienkus
Vice President,
Nutrition, Supply Chain
Asim Çifter
Vice President,
Nutrition, Asia Pacific
Michael A. Comilla
Vice President,
Investor Relations
Alison Davies
Vice President,
Internal Audit
Thomas C. Evers
Vice President,
Government Affairs
Rodrigo Ferreira
Vice President,
EPD Latin America
John S. Frels
Vice President,
Research
and Development,
Immunoassay/
Clinical Chemistry
Damian P. Halloran
Vice President,
Infectious Disease,
Rapid Diagnostics
Robert R. Kunkler
Vice President,
Point of Care
Ryan Lakin
Vice President,
Neuromodulation
John A. McCoy Jr.*
Vice President,
Finance and Controller
Matt Mittino
Vice President,
Molecular Diagnostics
Vivek Mohan
Vice President,
Established
Pharmaceuticals, India
Joseph L. Novak
Vice President, Taxes
Michaela
Pardubicka-Jenkins
Vice President,
Pediatric Nutrition
Joe Provost
Vice President,
Commercial Operations,
Electrophysiology
Ansgar Resch
Vice President, International
Commercial Operations,
Diabetes Care
Ric A. Schneider
Vice President,
Chief Operations and
Procurement Officer
Katharine Spayde
Vice President,
Heart Failure
Thomas R. Stanis
Vice President,
International
Commercial Operations
Paul Tan
Vice President, Core
Diagnostics, China
Marc Taub
Vice President,
Technical Operations,
Diabetes Care
James R. Wenner
Vice President,
Treasurer
Monica J. Wilkins
Vice President,
Regulatory, Quality,
and Compliance
Corporate Vice Presidents

-- 83 of 86 --

Abbott / 2025 Annual Report
Shareholder and Corporate Information
82
BIOWEARABLE NOTES
(pp. 12-13)
1. Fokkert, M. BMJ Open Diabetes
Research and Care (2019). https://
doi.org/10.1136/bmjdrc-2019-000809
2. Evans, M. Diabetes Therapy
(2022). https://doi.org/10.1007/
s13300-022-01253-9
3. Study was performed with the
outside U.S. version of the FreeStyle
Libre 14-day system. Data is
applicable to FreeStyle Libre [2 or
3 as applicable} system, as feature
sets are similar as FreeStyle Libre
14-day system, excluding alarms.
4. Data on File. Abbott Diabetes
Care, Inc.
5. Data on file, Abbott Diabetes Care,
Inc. Based on the number of users
worldwide for the FreeStyle Libre
portfolio compared to the number
of users for other leading personal
use sensor based glucose
monitoring systems.
6. Miller, Brandner et al. HbA1c
Reduction After Initiation of the
FreeStyle Libre System in Type 2
Diabetes Patients on Long-Acting
Insulin or Non-Insulin Therapy.
https://doi.org/10.2337/db20-84-LB
7. Leelarathna et al (FLASH-UK):
Leelarathna, L. New England Journal
of Medicine (2022).
8. The FreeStyle Libre systems apps
are only compatible with certain
mobile devices and operating
systems. Please check our website
for more information about device
compatibility before using the apps.
Use of the FreeStyle Libre systems
apps may require registration with
LibreView.
9. Libre Assist is a feature within Libre
app that uses generative artificial
intelligence to provide information
on how foods could impact your
glucose levels. Generative artificial
intelligence may not always be
accurate, and it should not be used
to make treatment decisions.
10. Predicted glucose impact
is based on user-provided food
data and may differ from actual
impact, which depends on sensor
readings and factors like activity,
stress, medication, and alcohol. For
personalized advice, consult your
healthcare provider.
11. Personalized food suggestions
are based on food preference
information inputted by the user.
12. Based on the number of pump
users having the ability to connect
with Libre technology.
13. Based on product features
including up to [14 or 15]-day wear
period, automatic readings every
minute, accuracy data, and single-
app setup with AID systems.
14. Perreault L, et al. Regression from
pre-diabetes to normal glucose
regulation in the diabetes prevention
program. Diabetes Care. 2009
Sep;32(9):15838. https://pubmed.
ncbi.nlm.nih.gov/19587364/
15. Katula JA, et al. Effects of a Digital
Diabetes Prevention Program: An
RCT. Am J Prev Med. 2022;62(4):567-
577. https://pubmed.ncbi.nlm.nih.
gov/35151522/
NEUROMODULATION NOTES
(pp. 14-15)
1. U.S. market only. Based off
comparison to volumetric
measurement of the following
smallest rechargeable SCS IPGs
in the U.S. market: Abbott Eterna™
SCS System, 13.6 cc; Boston
Scientific‡ WaveWriter Alpha‡ 16,
20.1 cc; Medtronic‡ Inceptiv‡, 13.77
cc; Nevro‡ Senza‡ Omnia‡, 26 cc;
Saluda‡ Evoke‡, 33 cc; Biotronik‡
Prospera‡, 29 cc. Sizing for EternaTM
SCS IPG is determined using
engineering model measurement(s).
Methods to calculate size may vary
among manufacturers.
2. Anywhere with a cellular or
Wi-Fi connection and sufficiently
charged patient controller.
3. Deep Brain Stimulation (DBS)
has not been approved by FDA for
treatment-resistant depression (TRD)
and the safety and effectiveness
of DBS for TRD has not been
established.
4. Upon implant of the Liberta
RC DBS System, 37 days of
therapy when programmed with
standard (nominal) stimulation
settings as described in device
instructions for use. Recommended
recharge frequency and duration
for competitor rechargeable
DBS systems described in their
respective IFU or clinical studies,
which may involve different patient
populations and other variables.
Not a head-to-head comparison
of stimulation settings or clinical
outcomes.
5. U.S. market only. Based off
comparison to volume of the
following smallest IPG offerings
from U.S. DBS manufacturers:
Abbott Liberta RC DBS System:
13.6cc, Boston Scientificǂ Vercise
Genusǂ R16: 20.1cc and
Medtronicǂ Perceptǂ RC: 13.77cc.
6. Upon implant of the Eterna
SCS System, approximately three
hours five times per year (69 to 74
days between charges) or 1 hour
per month (25 to 27 days between
charges) at standard (nominal)
settings for BurstDR programming:
30/90 dosing when programmed
with amplitude of 0.6mA and all
other BurstDR stimulation settings
are left at default. Recommended
recharge frequency and duration
for competitor product described
in their respective IFU or clinical
studies, which may involve different
patient populations and other
variables. Not a head-to-head
comparison of stimulation settings
or clinical outcomes.
LABORATORY DIAGNOSTICS
NOTE (pp. 28-29)
1. Alinity n is in development and not
commercially available.
Abbott trademarks and products
in-licensed by Abbott are shown in
italics in the text of this report.
© 2026 Abbott Laboratories
Some statements in this annual
report may be forward-looking
statements for purposes of the
Private Securities Litigation Reform
Act of 1995. Abbott cautions that
these forward-looking statements
are subject to risks and uncertainties
that may cause actual results to
differ materially from those indicated
in the forward-looking statements.
Economic, competitive,
governmental, technological
and other factors that may affect
Abbott’s operations are discussed
in Item 1A, “Risk Factors,” in
our Securities and Exchange
Commission 2024 Form 10-K and
are incorporated by reference.
We undertake no obligation to
release publicly any revisions to
forward-looking statements as
the result of subsequent events
or developments, except as
required by law.
The Abbott 2025 Annual Report
cover and text are printed on
recycled paper that contains a
minimum of 10% post-consumer
fiber and the financial pages on
30% post-consumer fiber.
Shares Listing
The ticker symbol for Abbott’s common
shares is ABT. The principal market for
Abbott’s common shares is the New York
Stock Exchange. Shares are also listed
on the NYSE Texas and traded on various
regional and electronic exchanges.
Outside the United States, Abbott’s shares
are listed on the Swiss Stock Exchange.
Quarterly Dividend Dates
Dividends are expected to be declared,
recorded, and paid on the following
schedule in 2026, pending approval by
the Board of Directors:
Quarter 	Declared Recorded Paid
First 	2/20/26 	4/15/26 	5/15/26
Second 	6/12/26 	7/15/26 	8/17/26
Third 	9/17/26 	10/15/26 	11/16/26
Fourth 	12/11/26 	1/15/27 	2/16/27
Tax Information for Shareholders
Abbott is an Illinois High Impact Business (HIB)
through June 2043 and is located in a U.S.
federal Foreign Trade Sub-Zone (Sub-Zone
22F). Dividends may be eligible for a
subtraction from base income for Illinois
income-tax purposes. If you have any
questions, please contact your tax advisor.
Dividend Reinvestment Plan
The Abbott Dividend Reinvestment Plan offers
registered shareholders an opportunity to
purchase additional shares, commission-free,
through automatic dividend reinvestment
and/or optional cash investments. Interested
persons may contact the transfer agent.
Dividend Direct Deposit
Shareholders may have quarterly dividends
deposited directly into a checking or savings
account at any financial institution that
participates in the Automated Clearing
House system. For more information, please
contact the transfer agent, listed at right.
Direct Registration System
In August 2008, Abbott implemented a Direct
Registration System (DRS) for all registered
shareholder transactions. Shareholders will be
sent a statement in lieu of a physical stock
certificate for Abbott Laboratories common
shares. Please contact the transfer agent,
listed at right, with any questions.
Annual Meeting
The Annual Meeting of Shareholders will be
held virtually at 8 a.m. Central Time on Friday,
April 24, 2026. Questions regarding the
Annual Meeting may be directed to the
Corporate Secretary. A copy of Abbott’s 2025
Form 10-K Annual Report, as filed with the
U.S. Securities and Exchange Commission,
is available on Abbott’s website at
www.abbott.com.
CEO and CFO Certifications
In 2025, Abbott’s chief executive officer (CEO)
provided to the New York Stock Exchange the
annual CEO certification regarding Abbott’s
compliance with the New York Stock
Exchange’s corporate-governance listing
standards. In addition, Abbott’s CEO and chief
financial officer (CFO) filed with the U.S.
Securities and Exchange Commission all
required certifications regarding the quality
of Abbott’s public disclosures in its fiscal
2025 reports.
Investor Relations
Dept. 362, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
Shareholder Services,
Transfer Agent and Registrar
Computershare
P.O. Box 43078
Providence, RI 02940-3078
888-332-2268 (U.S. or Canada)
781-575-2879 (outside U.S. or Canada)
www.computershare.com
Corporate Secretary
Dept. 364, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
Website
www.abbott.com
Abbott Online Annual Report
www.abbott.com/annualreport
Global Sustainability Report
www.abbott.com/sustainability
Shareholder Information
Shareholders with questions about their
accounts may contact the transfer agent,
listed above.
Individuals who would like to receive
additional information, or have questions
regarding Abbott’s business activities, may
call the Investor Newsline at the number
listed here, write Abbott Investor Relations
at the address above, or visit Abbott’s
website, www.abbott.com.
012441

-- 84 of 86 --

Back Cover:
ILIJA KEVO
Zagreb, Croatia
Alinity s
When Ilija was undergoing
treatment for leukemia, he
required many transfusions
of donated blood. These
were screened using
Abbott’s Alinity s analyzer.
Today, Ilija is cancer-free.

-- 85 of 86 --



-- 86 of 86 --